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ABSTRACT
Efforts to sequence cancer genomes have begun to uncover comprehensive lists of genes
altered in cancer. Unfortunately, the number and complexity of identified alterations has made
dissecting the underlying biology of cancer difficult, as many genes are not amenable to
manipulation by small molecules or antibodies. RNA interference (RNAi) provides a direct way
to assess and act on putative cancer targets. However, the translation of RNAi into the clinic has
been thwarted by the "delivery" challenge, as small interfering RNA (siRNA) therapeutics must
overcome clearance mechanisms and penetrate into tumor tissues to access cancer cells.
This thesis sought to develop nanotechnology-based platforms to rapidly discover and
validate cancer targets in vivo. First, we developed versatile surface chemistries for nanoparticle
tumor targeting. Leveraging new discoveries in amplified transvascular transport, we designed a
siRNA delivery system that integrates the tumor specificity and tissue-penetrating ability of
tumor-penetrating peptides with membrane penetration properties of protein transduction
domains to direct siRNA to tumors in vivo.
Second, we utilized this delivery system to bridge the gap between cancer genomic
discovery and in vivo target validation. Comprehensive analysis of ovarian cancer genomes
identified candidate targets that are undruggable by traditional approaches. Tumor-penetrating
delivery of siRNA against these genes potently impeded the growth of ovarian tumors in mice
and improved survival, thereby credentialing their roles in tumor initiation and maintenance.
Lastly, we described efforts extending this platform for clinical translation. Mechanistic
studies identified functional properties that favored receptor-specific siRNA delivery. We also
explored a strategy to improve the microdistribution of successively dosed siRNA therapeutics
through modulating the tumor microenvironment. Finally, we investigated the utility of the
system in primary human tumors derived from patients with ovarian cancer.
Together, these findings illustrate that the combination of cancer genomics with the
engineering of siRNA delivery nanomaterials establishes a platform for discovering genes
amenable to RNAi therapies. As efforts in genome sequencing accelerate, this platform
illustrates a path to clinical translation in humans.
Thesis Supervisor: Sangeeta N. Bhatia
Title: John and Dorothy Wilson Professor of Health Sciences & Technology and Electrical
Engineering & Computer Science
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tumor explants from A. Error bars indicate s.d. (n=3). ................................................................................. 86
Figure 3.18. Intratumoral localization of TP-LyP-1 targeted nanocomplexes. Histological analysis of fluorescein-
labeled siRNA distribution in MDA-MB-435 tumor sections (Green: TP-LyP1/siRNA nanocomplexes; Red:
CD31 (left) and p32 (right); Blue: DAPI counterstain). Scale bar is 50 pm. ............................................... 86
Figure 3.19. In vivo homing of nanocomplexes after intraperitoneal administration. (A) Circulation time of i.p.
injected, fluorescently-labeled siRNA (5 nmols) either in its naked form or complexed to a TPN. Error bars
indicate s.d. (n = 3). (B) Whole-animal fluorescence imaging at multiple time points after intraperitoneal
injection in mice. Arrows indicate bladder accumulation .............................................................................. 87
Figure 3.20. Duration of gene silencing by TPN. (A) Mice were injected intraperitoneally with tandem
peptide/siRNA nanocomplexes, and the duration of gene silencing was determined by whole-animal
bioluminescence imaging of luciferase expression on the indicated days. Error bars indicate s.d. (n=3); (B)
Representative bioluminescence images from mice in (A) ........................................................................... 87
Figure 3.21. In vivo siRNA delivery and gene knockdown by TPN. Top, mice bearing luciferase expressing T22H
tumors were injected i.p. with siRNA against luciferase bound to nanocomplexes. The amount of gene
silencing was measured by bioluminescence imaging 48 h later. Statistical analyses were performed with
ANOVA and Bonferroni post-test for pair-wise comparisons. Horizontal lines, mean values. (n = 4-6); **p<
0.01, ***p< 0.001. Bottom, representative bioluminescence images of luciferase activity of mice before and
after treatm en t. ................................................................................................................................................... 8 8
Figure 4.1. An integrated platform enables high-throughput genomic discovery and in vivo credentialing of cancer
genes. Analyses of ovarian cancer genomes nominate genes that are amplified and essential. The application
of TPN system for siRNA delivery overcomes the in vivo validation barrier (dotted line) by enabling rapid
validation of candidate genes in animal models. Follow-up studies could identify the mechanism of
transformation to establish novel therapeutic targets that can ultimately benefit patients. ........................... 93
Figure 4.2. Schematic of shRNA analysis. Analysis of median shRNA depletion scores for each amplified gene.
Copy number analysis using GISTIC of primary high-grade serous ovarian cancers identified 1825 recurrently
amplified genes in 63 regions of genomic amplification. Schematic showing the distribution (blue bars) of
median shRNA scores in cell lines that harbor copy number gain (log2 copy number ratio > 0.3) of a given
gene. shRNAs targeting the amplified gene (dots) are considered significant (red) if p-value<0.05 (red line).
Analysis is repeated for each of 1825 amplified genes in 63 recurrent regions of genomic amplification
identified in prim ary serous ovarian cancer. ................................................................................................. 96
Figure 4.3. Amplification of ID4 in primary high-grade serous ovarian tumors. SNP array colorgram depicts
genomic amplification of ID4 in subsets of primary ovarian tumors, sorted based on the degree of
amplification of ID4. Regions of genomic amplification and deletion are denoted in red and blue, respectively.
........................................................................................................................................................................... 9 7
Figure 4.4. ID4 expression in primary ovarian cancers. (A) Immunohistochemical analysis of ID4 in primary ovarian
cancers and normal tissues. Immunohistochemical staining of ID4 was performed on sections from tissue
microarrays composed of primary ovarian cancers (n=131) and normal tissues (n=85). Percent of samples that
were stained positive in ID4 is shown. (B) Representative micrograph of a primary ovarian cancer stained with
an an ti-ID 4 an tib o dy . ......................................................................................................................................... 9 7
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Figure 4.5. Boxplot showing ID4 expression in cancer cell lines derived from different lineages
(http://www.broadinstitute.org/ccle). The black dot in each boxplot is the median expression value for each
lineage, boxes represent the 25th to 75th percentile of the data and whiskers span the most extreme values of
the group. Ovarian cancer cell lines are m arked in red. ............................................................................... 98
Figure 4.6. ID4 suppression by shRNAs did not affect other ID family members. Immunoblot of IDI, ID2, ID3 and
ID4 in OVCAR-4 cells expressing a control shRNA targeting GFP or 1D4-specific shRNAs......................98
Figure 4.7. FISH Analysis of ID4 in ovarian cancer cells. Four (4) ovarian cancer cell lines were analyzed for
amplification of ID4 by FISH. OV-90 cells, which do not harbor 6 p2 2 amplifications, was used as a negative
c o n tro l. ............................................................................................................................................................... 9 9
Figure 4.8. Effects of ID4 suppression in ovarian cancer cell lines. Top, Effects of ID4 suppression on proliferation
of human cancer cell lines. Cells were infected with a control shRNA targeting GFP or 2 shRNAs targeting
ID4 and the proliferation was measured 6 d after infection. Error bars indicate s.d. of 6 replicate
measurements. Bottom, The relative ID4 mRNA levels; 6p22-amplified lines are marked in red. Error bars
indicate s.d. of 6 replicate m easurem ents.........................................................................................................100
Figure 4.9. Induction of apoptosis by ID4 suppression in ovarian cancer cell lines. Immunoblot of PARP and
caspase-3 after suppressing ID4 in 6p22-amplified cell lines. Arrows indicate the respective full length or
cleaved P A R P or C aspase-3.............................................................................................................................10 1
Figure 4.10. Establishment of 1D4-overexpressing immortalized ovarian surface epithelial (IOSE) cells. Immunoblot
of MEK, phospho-ERKl/2 and ID4 in immortalized ovarian surface epithelial cells expressing indicated
c o n stru c ts. ........................................................................................................................................................ 10 1
Figure 4.11. Potentiation of tumorigenicity in lOSEs overexpressing ID4 and other ID family members. IOSE-M
cells expressing the indicated constructs were implanted subcutaneously into immunodeficient mice. The
percent tumor formation is shown for each condition, and the number of tumors formed/number of injections
is indicated above each bar. H-RASv12 expressing IOSE cells were used as a positive control. ..................... 102
Figure 4.12. ID4 promotes anchorage independent growth. (A) ID4 promotes anchorage independent growth of
FTSEC-M cells. Error bars indicate s.d. (B) Anchorage independent growth of IOSE-M cells expressing ID4
or control vector. Error bars indicate s.d..........................................................................................................102
Figure 4.13. Surface expression of p32 in cancer cell lines. Six human cancer cell lines derived from ovarian cancer
(CaOV3, EFO21, OVCAR-8 and OVCAR-4), cervical cancer (HeLa), melanoma (MDA-MB-435), and a
mouse ovarian cancer cell line (T22H) were surveyed for surface expression of p32 by flow cytometry with a
polyclonal rabbit antibody directed against the full-length p32 peptide. A rabbit IgG isotype control was used
(black). U nstained cells are shaded in gray......................................................................................................105
Figure 4.14. ID4 suppression by TPN-mediated siRNA delivery in vitro. (A) Immunoblot of ID4 in two 6p22-
amplified ovarian cancer cell lines (OVCAR-4 and OVCAR-8) treated with TPNs containing two ID4-specific
siRNAs or a control siRNA targeting GFP. t-Tubulin is used as a loading control. (B) Effects of ID4
suppression on cell proliferation. Proliferation of ovarian cancer cell lines treated with TPNs containing GFP-
siRNA (white bars), untargeted TPN (TP-ARAL) carrying ID4-siRNA (hashed bars), and TPNs carrying ID4-
siRNA (black bars). Error bars indicate s.d. from 4 independent experiments. ***p<0.001...........................105
Figure 4.15. Effects of ID4 suppression on apoptosis. ID4 knockdown by TPNs carrying ID4-siRNA in OVCAR-8
ovarian cancer cells led to an increased proportion of the population that binds Annexin-V, relative to
untreated cells (mock), cells treated with TP-LyP- 1 (carrier) or with TPN carrying an irrelevant siRNA (siUT).
......................................................................................................................................................................... 10 6
Figure 4.16. Summary of Annexin-V assays (white bars) and cells entering S-phase by the Click-iT-EDU assay (red
bars). The percentages of apoptotic and S-phase cells were calculated. Three independent experiments were
pooled and analyzed as a combined data set. Error bars indicate s.d. from 3 independent experiments. n.s., not
sign ificant; ***p < 0 .00 1. .................................................................................................................................. 106
Figure 4.17. Ovarian tumor targeting by TPNs. (A) Quantification of siRNA fluorescence per area of subcutaneous
OVCAR-8 ovarian tumor xenografts harvested 6 h after tail-vein injection of LyP-1 TPNs (red bar),
untargeted nanocomplexes (ARAL TPNs, gray bar), or carrier-less siRNA (No carrier, white bar) labeled with
a near infrared fluorophore (VivoTag-750). Error bars indicated s.d. (n=4). (B)Near-infrared fluorescence
im ages of O V C A R -8 tum or xenografts. .......................................................................................................... 107
Figure 4.18. Time-course of tumor penenetration by TPN. Histological analysis of time-dependent homing of TPN
carrying FITC-labeled siRNA (pseudocolored green) in relation to cells (DAPI, blue) and blood vessels
(CD3 1, red) in mice bearing bilateral s.c. OVCAR-8 tumors. Scale bars, 50 pm............................................107
Figure 4.19. Quantification of the extravascular and intravascular fractions of TPNs. Data from representative
sections of 6 independent tumors is shown. Error bars indicate s.d. ***p<0.001............................................108
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Figure 4.20. Quantification of tumor parenchymal penetration by TPN. (A) Comparison of bulk tumor parenchymal
penetration of FITC-labeled siRNA in different TPN formulations: LyP-1 TPN (LyP-1), iRGD TPN (iRGD), a
non-penetrating nanocomplex (RGD4C), and lipofectamine (Lipo) in OVCAR-8 tumors at 1 h or 3 h post i.v.
injection (n = 6 per formulation). Scale bars, 50 4m. (B) Quantification of tumor fluorescence. Error bar
indicates averages + s.d. from 6 randomly selected views per condition. n.s., not significant; **p<0.01;
* * *p < 0 .0 0 1 . ..................................................................................................................................................... 10 8
Figure 4.22. Efficacy of TPN-mediated delivery of ID4-siRNA in in vivo.OVCAR-4 cells were xenografted
subcutaneously and allowed to form tumors of up to 5mm in diameter for 14 days before start of treatment
with indicated formulations every 3 d for 25 d (at 1mg siRNA/kg/injection, arrowheads). Mice in the carrier
group received TP-LyP-1 peptide without siRNA (at 6.5mg peptide/kg). Inset, the timeline of the experiment.
Tumor size was measured by digital caliper and the volume was calculated based on the modified ellipsoidal
formula volume = 1/2 (length x width2) and normalized to that at the start of treatment (day 14). Treatment
period is shaded in gray. n = 8-10 tumors per group. Error bars indicate s.d.; n.s., not significant; ***p<0.001.
......................................................................................................................................................................... 1 1 1
Figure 4.21. Theraepeutic effects of TPN/siID4 treatment in OVCAR-4 tumor-bearing mice. Weight of OVCAR-4
tumors at day 60. (n = 5-10 tumors per each cohort); *p<0.05; **p<0.01; n.s., not significant. ..................... 111
Figure 4.23. Effects of TPN-mediated ID4 suppression in OVCAR-4 tumor xenografts. Relative ID4 and p21
mRNA levels from tumors harvested from all cohorts at day 60.....................................................................112
Figure 4.24. Induction of apoptosis by TPN/siID4treatment. Quantification of TUNEL staining intensities from 6-10
randomly selected OVCAR-4 tumor sections after 30 d of TPN treatment.**p<0.01.....................................112
Figure 4.25. Therapeutic efficacy of TPNs in mice bearing disseminated tumors. Left, OVCAR-8 cells were
xenografted intraperitoneally and allowed to form tumors over 20 d. On day 21, mice were randomly divided
into 4 groups with matching tumor burdens and treated every 3 d for 14 d and then once weekly thereafter
with: TPNs carrying ID4-specific siRNA (red circles); saline (black squares); TPN carrying GFP-siRNA
(green triangles); and untargeted TP-ARAL nanocomplexes carrying ID4-specific siRNA (blue triangles), at
5mg siRNA/kg/injection (arrowheads). Inset, the timeline of the OVCAR-8 tumor therapy experiment. Total
tumor burden was followed by bioluminescence imaging (BLI). n = 5 per group. Error bars indicate s.d.; n.s.,
not significant; *p<0.05; ***p<O.001. Right, Representative whole-animal bioluminescence images of mice in
the groups treated in D confirmed disseminated intraperitoneal tumor burden. Images were taken on day 60.
......................................................................................................................................................................... 1 1 3
Figure 4.26. Kaplan-Meier plot of overall survival. Survival of animals bearing disseminated orthotopic OVCAR-8
xenograft tumors from cohorts shown in Figure 4.25 (n = 5 per group)..........................................................113
Figure 4.27. Bioluminescence imaging (BLI) of OVCAR-8 tumor burden. All cohorts of mice bearing orthotopic
OVCAR-8 ovarian tumor xenografts were imaged serially. Images shown were obtained on day 40 of
th erap eu tic trial. ............................................................................................................................................... 1 14
Figure 4.28. Photographs of representative OVCAR-8 tumor bearing mice from each cohort upon necropsy at day
60. Arrowheads indicate the presence of disseminated intraperitoneal ovarian tumor nodules. No visible
tum ors w ere seen in the TPN /siID 4 treated m ice.............................................................................................114
Figure 4.29. Effects of TPN-mediated siID4 delivery in vivo. Tumor sections harvested from all 4 cohorts on day 40
were stained for p32 (pseudocolored red) and ID4 (pseudocolored green) (top) and for induction of apoptotic
cell death (bottom ) by TUN EL (red). Scale bars, 50 pm . ................................................................................ 115
Figure 4.30. Downstream effects of ID4 suppression in OVCAR-8 tumors. Quantification of ID4 and TUNEL
intensities from OVCAR-8 tumors after TPN treatment. Statistical analyses were performed using ANOVA;
E rror bars indicate s.d. **p< 0.01 . .................................................................................................................... 115
Figure 4.31. Quantification of p32 intensities from OVCAR-8 tumors after TPN treatment....................................116
Figure 4.32. Lack of immunostimulation by TPN. Immunocompetent Balb/c mice were injected intraperitoneally
with TPNs and 6 h later, serum samples were tested for levels of: (A) interferon-alpha (IFN-a), (B) IL-6, and
(C) TNF-a, by ELISA. The immunostimulatory siRNA sequence, sipgal-728, was complexed to either
lipofectamine or TP-LyP 1 and these were used as positive controls for non-specific immunostimulation. n = 4-
8 per group. Error bars indicate s.d. *p<O.05; **p<0.01; ***p<0.001.............................................................116
Figure 4.33. Effects on body weight from TPN treatment. (A) Total body weight of OVCAR-4 subcutaneous tumor
xenograft-bearing mice over the course of TPN treatment. Error bars indicate s.d. (B) Total body weight of
OVCAR-8 orthotopic tumor xenograft-bearing mice during TPN/siID4 treatment. Error bars indicate s.d.... 117
Figure 4.34. Absence of general toxicity after TPN treatment. Organs were harvested from OVCAR-8 tumor bearing
mice after TPN treatment for 40 d (5 mg siRNA/kg) and stained with H&E: (A) bladder. (B) kidney. (C) liver.
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(D) spleen. (E) heart. (F) ovary. No relevant histological or morphological evidence of toxicity was observed
in these organs. Scale bar is 50 pm . ................................................................................................................. 117
Figure 4.35. ID4 regulates HOXA9 activity. Gene expression profiling and GSEA were performed on IOSE-M cells
expressing ID4 or a control vector. Top, Enrichment plots show the running enrichment score (y-axis) in green
for the ranked list of genes (x-axis) based on their differential expression (signal to noise value) between cells
expressing ID4 or a control vector. Black bars at the bottom of the figure indicate the location of genes in a
gene set upregulated by expression of NUP98-HOXA9 fusion protein generated 6 h (A), 3 d (B), and 8 d (C)
after induction within the ranked list. Significant upregulation of these genes (p=0.001) was observed in cells
expressing ID4. Bottom, Heatmaps showing the expression levels induced by ID4 overexpression (triplicate
measurements) of a subset of genes within each of the gene set. High and low expression levels are indicated
by red and blue colors, respectively. Members of the homeobox family of transcription factors are marked in
re d . ................................................................................................................................................................... 1 19
Figure 4.36. Overexpression of ID4 in IOSE-M cells increases mRNA levels of HOXA9, HOXA7 and HOXA3.
Quantitative PCR analysis of HOXA9, HOXA7 and HOXA3 in IOSE-M cells overexpressing ID4 or a control
vector. Error bars indicate s.d. of 6 replicate m easurem ents............................................................................120
Figure 4.37. Suppression of ID4 reduces HOXA9, HOXA7 and HOXA3. (A) Quantitative PCR analysis of HOXA9,
HOXA7 and HOXA3 in OVCAR-8 cells 3 days after infection with a control shRNA targeting GFP or two
shRNAs targeting ID4. Error bars indicate s.d. of 6 replicate measurements. (B) Suppression of ID4 reduces
expression of HOXA9 proteins. Immunoblot of ID4 or HOXA9 in OVCAR-4, NIH:OVCAR-3 and OVCAR-8
cells expressing a control shRNA targeting GFP or 1D4-specific shRNAs. Arrow indicates the specific
H OX A 9 band. p-actin included as a loading control. ...................................................................................... 120
Figure 4.38. Suppression of HOXA9 protein levels. Immunoblot of HOXA9 in IOSE-M cells expressing indicated
c o n stru cts. ........................................................................................................................................................ 12 1
Figure 4.39. Effect of suppressing HOXA9 on proliferation of IOSE-M cells. Cells expressing indicated constructs
were plated in triplicate and counted daily. Suppression of HOXA9 by the most effective HOXA9-specific
shRNA (shHOXA9#2) resulted in 30% inhibition on cell proliferation 120 h after plating............................121
Figure 4.40. HOXA9 is necessary for ID4-mediated transformation. (A) HOXA9 is necessary for 1D4-mediated
transformation. Suppression of HOXA9 by previously described shRNAs (54) inhibited anchorage-
independent growth of 1D4-overexpressing IOSE-M cells. (B) Suppression of HOXA9 suppressed ID4-
induced tumorigenicity in immunodeficient mice. 1D4-overexpressing IOSE-M cells expressing indicated
shRNAs were subcutaneously implanted into immunodeficient mice. Tumors were monitored for 5 months.
Percent tumor formation based on number of injection sites is depicted. ........................................................ 122
Figure 4.41. ID4 expression in ovarian tumors correlates with HOXA9 activity. Expression data from primary
ovarian tumors were used to perform GSEA on 44 samples with low ID4 expression levels vs. 45 samples
with high ID4 expression (thresholds were 1 s.d. below and above the mean expression of all the samples).
Enrichment plots are as described in C. Black bars at the bottom of the figure indicate the location of genes in
a NUP98-HOXA9 downregulated gene set (TAKEDATARGETS OF NUP8_HOXA9 FUSION_ 10D_ DN).
Significant enrichment of these genes (p = 0.004) was observed in tumors with low ID4 levels....................122
Figure 4.42. ID4 amplification in ovarian tumors correlates with decreased p21 activity. Expression profiling of
primary ovarian tumors with matched copy number data was used to perform GSEA on amplified ID4 (log2
copy number ratio >0.3) and non-amplified 1D4 samples (log 2 copy number ratio <0). All genes were ranked
by their differential expression (signal to noise) between 81 non-amplified and 109 amplified ID4 primary
tumors. Black bars at the bottom of the figure indicate the location of genes in the p21WAFPl target gene set
(P21_P53_ANYDN); significant upregulation (p=0.016) of the gene set was observed in amplified tumors.
......................................................................................................................................................................... 1 2 3
Figure 4.43. An integrated platform to credential oncogenes in vivo. (A) Structural genomic analyses of tumors from
patients. (B) Schematic of ovarian-amplified gene analysis. Distribution (blue bars) of median shRNA scores
are shown in cell lines that harbor copy number gain of a given gene. shRNAs targeting the amplified gene
(dots) are considered significant (red) if z-score < -2. Analysis was repeated for each of 1825 amplified genes.
(C) Development of a tumor-penetrating siRNA nanocomplex (TPN) to deliver siRNA to tumor cells in a
receptor-specific manner and validates gene targets in mouse models. (D) Follow-up studies to identify the
mechanism of transformation and establish novel therapeutic targets ............................................................. 130
Figure 5.1. The identification of CYCLOPS genes amongst the genes that undergo copy number loss in cancer. (A)
The percentage of the cancer genome that undergoes copy number loss. (B) The size of genomic deletions that
result in copy number loss in cancer genomes. The length of individual deletions (as a fraction of the
chromosome arm where they occur) was determined as previously described................................................137
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Figure 5.2. Schematic describing one mechanism by which tumor suppressor gene inactivation results in partial loss
of non-driver genes. Tumor suppressors often require bi-allelic inactivation for tumor initiation or
maintenance. Here, one allele is lost as a result of an alteration that affects a small genomic region that
includes the tumor suppressor gene (in red). The second allele is lost as a result of chromosome arm loss,
leading to com plete tum or suppressor inactivation..........................................................................................137
Figure 5.3. Expression of PSMC2 in ovarian cancer cell lines. (A) PSMC2 levels in ovarian cancer cell lines.
Lysates collected from ten ovarian cancer lines and one immortalized ovarian surface epithelial cell line
(IOSE) were analyzed by immunoblot. Cell lines with partial PSMC2 copy number loss are indicated.
(B) PSMC2 levels in cells that express an inducible shRNA that targets PSMC2...........................................138
Figure 5.4. A non-linear relationship between PSMC2 levels and proliferation of ovarian cancer cells. A2780 (Left)
and OVCAR-8 (Right) cells were cultured in varying concentrations of doxycycline. Cells were collected
three days after to assess the levels of PSMC2 mRNA by qPCR. In parallel, cell proliferation was determined
and norm alized to the untreated sam ples. ........................................................................................................ 138
Table 5.1. A list of genes that exhibit "Copy-number alterations Yielding Cancer Liabilities Owing to Partial losS".
......................................................................................................................................................................... 1 3 9
Figure 5.5. Surface expression of p32, the cognate receptor for TPN. Immortalized ovarian surface epithelial (IOSE)
cells and two ovarian cancer cell lines (A2780 and OVCAR-8) were examined by flow cytometry for
overexpression of p32 receptor on the surface. Isotype-matched control are shown in gray...........................142
Figure 5.6. Uptake of TPN in A2780 and OVCAR-8 cells. Ovarian cancer cell lines are incubated with TPN
carrying siRNA labeled with a near-infrared fluorophore (VivoTag750) and cellular uptake was assessed by
flow cytometry. To probe the receptor-specificity of TPN uptake, a monoclonal antibody against p32 (p3 2
mAb) was added along with TPN (red). Control cells received an isotype-matched antibody (gray).............143
Figure 5.7. TPN suppression of PSMC2 in ovarian cancer cell lines impact their viability. (A) Immunoblots of
PSMC2 levels after treatment with TPN carrying a pool of PSMC2-specific siRNAs. Control cells received
TPN carrying a control siRNA (GFP), lipofectamine carrying PSMC2-siRNA, or untargeted control
nanocomplexes (ARAL) carrying PSMC2-siRNA. (B) A2780 and OVCAR-8 cellular proliferation measured
by total ATP content after treatment with indicated TPN formulations...........................................................143
Figure 5.8. Immunoblotting of lysates from residual OVCAR-8 tumors. Elactin was used as the loading control.. 144
Figure 5.9. Therapeutic effects of PSMC2 suppression in mice bearing orthotopic OVCAR-8 xenograft tumors. (A)
Tumor burden over time in mice treated with TPN/siPSMC2. *p<0.05, ***p<0.001, by one-way ANOVA. (B)
Tumor burden over time in mice bearing orthotopic tumors derived from OVCAR-8 cells expressing a V5-
tagg ed P S M C 2 . ................................................................................................................................................ 14 4
Figure 5.10. Therapeutic effects of PSMC2 suppression in mice bearing A2780 orthotopic ovarian tumor xenografts.
Mice with existing tumors were treated with TPN carrying PSMC2-specific siRNA and tumor burden was
monitored overtime via non-invasive whole-animal bioluminescence imaging. ............................................. 145
Figure 5.11. Therapeutic effects of PSMC2 suppression by TPN in the dox-inducible shRNA system. (A) Mice
bearing A2780 orthotopic tumor xenografts were fed with doxycycline and treated with TPN carrying
PSMC2-specific siRNA every 3 days for 20 days (n = 5). Control cohorts of received either TPN carrying
GFP-specific siRNA (n = 5) or phosphate-buffered saline (PBS, n = 5). (B) Overall survival of mice that were
fed with doxycycline and treated with TPN/siPSMC2 (sh7183 + Dox, n = 8), compared against mice that were
only treated with TPN/siPSM C2 (sh7183 - Dox, n = 6)..................................................................................145
Figure 6.1. Schematic representation of the tumor penetrating nanocomplex (TPN). siRNA (blue) is non-covalently
bound to tandem peptides composed of a cyclic tumor-specific domain (LyP-1, green) and various cell-
penetrating peptide domains (purple) separated by a 4-glycine spacer (gray). A subset of the tandem peptides
tested were N-myristoylated (myr, orange). Cell-penetrating peptide domains tested include representatives
from both polycationic and am phipathic CPPs. ............................................................................................... 159
Figure 6.2. Encapsulation of siRNA by tandem peptides.Tandem peptides were mixed with siRNA at varying molar
ratios, and the amount of siRNA encapsulated in nanocomplexes was determined by measuring the
fluorescence of a nucleic-acid intercalating dye (TO-PRO-3) normalized to dye fluorescence with siRNA
a lo n e ................................................................................................................................................................. 1 5 9
Figure 6.3. Representative TEM of a tandem peptide/siRNA nanocomplex formed in water and negatively stained
w ith uranyl acetate; scale bar = 100 nm ........................................................................................................... 160
Figure 6.4. Size histograms of TPN over time in mouse serum at 370 C. .................................................................. 160
Figure 6.5. Characterization and stability of TPNs. (A) Hydrodynamic size histograms of TPN from dynamic light
scattering measurements. (B) Stability of TPNs in saline at 37 'C, as measured by intercalation of TO-PRO-3
14
dye. The final data point (red, marked with ^) represents disruption with 0.1% Triton-X 100 detergent. Error
bars indicate s.d. from three independent experim ents. ................................................................................... 160
Table 6.1. Structural properties of nanocomplexes. (A) The myr- prefix denotes NH2-terminal myristoylation. (dR)n
= oligoarginine where n is the number of d-Arginine residues; PEN = penetratin; TAT = HIV TAT (48-60);
TP = transportan; VP22 = HSV- 1 VP22 protein. (B) Mean hydrodynamic size based on dynamic light
scattering measurements. Errors indicate s.d. from at least 3 separate measurements. (C) Zeta-potential of
nanocomplexes. Errors indicate s.d. from at least 3 independent measurements. ND, not determined. .......... 161
Figure 6.6. Cytotoxicity of TPNs. (A) Viability of HeLa cells after 4 h treatment with myristoylated tandem peptides
at varying concentrations as determined by the MTT assay. Total viability was normalized to cells mock
treated with media. (B) Viability of HeLa cells after 4 h treatment with unmyristoylated tandem peptide
carriers. Error bars indicate s.d. from at least 4 independent measurements....................................................164
Figure 6.7. Cellular uptake of TPNs. OVCAR-8 ovarian cancer cells were incubated with TPNs carrying siRNA
labeled with a near infrared fluorophore (VivoTag-S750). Cellular uptake is assessed by flow cytometry for
both non-myristoylated and myristoylated tandem peptides. Error bars indicate s.d.from 4-6 independent
ex p erim en ts......................................................................................................................................................16 4
Figure 6.8. Cellular uptake of TPNs composed of TAMRA-labeled peptides (blue) and VivoTag-S750-labeled
siRNA (red) in OVCAR-8 cells. Error bars indicate s.d.from 4-6 independent experiments. ........... 165
Figure 6.9. p32-specificity of TPN uptake. Left,TPN uptake by OVCAR-8 cells in the presence of increasing
concentrations of a p32-specific monoclonal antibody (mAb 60.11) directed against the NH2-terminus of p32
polypeptide. Uptake of nanocomplexes was normalized to that without antibody inhibition. Error bars indicate
s.d. from 6 independent experiments. Right, Representative histograms from flow cytometry for cellular
uptake of myr-12R-LyP-1 (top, m12R) and myr-TP-LyP-1 (bottom, mTP), in the presence of indicated
concentrations of mAb 60.11 (black and gray) or a IgG control (red).............................................................165
Figure 6.10. TPN-mediated receptor-specific gene silencing in vitro. (A) HeLa cells stably expressing destabilized
GFP were transfected with TPNs carrying siRNA against GFP. The amount of GFP knockdown was
determined by flow cytometry24 h later. Lipofectamine was used as a positive control. Error bars represent
s.d. from cumulative data of three independent experiments. (B) Representative histograms for myr-TP-LyP 1
nanocomplexes carrying GFP-specific siRNA. Mock treated cells are shaded in gray...................................167
Figure 6.11. Gene silencing by unmyristoylated TPNs. (A) HeLa cells expressing destabilized GFP were transfected
with non-myristoylated tandem peptides complexed to siRNA against GFP and analyzed by flow cytometry 24
h later. Lipofectamine was used as a positive control. Error bars indicate s.d. from 3 separate experiments.. 167
Figure 6.12. Gene suppression by TPN-mediated siRNA delivery. (A) GFP suppression by myristoylated TPNs
carrying different concentrations of siRNA (100 nM, 50 nM, or 25 nM). For each siRNA concentration, the
percent GFP knockdown for a particular TPN was shown after normalizing by the mean GFP knockdown of
all TPN candidates at that siRNA concentration. The heat map is pseudocolored to indicate high efficiency in
GFP knockdown (red) and low efficiency in knockdown (green). (B) Kinetics of GFP suppression by TPN
candidates as determined by flow cytometry measurements at the indicated time points (24 h, 48 h, and 72 h)
p o st tran sfectio n . .............................................................................................................................................. 16 8
Figure 6.13. Fitness of nanocomplex candidates. (A) TPN receptor-specificity quantified as the concentration of
p32-specific monoclonal antibody to inhibit TPN uptake by 50% (IC 5 0 ). Increasing concentrations of mAb
60.11 was added to cells for 1 h without TPN and subsequently in the presence of TPN for 4 h. Percent
inhibition of TPN uptake was determined by flow cytometry. IC50 values were derived by fitting a standard
normalized dose-response curve for inhibitory binding effects. (B) The fitness of each tandem peptide, as
determined by the sum of knockdown efficiency and p32-specificity.............................................................169
Figure 6.14. Intracellular trafficking mechanisms of TPNs. Top, Fluorescence microscopy images of human ovarian
cancer cell line (OVCAR-8) transfected with Rab5a (CellLightTM Early Endosomes-GFP) 24 h prior (Early),
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1. Background and Significance
1.0 Overall goals
Efforts in genome sequencing have begun to uncover comprehensive lists of genes
altered in cancer [1-2]. Unfortunately, the complexity and sheer volume of data that emerges
from these efforts has made dissecting the underlying biology of cancer extremely difficult. To
utilize genomic discoveries as a starting point for therapeutic development programs, one needs
to rapidly interrogate the functional importance of genes in vitro and in vivo to identify the subset
of genes that can be targeted by therapeutics. However, the number and types of candidate genes
preclude high-throughput functional validation, as many genes do not represent targets amenable
to inhibition by traditional small molecule or antibody-based approaches [1].
RNA interference (RNAi) provides a means to assess and act on candidate genes by
suppressing their expression with high specificity and potency [2-4]. However, the translation of
RNAi into the clinic has been thwarted by the so-called "delivery" challenge since small
interfering RNA (siRNA) molecules have poor in vivo pharmacokinetic properties [5-6].
Nonetheless, existing nanoparticle-based delivery methods do not provide a reliable means to
deliver siRNA, partially due to the requirements that siRNA must traverse through the tumor
interstitium, cross the cell membrane and enter the cytosol of cancer cells to act [7]. Thus, tumor-
targeted and tissue-penetrating delivery of siRNA therapeutics is yet to be achieved.
The overall goal of this thesis is to engineer a nanotechnology-based platform that
overcomes the delivery barrier and enables the rapid in vivo evaluation of oncogenomic targets.
Leveraging new discoveries in amplified transvascular transport, the delivery system described
herein penetrates into the tumor and targets specific tumor cells, delivers siRNA therapeutics
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against essential genes identified from comprehensive analysis of cancer genomes, and
establishes an integrated platform for identifying and credentialing genes involved in cancer.
1.1 Ovarian cancer
1.1.1 Incidence and diagnosis
Ovarian cancer is the second most common gynecologic malignancy and the most lethal
of all gynecologic cancers. There are an approximately 21,500 new cases and nearly 15,000
cancer-related deaths annually in the United States, making it the fifth leading cause of cancer
deaths in women [8]. Worldwide, over 220,000 women were diagnosed with ovarian cancer in
2008 and over 140,000 died from this deadly disease [9].
One of the main causes of the relatively high mortality rate is the lack of tools available
to detect ovarian cancer at the earliest stage. Only 25% of epithelial ovarian cancers (EOC) are
diagnosed at Stage I; most patients who present have advanced Stage III-IV disease. This is
thought to be due to a lack of specific, pathognomonic signs of early stage disease - symptoms
reported by patients with ovarian cancer include bloating, increased abdominal girth, difficulty
swallowing, urinary changes, or abdominal pain. To complicate matters further, there is a lack of
blood or urinary biomarkers that can detect early events in carcinogenesis with high sensitivity
and specificity. The circulating blood biomarker CA-125, a serum glycoprotein that is elevated
in a subset of patients with EOC, is only 50% sensitive for Stage I disease [10] and is not
detected in over 20% of ovarian cancer tissues studied [11]. Anatomical imaging techniques such
as x-ray, computed tomography (CT) or magnetic resonance imaging (MRI) are poor at detecting
small pelvic masses or predicting if an anatomic adnexal mass found on imaging is malignant.
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Transvaginal ultrasound examination is typically employed in combination with CA-125
monitoring to achieve greater sensitivity. However, in patients with early-stage disease,
biochemical alterations that arise due to genetic insults typically occur before gross anatomical
changes. As a result, existing screening methods that are aimed toward detecting structural
abnormalities often fail to provide molecular insights into the process of cancer initiation and
progression, and are therefore inherently limited in detecting early-stage disease.
1.1.2 Management
Unlike many types of abdominal cancers that metastasize via extravasation into the
bloodstream and seeding in distal extra-abdominal organs, ovarian cancer is typically restricted
to the peritoneal cavity and intraperitoneal organs such as the uterus, small and large intestines,
and the peritoneal membrane. Maximal surgical cytoreduction remains to be the optimal initial
clinical management for ovarian disease, even when complete removal of the tumor is not
possible [12-13]. Indeed, retrospective studies have shown that the size of tumor nodules
remaining after initial cytoreduction surgery is inversely correlated with patient survival [14-15].
In cases where the disease has begun to metastasize to other peritoneal organs or where
complete resection is impossible, combination chemotherapy is typically used to eradicate
residual cancer cells. Of note, since a majority of ovarian cancers localize to the peritoneum and
abdominal organs, intraperitoneal (i.p.) administration of chemotherapy has been shown to
achieve >10-fold increase in drug concentration near the tumor [16-17]. However, i.p. treatment
is often associated with higher rates of complications than intravenous (i.v.) chemotherapy due to
side-effects such as GI toxicity, neuropathy, and myelotoxicity. Nevertheless, for both
intraperitoneal and intravenous chemotherapy, a combination of microtubule-inhibiting taxane-
based drugs (such as docetaxel and paclitaxel) and platinum-based DNA alkylating compounds
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(such as cisplatin and carboplatin) are utilized [18]. First introduced in the late 1970's,
taxane/platinum-based therapy remains as the standard of care today. These agents act via
exploiting general biochemical differences between quiescent normal cells and rapidly
proliferating tumor cells; they do not target specific molecular abnormalities found in ovarian
cancer cells from individual patients. As a result, many patients re-present with recurrent and
progressively more drug-resistant disease [19]. Currently, overall 5-year survival for women
with ovarian cancer of all stages is 50%, but only 20-30% for women with advanced-stage
disease. This is significantly lower than that of other malignancies such as breast cancer, whereas
the 5-year overall survival is well over 80% (Figure 1.1). Therefore, there is a desperate need to
develop "personalized" therapeutic strategies that target ovarian-specific lesions and is tailored
towards the specific genotype of each patient.
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Figure 1.1. Clinical outcomes of women with ovarian and breast cancers. (A) Relative survival by
survival time for women of all ages and all races between 1988-2007. (B) 5-Year relative survival by year
of diagnosis with ovarian cancer and breast cancer between 1975-2003. The 5-year survival estimates are
calculated using monthly intervals. From: Fast Stats: An interactive tool for access to SEER cancer
statistics. Surveillance Research Program, National Cancer Institute. http://seer.cancer.gov/faststats.
(Accessed on 3-14-2012)
Despite advancement over the last few decades in our understanding of the biology
underlying cancer initiation, progression, and metastasis, we have not seen equal progress in the
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clinical management of cancer patients. Two main bottlenecks exist between translating
discoveries made at the bench into therapeutic regimens used in the clinic. The first barrier lies in
the development of new drugs based on the newfound knowledge of genes and signaling
pathways underlying oncogenesis. With efforts from high-throughput sequencing and functional
genomics, we have recently begun to enumerate all genetic alterations that could have functional
consequences within a particular tumor. Therefore, the next generation of drugs will likely target
these newly identified genetic mutations. Novel "personalized" therapies will be designed for
each individual patient by taking into account the tremendous genotypic and phenotypic
heterogeneity within cancers. While a number of personalized therapies currently exist in our
drug armamentarium against cancer, more targeted agents should be identified and rapidly tested
in the pipeline as our understanding of tumor biology becomes more comprehensive. In Section
1.2 of the thesis, advancements in high-throughput sequencing of cancer genomes and
development of personalized cancer medicine are discussed in more detail, with a special focus
on personalizing the management of ovarian cancer.
The second, and arguably more critical, barrier lies in the delivery of therapeutics to the
parenchyma of bulky tumors. In systemic disease processes such as cancer where localized drug
delivery is generally ineffective to target every tumor cell, intravenously or intraperitoneally
administered therapeutics must stably traverse the blood stream and overcome several major
transport hurdles before reaching the tumor cell [20]. This is a significant problem that not only
affects conventional chemotherapies, but also novel targeted agents including monoclonal
antibodies and nucleic acid therapeutics, where their relative large size can further hinder drug
diffusion and intratumoral transport. Specifically, these barriers include distribution to blood
vessels that supply the tumor, extravasation from the vasculature and into the tumor parenchyma,
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and penetration through the dense tumor interstitial matrix to reach cancer cells of interest. For
macromolecules such as DNA and siRNA, there is also the added requirement of translocation
across cellular membranes and entry into the cytosol where the molecule would become active.
In Sections 1.3 through 1.5, challenges in delivering drugs to cancer cells in vivo and approaches
to overcome them are discussed.
1.2 Personalizing cancer therapy
1.2.1 Targeted therapy
With recent advances in high-throughput genome sequencing technologies and methods
to identify genetic alterations associated with malignant phenotypes, there has been an explosion
of molecularly-targeted therapeutics for many different types of cancers. In contrast to
conventional genotoxic chemotherapeutics that exploit general differences in cellular
proliferation, targeted agents have higher therapeutic indices because they can be exquisitely
specific towards cancer cells harboring particular genetic alterations, thereby alleviating
toxicities due to off-target effects on normal cells. For example, in patients with chronic myeloid
leukemia (CML) harboring the BCR-ABL translocation, the selective Abl kinase small-molecule
inhibitor imatinib (Gleevec) is superior over conventional chemotherapy in inducing a
therapeutic response [21]. Elsewhere, in 10% to 20% of patients with non-small-cell lung cancer
(NSCLC) who also have activating mutations within the kinase domain of the epidermal growth
factor receptor (EGFR), treatment with small molecule tyrosine kinase inhibitors such as
erlotinib and gefitnib has led to dramatic responses [22]. Such findings highlight the critical
importance of utilizing genomic tools to analyze individual tumors, identifying the subset of
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patients who harbor genetic mutations that drive oncogenesis that are also druggable, and
ultimately treating them with the appropriate personalized therapy to maximize clinical response.
In contrast, one has not seen the same advancement in the development of personalized
therapies for ovarian cancer. Clinical trials to date have employed conventional
chemotherapeutics or combinations thereof to treat large cohorts of patients; however,
improvements in progression-free or overall survival have been moderate. Currently, more
clinical trials have been gearing towards smaller subsets of patients with new agents that target
cancer-specific genetic and epigenetic alterations. Nonetheless, a more concerted and accelerated
effort is needed to identify genetic abnormalities for earlier screening, stratify patients based on
better biomarkers, and develop molecularly-targeted therapeutics.
Towards this goal, progress has been made at the bench over the past two decades in
advancing our understanding of the molecular biology of ovarian cancer. Like many other
neoplastic processes, ovarian cancer cells promote neoangiogenesis by producing factors and
cytokines such as vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) [23].
Treatment of ovarian cancer patients with bevacizumab, a monoclonal antibody that inhibits
VEGF-mediated signaling, prolonged median progression-free survival both as a first-line
therapy and as an adjuvant therapy in recurrent disease [24-25]. Elsewhere, novel tyrosine kinase
inhibitors such as vandetanib that target VEGF and growth factor receptors on pericytes is
currently being tested in combination with docetaxel in patients with persistent or recurrent
peritoneal malignancies, including cancers of the ovary and the fallopian tube [26-27].
Genomic sequencing studies have provided unprecedented insight into the genetic basis
for ovarian tumorigenesis. While a significant fraction of ovarian cancers are clonal [28] and
arise from the progeny of a single cell type, there is also great heterogeneity both in the
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histopathological and genetic makeup amongst ovarian cancers. Many subtypes of ovarian
cancer do not share molecular similarities and therefore, respond differently to chemotherapy.
Only a fraction (10%- 15%) of ovarian cancer is hereditary and associated with germline
mutations in the breast/ovarian cancer susceptibility genes, BR CA] or BRCA2. In contrast, in
patients who do not have significant family history but develop sporadic high-grade serous
ovarian cancers (HGSOC), one of the most common and lethal subtypes of ovarian cancer,
genome-wide analyses failed to yield a significant number genes that are also amenable to drug
intervention. To unbiasedly enumerate all genetic alterations found in ovarian cancer, recent
'omics' efforts led by The Cancer Genome Atlas (TCGA) research network have sequenced over
300 HGSOC tumor specimens. About 50% of which show germline or somatic mutations
involving the homologous recombination repair pathway, and over 90% have somatic mutations
in TP53 [29]. Moreover, ovarian cancer exhibits a high degree of genomic instability as
evidenced by the large numbers of regions of recurrent amplification events [63] and focal
deletion events [55]. Amongst genes that are amplified in ovarian cancer are known oncogenes
such as MYC, KRAS, AKT1, and HER2; as well as novel candidates such as the p53 target gene
IRFBP2, the DNA-binding protein inhibitor 1D4, and the embryonic development protein PAX8.
This genomic heterogeneity suggests that most cases of ovarian cancer have accumulated
amplified copies of oncogenes and tumor suppressor deletions, and have therefore likely evolved
redundant survival pathways. Therefore, agents that target a single mutation or signaling
pathway is unlikely to be curative.
Over the last decade, new evidence has emerged to suggest that epithelial cells of the
fallopian tube fimbriae are the primary cells-of-origin in HGSOC [30-32]. A recent study further
validated the "fallopian tube hypothesis" in Dicer-Pten double knockout mice that developed
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HGSOC from primary fallopian tube tumors [33]. Thus, new cell lines and animal models can
now serve as better paradigms and more accurate in vitro and in vivo models in recapitulating the
initiation and progression of ovarian cancer. Moreover, together with integrated genomics efforts
that comprehensively characterizes ovarian cancer genomes, it is now possible to systematically
annotate the genome to identify cancer drivers, distill them down to ones amenable to therapeutic
intervention, and develop personalized therapies based on small-molecules or RNA interference.
1.2.2 Functional genomics
Advances in high-throughput genome sequencing such as single nucleotide
polymorphism (SNP) arrays and massively parallel sequencing have made it possible to
enumerate all possible genetic alterations that exist in glioblastomas (GBM) and ovarian cancers
[29, 34]. However, the sheer complexity and volume of data that emerges from these efforts
make translation of genomic discoveries into targeted therapeutics extremely difficult. While a
comprehensive inventory of genetic mutations in a given tumor is an essential first step, little is
known about the functions of candidate genes that emerge from these efforts. To accelerate
clinical translation, one also needs high-throughput approaches in parallel to functionally
annotate genes and determine the phenotypic consequences of their perturbations. This will
enable the distillation of cancer targets from structural characterizations and dissection of the
underlying biology of ovarian cancer. Therefore, the next key challenge is to identify which of
the myriad of genes implicated in genome sequencing efforts are true cancer drivers - whose
protein products have causal roles in tumor initiation, maintenance, and metastasis.
To decipher the functional role of genetic alterations, one approach is to over-express
genes of interest and determine the phenotypic consequences. In these gain-of-function
approaches, libraries of human cDNAs and open reading frames (ORFs) have been utilized to
28
uncover candidate gene loci that when overexpressed, permits cell transformation [35-37]. More
recently, many have investigated the role of microRNAs (miRNA) in cellular transformation.
miRNAs are endogeneous small RNAs that represses the expression of numerous downstream
target genes, either through post-transcriptional regulation via imperfect base-pairing or
degradation of the mRNA transcript [38-40]. Many candidate miRNAs and their downstream
target genes have been implicated in oncogenesis. Croce et al. identified the loss of miR-15a and
miR- 16 in chronic lymphocytic leukemias (CLL) [41]. Overexpression of the miR- 17-92 cluster
has been associated with oncogenic activity in diverse tumor subtypes such as B cell lymphomas
[37]. The under-expression of miR-34a, a downstream target of p53 with tumor suppressing
activity, is found in prostate cancer [42]. In the future, the further elucidation of miRNA targets
will enable the identification of gene networks that drive carcinogenesis.
1.2.3 RNA interference
A complementary approach to probe gene function is through loss-of-function assays.
However, traditional techniques to create gene knockouts are labor-intensive and require specific
genetic manipulations that are not amenable for high-throughput applications. Fortunately, with
the advent of genome-scale RNA interference (RNAi) libraries, large scale loss-of-function
screens are now possible [4]. RNAi is a conserved mechanism in eukaryotic cells for defense
against double-stranded RNA (dsRNA) introduced into cells by viruses and/or transposons [2-3,
43]. Briefly, the dsRNA is first recognized by a ribonuclease III enzyme, Dicer, and cleaved into
small fragments of 21-23 nucleotides [44-45]. These dsRNA fragments, also known as short
interfering RNAs (siRNA), contain two-nucleotide 3' overhangs, 5' phosphate and 3' hydroxyl
termini. The sequences form a sense (passenger) strand and an antisense (guide) strand that will
subsequently direct the post-transcriptional degradation of mRNA. The siRNA is incorporated
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into a protein complex known as RNA-induced silencing complex (RISC), and the sense strand
is cleaved by a cleavage enzyme Argonaute 2 within RISC as dictated by the decreased
thermodynamic instability at its 3' terminus [46]. The remaining antisense (guide) strand of the
siRNA is then directed to the complementary mRNA sequence to initiate post-transcriptional
gene suppression by either transcript degradation or translational suppression (Figure 1.2) [47].
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Figure 1.2. Mechanism of RNA interference mediated by short, double-stranded RNAs. (A) Upon
introduction to the cytosol, dsRNA molecules are cleaved by Dicer into 21-23 nt dsRNA fragments
known as siRNAs. (B,C) siRNA duplexes are subsequently loaded into the RNA-induced silencing
complex (RISC). (D) The sense (passenger) strand is degraded by Ago2 protein within RISC. (E) The
remaining antisense (guide) strand mediates recognition of complementary mRNA sequences. (F) Post-
transcriptional gene silencing is achieved through cleavage of the complementary mRNA.
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RNAi is highly effective in inducing post-transcriptional gene suppression. Since siRNA
and shRNA can be synthesized in large quantities at relatively low cost, genome-wide RNAi
libraries have been utilized to identify genes whose suppression induces a particular phenotype,
such as changes in viability, apoptosis, or anchorage-independent growth. One such approach,
termed Project Achilles, integrated genome-wide loss-of-function studies using pooled shRNA
libraries with structural analyses of cancer genomes to identify genes that are amplified and
essential for the survival of cancer cell lines. Specifically, by performing highly parallel RNAi
screens against 11,194 genes in 102 established human cancer cell lines in vitro, Cheung et al.
found 54 putative oncogenes that are essential for the proliferation of ovarian cancer cells and
are also amplified in copy number in primary ovarian tumors [48].
Taken together, as our understanding of the cancer genome continues to evolve, the
future development of both gain-of-function and loss-of-function approaches will provide
powerful tools to identify new gene targets, dissect pathways that drive cancer growth and
survival, and understand new cancer biology. Furthermore, the integration of structural genomics
and functional genomics will accelerate the identification of new genes that have functional roles
in cancer initiation, progression, and metastasis.
1.2.4 RNA-based therapeutics
RNA interference has enormous potential to become clinical therapeutics themselves,
since exogenous siRNA can directly inhibit the function of candidate oncogenes, thereby
perturbing the viability of cancer cells whose survival depend on the activity of those genes. This
approach is particularly attractive for cancers that have a complex and mobile genotype, since
multiple siRNA sequences can be applied to suppress distinct genes that are essential but
"undruggable" by conventional approaches [1]. In contrast to small molecule drugs that function
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at defined molar ratios by binding to specific locations on the target protein, RNAi is inherently
self-catalytic: the incorporation of one siRNA molecule into RISC can degrade multiple
complementary mRNA transcripts. Furthermore, while small molecules often cannot distinguish
isoforms of the same protein, siRNAs can target any gene of interest since RNAi-mediated
degradation mRNA is specific to the nucleotide sequence.
Additionally, RNAi is more attractive than antibody-based approaches. This is because
monoclonal antibodies only bind to targets that are either membrane-bound receptors or secreted
proteins localized to the extracellular milieu. By contrast, siRNA can theoretically degrade the
mRNA transcript of any protein regardless of its intra-/extra-cellular localization. Finally, owing
to the rapid advances in genome sequencing, new siRNA molecules can be identified and
synthesized at large quantities with a quick turn-around time, enabling high-throughput drug
discovery and development.
Indeed, RNA-based therapeutics has been employed in clinical trials for a variety of
indications including neoplastic, cardiovascular, and infectious diseases. More recently, siRNA
therapeutics have been tested in clinical trials to inhibit aberrantly functioning genes in diseases
not limited to cancer, including age-related macular degeneration, viral infections from
respiratory syncytial virus (RSV) and Hepatitis C , and dermatological illnesses [49-51]. The
majority of these trials involved localized injections of naked, unmodified siRNAs. For example,
siRNAs directed against the gene that encodes vascular endothelial growth factor (VEGF) and its
receptor (VEGF-R) were administered into the eyes of patients with age-related macular
degeneration (AMD), resulting in improved vision with minimal toxic side effects [52].
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1.3 Tumor drug delivery
1.3.1 Challenges in siRNA delivery
Small molecule drugs are typically structurally lipophilic and low in molecular weight,
properties that impart favorable ADME pharmacokinetic properties [53]. According to the
Lipinski's Rule of "drug-likeness", the compound should have a molecular mass of less than 500
daltons, no more than 5 hydrogen bond donors, no more than 10 hydrogen bond acceptors, and
an octanol-water partition coefficient log P less than 5 [54]. A drug that obeys a majority of these
rules can typically maintain high circulating levels upon systemic administration. By contrast,
siRNA molecules do not obey Lipinski's rules. They are relatively large with a molecular weight
between 13,000 and 15,000 Da; they contain a large number (typically > 40) of anionic charges
due to the negatively-charged phosphodiester backbone; and they are hydrophilic due to the
presence of sugar moieties [7]. As a result, intravenously administered unmodified siRNAs are
immediately chaperoned with opsonins and cleared from circulation within minutes after i.v.
injection [55]. Furthermore, nucleic acids are unstable in serum due to degradation by RNase A-
type nucleases, thereby limiting their bioavailability to tissues of interest [6]. To circumvent the
poor pharmacokinetic properties, localized delivery has been utilized for indications where the
affected organ is directly accessible and isolated from the other organs. These include the eye,
dermis and vaginal epithelium [56-58]. In particular, intranasal or intratracheal inhalation of
siRNA directed against genes essential for replication of RSV and SARS coronavirus has been
efficacious in controlling infections [59-60]. siRNA targeting the nucleocapsid N gene of RSV
showed low toxicity in Phase I and significant efficacy in phase II trials [50].
siRNA inevitably end up entrapped in endosomes subsequent to cellular uptake [61].
Endosomes undergo maturation where the interior compartment is gradually acidified (pH ~ 5.5-
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6.5) by H+ ATPases. Subsequently, the endosomes fuse with lysomal compartments into
endolysosomes [62]. The acidic pH (- 4-5) will also activate special lysosomal enzymes that
degrade entrapped siRNA, which results in little release into the cytoplasm [63]. Subsequent to
endolysosomal escape, the siRNA molecule must readily dissociate from its carrier to be loaded
into the RNA-induced silencing complex (RISC). Carriers such as PEI that contain a large
number of positively charged tertiary amines may retard the dissociation of siRNA. Indeed,
studies have shown that carrier dissociation rates can significantly impact the efficiency of DNA
transfection [64]. Moreover, it has been demonstrated that steric hindrance from quantum dots in
close proximity to siRNA can impact the magnitude of RNAi [65].
The immune system has natural defense mechanisms against dsRNA in the setting of
viral infections [66-67]. Unsurprisingly, the introduction of siRNA can trigger immune responses
[68-69]. Toll-like receptors including TLR3, TLR7, and TLR8 are activated when they encounter
RNA duplexes in endolysosomes [70]. These TLRs belong to a class of pattern recognition
receptors that respond to single stranded and double stranded RNAs from viral pathogens.
Following endocytosis of siRNA, TLRs located on the endosomes are engaged and induces
nuclear translocation of NF-KB and initiates transcription of genes such as interferon-a (IFN- a)
and other inflammatory cytokines [71]. In addition, cytoplasmic RNA sensors such as dsRNA-
binding protein kinase (PKR) and cytoplasmic RNA sensor (RIG-1) can also activate innate
immune responses [71]. Fortunately, the magnitude of immunostimulatory effects can be
modulated by optimizing the siRNA sequence and properties of the nanoparticle carrier. Known
immunostimulatory sequences such as GU-rich motifs have been rationally excluded in various
design algorithms [69, 72]. Moreover, backbone modifications with 2'-OMe and 2'-deoxy have
improved the "stealth" nature of siRNA and evasion of immune recognition [73].
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Much like the mechanism of miRNA-mediated translational repression, siRNA could
suppress the expression of genes whose mRNA transcripts only share partial sequence homology
[74-76]. The off-target silencing can introduce a host of transcript level changes in genes distinct
from the expected target, thereby confounding the results [77]. Moreover, since endogenous
microRNAs regulate gene expression via a shared pathway, the over-introduction of exogenous
siRNA can have undesired off-target effects through saturation of the RISC machinery, de-
repress miRNA-regulated genes, and cause phenotypic changes due to alterations in genes
unrelated to the target [78].
1.3.2 Transport barriers for drug delivery
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Figure 1.3. Barriers to systemic delivery of siRNA. Naked siRNA and nanoparticle carriers with
siRNA payloads must negotiate several transport barriers before reaching the target cell. Namely, (A)
Upon systemic administration, siRNA should stably circulate in blood until reaching the site of disease.
(B) Once the siRNA cargo is distributed to blood vessels supplying the tumor, it must extravasate from
the bloodstream via either passive diffusion or active transvascular transport. (C) After extravasation, the
siRNA therapeutic should overcome high interstitial pressures and penetrate into the tumor parenchyma.
(D)siRNA payloads are taken up by tumor cells via endocytosis. (E) Escape from endosomal entrapment
by siRNAs is necessary to ensure localization to the cytosol and incorporation into RISC.
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For widespread clinical translation, however, systemic delivery of siRNA therapeutics is
required for diseases such as cancer where the affected tissue(s) cannot be locally accessible. An
ideal siRNA carrier must successfully negotiate several transport barriers after systemic
administration (Figure 1.3). Solid tumors exhibit tremendous disorganization in their vascular
supply. Due to uncontrolled proliferation of tumor cells that is not matched by the accompanying
growth of endothelial cells, tumor blood supply is typically heterogeneous and sparse compared
to normal tissue counterparts [79-80]. In addition, other features unique to the tumor such as
abnormal blood flow, variations in blood flow resistance due to disrupted vessel architecture, and
physical pressure from the presence of hyper-proliferating tumor cells can all contribute to
perfusion heterogeneity [81-82]. Consequently, subpopulations of tumor cells, especially ones
located in the avascular and necrotic core of the tumor, are poorly perfused and undergo
anaerobic metabolism due to nutrient and oxygen deprivation [83-84]. These hypoxic and
nutrient-deprived cells may be only exposed to a sub-threshold fraction of the injected drug,
significantly reducing the therapeutic efficacy.
Elevated interstitial fluid pressure (IFP) can also contribute to the poor systemic delivery
of drugs to tumors [85]. This is partly due to a lack of functional lymphatics, which results in the
build-up of fluid in the tumor interstitium and equalization of oncotic and hydrostatic pressures
across the intravascular and extravascular spaces [86-87]. As a result, convection is negligible
within the tumor parenchyma except at the tumor periphery. Nevertheless, once the drug has
extravasated from the blood vessel into the tumor mostly via diffusion, it must now traverse
through the dense interstitial matrix to reach epithelial tumor cells. The tumor extracellular
matrix (ECM) is composed of a network of connective tissue such as collagen, proteoglycans,
glycosaminoglycans, various proteins such as clotted proteins, fibrin and fibronectin, and stromal
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cells including fibroblasts and tumor-associated inflammatory cells [88]. Together, they provide
a significant barrier for fluid flow and drug transport. Indeed, it has been demonstrated that the
diffusion coefficient of IgG measured in several tumors in vivo correlated with collagen content
within the tumor; tumors with favorable transport characteristics typically displayed well-
organized collagen architecture [89]. Furthermore, as tumors progress, the ECM undergoes
extensive remodeling accompanied by an infiltration of inflammatory cells and concomitant
activation of enzymes such as matrix metalloproteases (MMPs) [90].
1.3.3 Strategies for tumor targeting
The in vivo therapeutic index of anticancer drugs is dependent on its ability to affect
tumor cells while minimally impacting normal tissues. This tissue specificity is especially critical
for drugs that target features that are shared between hyperproliferating cancer cells and normal
proliferative cells, as many chemotherapeutics fail due to dose-limiting toxicities in off-target
tissues. Therefore, an optimal strategy to maximize therapeutic efficacy involves simultaneously
enhancing drug delivery to tumors while minimizing delivery to normal tissues.
The recent advent of nanotechnology has sparked an explosion of nanoparticle
formulations to accomplish this task. Nanoparticles, broadly defined as materials on the order of
tens to hundreds of nanometers in size, represent a promising approach to overcome the delivery
barrier [91]. Currently, several nanoparticle-based chemotherapies have been approved for
clinical use owing to their superior pharmacokinetic properties and fewer side-effects compared
to small molecule counterparts. These include Abraxane (albumin nanoparticle-bound paclitaxel)
and Doxil (liposomal doxorubicin), both distribute to tumors via the enhanced permeability and
retention (EPR) effect by exploiting structural abnormalities in the tumor vasculature such as
disrupted endothelial linings [92-93]. Nevertheless, EPR can be highly variable and is not a
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constant feature of all tumor subtypes [94], thereby limiting the potential for clinical translation.
Furthermore, blood vessel fenestrations could be insignificant and passive targeting may be
ultimately ineffective, as the high IFP in tumors would counteract convective flow. As a
consequence, the diffusion of large macromolecular therapeutics such as proteins and
nanoparticles into the tumor parenchyma can be too slow to be effective [95].
To precisely direct therapeutics to tumors, an alternative strategy is through exploiting
the differential expression of molecular markers between cancer cells and normal cells.
Nanoparticles can be engineered to display affinity ligands such as small molecules, peptides,
and antibodies directed at tumor-specific markers. These markers include vascular surface
proteins such as avp3 and avp5 integrins on the tumor endothelium, overexpressed or mal-
expressed cell-surface proteins such as transferring receptor and epidermal growth factor
receptor (EGFR), membrane lipids such as phosphatidylserine, and overactive proteases such as
matrix-metalloproteases (MMPs) [96-99]. Screening technologies using libraries of small
molecules, aptamers, and bacteroiophage-displayed peptides can unbiasedly select ligands with
high affinity and specificity towards a molecular target [100-103].
While tumor blood vessel delivery and macroscopic accumulation may be sufficient for
applications such as tumor detection by imaging, delivery to epithelial tumor cells deep in the
tumor parenchyma is often required to eradicate disease. Indeed, the efficacy of
chemotherapeutics is determined by how well the drug can leave tumor blood vessels, penetrate
into the tumor tissue, and reach all cancer cells [104]. Treatments with macromolecular drugs
such as antibodies that target tumor cells would be minimally effective if only delivered to blood
vessels, since a fraction of tumor cells are not located near perfusing vasculature. Moreover, for
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nucleic-acid based therapeutics such as DNA and siRNA, delivery to specific intracellular
compartments within a tumor cell such as the cytosol is required for function.
1.3.4 Strategies for tumor penetration
In tumors with extensive stromal involvement, the response rate to chemotherapy is poor
and development of drug resistance is common [105-106]. To improve tumor interstitial
transport, approaches have been developed to reduce blood flow resistance, increase
permeability, or both. Treatment with antiangiogenic agents showed normalization of
vasculature, reduction of interstitial pressure, and improvement in drug penetration [107-109]. In
patients with lymphoma or melanoma, an improved response to chemotherapy is seen with lower
interstitial fluid pressure [110]. Bevacizumab (Avastin), a monoclonal antibody that inhibits
VEGF, is the first clinically approved angiogenesis inhibitor for treatment of metastatic colon
cancers. Elsewhere, vascular disrupting agents (VDA) such as tumor necrosis factor (TNF) and
combretastatin A4 have been shown to shut down vessels supplying the tumor [111]. However,
systemic administration of VDAs can have toxic side effects due to non-specificity towards
normal blood vessels [112]. Alternatively, ECM-modifying molecules such as collagenase and
hyaluronidase have been used to increase the transport of model drugs [113-114]. Modulation of
the pancreatic tumor stroma via inhibition of hedgehog signaling or degradation by pegylated
hyaluronidase enzyme can enhance the delivery of gemcitabine chemotherapy into the tumor and
significantly improve survival [115-116]. However, these approaches are not tumor-specific;
systemic administration of these agents can lead to the undesired degradation of normal
connective tissue and toxicity. Moreover, remodeling of extracellular matrix could potentially
increase the probability of metastasis.
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One promising solution, recently described by Ruoslahti et al., utilizes a newly
discovered class of peptides that are both tumor-specific and tissue-penetrating to enhance the
delivery of drugs to tumors [117-118]. One such peptide, iRGD (internalizing RGD;
CRGDKGPDC), contains two features that endow tumor-specificity and tumor-penetration
abilities. Namely, the RGD motif directs to integrins expressed on the surface of angiogenic
endothelial cells, thereby conferring tumor-specificity. Additionally, the presence of the
arginine/lysine-X-X-argine/lysine (RXXR) motif at the C-terminus (CendR motif) enables
binding to neuropilin- 1 (NRP 1) and subsequent increase in tumor vascular permeability.
Importantly, activation of NRP 1 is dependent on the proteolytic processing of cyclic iRGD on
the tumor cell surface, thereby unveiling the RXXR motif in a tumor-specific manner. In
xenografts and genetically-engineered mouse models of cancer, iRGD enhances the co-delivery
of small molecules, monoclonal antibodies, and nanoparticles into the tumor [119].
The precise mechanism by which CendR peptides enhance tumor penetration is still
under investigation. Similar to vasoreactive agents such as bradykinin and endothelin that
promote drug delivery through increasing vessel pore size, the effects of iRGD could be also
attributed to the "stimulated permeability and retention" effects [120-122]. In addition, a VEGF-
like effect is possible since VEGF 165 is a natural ligand for NRP1 [123-124]. Finally, the
antiangiogenic properties of iRGD could lead to the normalization of tumor vasculature via
blockade of NRP1- and integrin-mediated signaling [125].
1.4 Tools for siRNA delivery
While RNA interference is an extremely powerful discovery tool to interrogate gene
function and identify novel pathways in mammalian systems, the development of RNAi-based
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clinical therapeutics is fraught with challenges in delivery [5]. Over the years, a large array of
tools has been developed to improve the drug-likeness of siRNA, either through chemical
modifications or the deployment of carrier systems that chaperone siRNA payloads to their in
vivo destinations. To date, a diverse set of biomaterials have been investigated including
liposomes, proteins, polymers, and peptides [126-129] (Figure 1.4). This section will focus on
the design of chemically-modified siRNAs and development of siRNA delivery systems.
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Figure 1.4. Tools for siRNA delivery. (A) siRNA molecules are modified with lipohilic moieties such
as cholesterol to extend in vivo stability and half-life. (B) siRNA chemically linked to aptamers (blue)
that target specific molecular targets allows cell type-selective delivery. (C) PEGylated liposomes made
of cationic or neutral lipid bilayers can encapsulate siRNAs in the interior. (D) Lipid-like molecules,
such as the 98N12-5 lipidoid, can form nanoparticles with siRNA. (E) Antibodies fused to positively-
charged proteins such as protamine can target cells expressing specific receptors and deliver siRNA into
the cytosol. (F) Polymers such as cyclodextrin-containing polymer (CDP) can be formulated with PEG,
targeting moieties, and siRNA payloads via self-assembly for cancer-targeted delivery.
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1.4.1 Chemical modifications
Chemical modifications of siRNA have been employed to improve stability and
sequence-specificity. siRNAs are susceptible to degradation by endo- and exo-nucleases that are
present in the serum. To improve serum stability, 2'-modifications have been applied to the sugar
moieties to confer resistance against endonuclease activity [75]. Moreover, phosphorothioate
backbone linkages in the 3'-end of the guide strand reduced susceptibility to exonuclease-
mediated degradation [130]. To extend the in vivo half-life and improve tissue biodistribution,
conjugation of lipophilic moieties to the termini of the passenger strand of RNA duplexes have
been reported. Cholesterol-conjugated siRNAs can associate with LDL and hijack lipid
trafficking pathways to target hepatocytes [131]. Delivery of siRNA targeting apolipoprotein B
(apoB) in mice reduced circulating levels of apoB by up to 70% and total cholesterol levels by
40% [132]. Extending on these results, it has been demonstrated that diverse lipophilic moieties
including long saturated fatty acids (stearoyl, C18; and docosanyl, C22), but not short chain fatty
acids, can be conjugated to siRNA to enhance the knockdown of apoB in vivo.
While this discovery represents an important step forward, the large dose (50 mg
siRNA/kg) required makes it too costly for clinical translation. One approach to reduce the dose
of siRNA is by targeting the delivery of siRNA to the diseased organ. Aptamers,
oligonucleotides composed of either ssDNA or ssRNA (20-40), recognize specific proteins
owing to its unique three-dimensional structure and can be incorporated into the siRNA
sequence. Using a screening process known as systematic evolution of ligands by exponential
enrichment (SELEX), aptamers with exquisite specificity and high binding affinity to a select
molecule can be isolated [133]. Aptamer-siRNA chimeras targeting the prostate-specific
membrane antigen (PSMA) suppressed the growth of prostate tumor xenografts in mice [102,
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127]. Elsewhere, siRNA-conjugated aptamers targeting either HIV proteins or CD4 cells
inhibited HIV viral replication and disease transmission in humanized mice [134].
1.4.2 Lipids
Nanomaterials made of lipids and/or lipid-like molecules have been employed as drug
delivery vehicles in the clinic [135]. Liposomes are attractive delivery vehicles because they are
biocompatible, non-immunogenic, and versatile in encapsulating both hydrophilic and
hydrophobic drugs [136]. The liposomal doxorubicin (Doxil) showed significantly reduced
cardiotoxicity and has been approved for clinical treatment of ovarian cancer, multiple myeloma,
and AIDS-related Kaposi sarcoma. Liposomes have been utilized to delivery nucleic acids in
mouse models as well as in humans [137-138]. Stable nucleic acid-lipid particles (SNALPs)
carrying siRNA against apoB suppressed ApoB expression in the liver of primates [139].
Toxicity studies indicated little to no toxicity observed in the animals, and Tekmira
Pharmaceuticals is conducting Phase I trials using SNALPs in patients with primary liver cancers
or liver metastases. To expand the chemical diversity of lipids, high-throughput combinatorial
methods have been developed to synthesize structurally-diverse lipid-like materials ("lipidoids")
[126]. Lipidoids provide a promising approach to knock down target genes in hepatocytes, such
as factor VII, in the liver of mice, rats, and primates. More recently, lipidoid-mediated silencing
of the chemokine receptor 2 (CCR2) in inflammatory monocytes was efficacious in controlling
inflammation in diverse pathological processes ranging from atherosclerosis to cancer-associated
inflammation [140]. Elsewhere, liposomes have been endowed with targeting moieties to direct
them to specific cells. Liposomes coated with antibodies targeting P7 integrins suppressed
inflammation in an animal model of colitis [141]. Furthermore, targeting with vitamin A was
able to target activated stellate cells in the liver to reverse liver fibrosis [142].
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While initial preclinical results have been promising, evidence suggested that cationic
lipids can stimulate the immune system [143]. For example, while SNALPs carrying siRNAs
targeting the polymerase gene of Ebola protected guinea pigs against viraemia, activation of
interferon-a and interferon-p was also observed [144]. To minimize charge-mediated
immunostimulatory effects, neutral 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC)
liposomes have been employed for tumor-targeted siRNA delivery [145-146]. Compared to
conventional cationic systems, neutral liposomes deliver 10- to 30-fold higher siRNA payloads
into target cells likely owing to improved biodistribution. Systemic delivery of DOPC liposomes
carrying siRNAs targeting genes overexpressed in melanoma, such as the thrombin receptor
protease-activated receptor-I (PAR-]), led to significant reductions in tumor growth and
metastasis [147]. Elsewhere, liposome-mediated delivery of siRNA suppressed genes involved in
ovarian tumorigenesis (IL-8, SIK2 and EphA2) in human ovarian cancer xenografts [147-150].
1.4.3 Proteins
Since the backbone of the RNA duplex is negatively charged, a cationic protein can
condense siRNAs into nanoparticles. Several realizations using naturally-occurring and
engineered proteins have been achieved. Antibodies targeting the HIV envelope protein gp 160
were fused to the protamine, a class of arginine-rich nuclear proteins, and resulted in gene
silencing in a cell type-selective manner in mouse models of HIV and melanoma [128]. More
recently, RNA-binding proteins known as dsRNA Binding Domains (DRBD) has been utilized
in conjunction with the TAT protein transduction domain for siRNA delivery. TAT-DRBD
chimeras induced potent RNAi response in difficult-to-transfect cell lines such as T cells,
primary human umbilical vein endothelial cells (HUVECs) and human embryonic stem cells
(hESCs), with minimal innate immune response and no detectable cytotoxicity [151]. Separately,
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efforts in protein engineering have led to the development of novel proteins tailored for gene
delivery applications. One approach applied protein resurfacing techniques to mutate non-
conserved residues on GFP without abolishing structure or function. The resulting
"supercharged" GFP contained a +36 net positive charge, avidly complexed with nucleic acids,
and delivered payloads to suppress gene expression in a variety of mammalian cell lines [152].
1.4.4 Polymers
Cationic polymers can also bind nucleic acids and form nanometer-sized particles
amenable for transfection. Chitosans are attractive due to their cationic charge, biodegradability,
biocompatibility, and permeability-enhancing properties. By optimizing the formulation
conditions and polymer structure, chitosan was effective in delivering siRNA via intranasal or
intravenous administration in animal models [153-154]. Separately, atelocollagen, a type I
collagen from trypsin-digested bovine dermis, has been used to deliver siRNA with low toxicity
and immunogenicity [155].
While naturally occurring polymers have shown promise, synthetic polymers offer the
advantage that they can be precisely engineered for specific applications. Poly (ehyleneimine)
(PEI) has been utilized to delivery nucleic acid-based drugs [156]. The excess tertiary amines on
the PEI side chains can act as proton sponges while inside the endosomal compartment, thereby
increasing the influx of chloride and water that ultimately ruptures the endosome. Additionally,
PEI can be modified with targeting ligands such as RGD peptides to enhance its affinity for the
tumor vasculature [157]. Unfortunately, PEI bearing a high degree of branched amines is non-
biodegradable and has high cytotoxicity, thereby limiting its clinical utilization.
Cyclodextrins are polymers bearing a cyclic backbone based on glucose moieties that
spontaneously assemble with siRNA into sub-100nm nanoparticles. Cyclodextrin-containing
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polycation (CDP) systems bearing transferrin-coupled PEG have been shown to be efficacious in
a mouse model of metastatic Ewing's sarcoma by delivering siRNAs against the EWS-FLI]
fusion gene [158]. A similar system containing siRNAs against ribonucleotide reductase M2
subunit (RRM2) is currently being tested in patients with refractory solid tumors. Preliminary
results indicated that the treatment is well-tolerated and knockdown is observed in tumor
biopsies [159]. However, preclinical biodistribution data for CDP-based systems is poor and
efforts to improve the intratumoral accumulation of siRNA payloads are needed.
1.4.5 Cell-penetrating peptides
Cell-penetrating peptides (CPPs, also known as Protein Transduction Domains) are short
cationic or amphipathic peptides that can cross the cell membrane. Well-characterized CPPs
include the peptide fragment derived from the 48-60 amino acid residues of the HIV TAT
protein, antennapedia homeotic transcription factor derived peptide Penetratin, Herpes simplex
virus protein VP22, a fusion of the neuropeptide galanin and mastoparan (Transportan), and
synthetic poly-Arginines [160-161]. CPPs can be chemically linked to 5' thiol-containing siRNA
via a disulfide linkage. Penetratin and transportan conjugated to siRNAs using this method have
shown in vitro efficacy [162]. However, it is unclear whether the active component of siRNA
delivery is indeed CPP-siRNA conjugates, since charge-neutralization by siRNA could
theoretically abrogate cell internalization [1631.
Alternatively, CPPs can complex with siRNA non-covalently to form stable
nanoparticles. For example, TAT-derivatized proteins have been shown to deliver siRNA into
primary and transformed cells, with minimal off-target effects and low cytotoxicity [151]. Poly-
Arginine derivatives, such as cholesteryl oligo-D-nonaarginine (Chol-R9), are capable of
simultaneously binding siRNAs and interacting with hydrophobic membrane lipids. Chol-R9
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mediated delivery of VEGF-siRNA decreased the growth of tumor xenografts after intratumoral
injection [164]. Recently, a rabies virus glycoprotein-derived peptide modified with poly-
Arginine's was able to cross the blood-brain barrier, deliver siRNA to neurons in vivo, and
protect mice from lethal encephalitis infection [165-166]. Elsewhere, amphipathic CPPs
containing pH-titratable moieties, such as CADY and PepFect6 [167-168], have been shown to
package siRNA into stable nanoparticles and trigger proton-sponge effects to aid in endosomal
escape. However, all CPPs share the common feature of ubiquitous cell internalization: they are
not cell-selective and translocate across the membrane of nearly all cell types in vitro and in vivo
[151]. As a result, their translational potential for tumor-specific delivery is inherently limited.
In sum, since the discovery of RNA interference in mammalian cells in 2002, a wide
array of systems for delivering siRNA have been developed [43]. The power of inhibiting the
function of any gene using systemically administered siRNAs, especially ones that are
undruggable by small molecule- or antibody-based approaches, will represent a paradigm
shifting advancement in medicine. Furthermore, the added ability to amplify tumor parenchymal
delivery of therapeutics using CendR peptides such as iRGD and LyP- 1 could further enhance
drug efficacy. With the explosion of genomics data and identification of novel oncogenes, a
tumor-penetrating platform to target those lesions would be tremendously powerful. In this
thesis, we develop a modular siRNA delivery system that overcomes the challenge of
transporting therapeutics into the tumor parenchyma. Specifically, the system integrates the
tumor specificity and tissue-penetrating abilities of CendR peptides with membrane penetration
properties of canonical protein transduction domains. Using this system, siRNA therapeutics
extravasated into the tumor interstitium, induced potent gene silencing, and suppressed the
growth of disseminated ovarian tumors in mice.
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1.5 Thesis Aims
The overall goal of the thesis is to develop an integrated platform for the in vivo
discovery and validation of cancer targets, by combining novel nanomaterials for siRNA
delivery with systematic efforts to identify essential genes in cancer cells. First, we developed
versatile surface chemistries to target nanoparticles in vivo. We designed tandem peptides
bearing membrane-translocation and CendR tumor-penetration motifs to act as tumor-specific
siRNA carriers. We investigated the utility of the delivery system through the integrated
interrogation of essential genes identified from whole-genome studies of human cancers. Finally,
we extended the system to primary samples from ovarian cancer patients for clinical translation.
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Figure 1.5. Schematic for Aim 1. (A) 'Click' attachment of LyP- 1 onto iron-oxide nanoparticles for
tumor targeting in vivo. (B) Screening of tandem peptides bearing cell-penetrating domains and a fixed
cyclic tumor-penetrating domain (LyP- 1, red) for delivery of siRNA in a cell type-specific fashion.
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In Aim 1, we described the development of tumor-targeted and tissue-penetrating
nanomaterials (Figure 1.5). We developed conjugation chemistries based on the "Click" reaction
for attachment of LyP- 1 peptides onto the surface of nanoparticles. To develop a system for
siRNA delivery, we designed a library of tandem peptides bearing distinct cell-penetrating
domains and LyP- 1 as the tumor-penetrating domain. Upon complexation with siRNA, the
resulting tumor-penetrating nanocomplexes (TPN) were taken up by tumor cells in a receptor-
specific manner. TPN extended the circulation time of siRNA, protected them from degradation,
and improved their tumor accumulation and tissue parenchymal targeting.
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Figure 1.6. Schematic of Aim 2. An integrated platform enables high-throughput genomic discovery and
rapid in vivo credentialing of cancer genes. Analyses of cancer genomes nominate candidate genes that
are amplified and essential. The application of TPN for siRNA delivery overcomes the in vivo validation
barrier (dotted line) by credentialing candidate genes and discover their mechanism of transformation.
This will establish novel therapeutic targets to ultimately benefit patients.
In Aim 2 of the thesis, we explored the utility of the TPN system as a platform for
credentialing cancer targets (Figure 1.6). Integration of approaches that enumerate the structural
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alterations in ovarian cancer genomes with technologies that identify genes essential for cancer
provided a list of genes that are amplified and essential in ovarian cancer. In particular, the helix-
loop-helix transcriptional regulator, ID4, was recurrently amplified in over 30% of primary
ovarian tumors and essential for ovarian cancer cell lines. To validate ID4 as a target amenable
to therapeutic intervention in vivo, we applied TPN carrying siRNA targeting ID4 to mouse
models of ovarian cancer. Knockdown of ID4 suppressed the growth of aggressive tumors and
improvement in overall survival. The versatility and modularity of the TPN system was
investigated by targeting additional undruggable genes in ovarian cancer, including the tight-
junction protein Claudin-3 (CLDN3), and the 19S proteasome regulatory complex PSMC2.
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Figure 1.7. Schematic of Aim 3. Mechanistic studies to characterize pathways by which TPNs deliver
siRNA payloads into select cancer cells. (A) Biophysical structural characterization of TPNs. (B)
Quantitative analysis of TPN uptake in cancer cells expressing the cognate receptor, p32. (C)
Measurement of rates of siRNA escape from endosomal entrapment. (D) Quantification of siRNA
dissociation from the carrier and release into the cytosol.
In Aim 3 of the thesis, we describe the mechanism and trafficking pathways by which
TPN undertake to deliver siRNA in a cell type-specific manner (Figure 1.7). We characterized
the physiochemical and functional properties of TPN including the valence of the tumor-
penetrating ligand, the rate of endocytosis and endosomal escape, and dissociation of siRNA
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from the carrier. We employed least square regression to derive structure-activity relationships
and identified properties that favored receptor-specific siRNA delivery.
In Aim 4 of the thesis, we apply the integrated platform developed in Aims 1&2 in
clinical translational studies (Figure 1.8). First, we explored a novel strategy to achieve
sustained, high intratumoral accumulation of therapeutics by modulation of p32 receptor
expression in the tumor microenvironment. We studied the effect of localized p32 suppression on
TPN distribution in vivo. The utility of TPN delivery ofp32-specific siRNA for tumor imaging
by positron-emission tomography (PET) was also examined. Finally, the therapeutic activity of
TPN-mediated siRNA delivery is investigated in primary cells derived from the ascites fluids of
ovarian cancer patients. The generalizability of TPN targeting was also examined in a human
tissue microarray containing tumor samples from ovarian cancer patients.
Patient Fresh tumor cells Primary cancer cells
from ascites
Ovarian TMA
Figure 1.8. Schematic for Aim 4. Translational applications of the TPN system. The clinical
feasibility of TPN-mediated siRNA delivery is examined in primary patient-derived ovarian cancer
cells and ovarian tissue microarrays (TMA).
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2 A versatile surface chemistry - In vivo tumor cell targeting
with 'Click' nanoparticles
2.0 Abstract
The in vivo fate of nanomaterials strongly determines their biomedical efficacy. Accordingly,
much effort has been invested into the development of library screening methods to select
targeting ligands for a diversity of sites in vivo. Still, broad application of chemical and
biological screens to the in vivo targeting of nanomaterials requires ligand attachment
chemistries that are generalizable, efficient, covalent, orthogonal to diverse biochemical libraries,
applicable under aqueous conditions, and stable in in vivo environments. To date, the copper(I)-
catalyzed Huisgen 1,3-dipolar cycloaddition or "click" reaction has shown considerable promise
as a method for developing targeted nanomaterials in vitro. Here, we investigate the utility of
"click" chemistry for the in vivo targeting of inorganic nanoparticles to tumors. We find that
"click" chemistry allows cyclic LyP- 1 targeting peptides to be specifically linked to azido-
nanoparticles and to direct their binding to p32-expressing tumor cells in vitro. Moreover,
"click" nanoparticles are able to stably circulate for hours in vivo following intravenous
administration (> 5h circulation time), extravasate into tumors, and penetrate the tumor
interstitium to specifically bind p32-expressing cells in tumors. In the future, in vivo use of
"click" nanomaterials should expedite the progression from ligand discovery to in vivo
evaluation and diversify approaches toward multifunctional nanoparticle development.
(Reprinted (adapted) with permission from [169]. Copyright (2008) American Chemical Society)
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2.1 Introduction
The ability to target nanomaterials to precise biological locations would have wide-
ranging impact in medicine. In living systems, highly controlled transportation networks
continually shuttle payloads to and from specific molecular addresses. The efficiency of these
systems provides strong motivation for the advancement of targeted nanoparticle technologies,
particularly for the diagnosis and treatment of human diseases. Towards this goal, high
throughput strategies for ligand discovery have generated a multitude of chemical and biological
motifs with the potential to direct nanomaterials to specific biomolecular targets. However,
translation of these ligands towards in vivo nanoparticle targeting has been limited by the number
of nanoparticle attachment methods that are efficient, generalizable, aqueous-compatible,
chemically orthogonal to broad ranges of functional groups, and suitable for in vivo applications.
Previous work has demonstrated that in vivo bacteriophage display may be used to select
for peptide sequences that mimic the ability of endogenous shuttles to target vascular and
parenchymal tissue addresses [101, 170-173]. Already, linear peptide candidates of phage
screens, as well as small molecule targeting candidates, have been translated towards
nanomaterial targeting [103, 174-176], primarily via use of exogenous or non-essential thiols,
carboxylic acids, or amines. Still, some of the most powerful targeting motifs developed to date
are those that contain essential thiol, amine, and carboxyl groups, thereby prohibiting their
specific attachment via traditional methods. In particular, conformationally-constrained,
disulfide-cyclized targeting peptides are desirable for their enhanced affinity to biological
receptors [177-178], and resistance to proteolytic degradation in vivo relative to their linear
counterparts [179-180]. However, specific intramolecular cyclization makes it difficult to add
exogenous cysteine residues, while essential amines and carboxyl groups prohibit selective
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conjugation via exogenous lysine, aspartic acid, or glutamic acid residues. Additionally, non-
covalent methods of ligand attachment relying on hydrophobic or electrostatic effects, although
widely used in vitro [181-183], are unlikely to remain stable in blood or to resist rapid clearance
in vivo.
Recently, the copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition or "click" chemistry
has emerged as an extraordinarily selective chemistry and an attractive solution in applications
where commonly used thiol-reactive (maleimide, 2-pyridyldithio, iodoacetyl) or amine-reactive
(NHS, epoxy, aldehyde, EDC) chemistries are not suitable [184]. In vitro, "click" chemistry has
been utilized to generate functionalized polymers [185-187], surfaces [188-190], and
nanoparticles [191-199], and meets the criteria for broad utility in nanoparticle functionalization
(chemical orthogonality, aqueous efficiency, applicability for diverse substrates). However the
use of "click" nanoparticles for in vivo applications has not been investigated. Particularly, as
opposed to small molecule reagents with circulation times on the order of minutes [176], ligand
attachments on long circulating nanomaterials must remain stable against in vivo degradation for
hours while nanoparticles circulate systemically and identify molecular targets.
Here, we find that alkyne-azide "click" chemistry provides a facile, single-step method
for specifically linking the cyclic tumor-targeting peptide LyP-1 (CGNKRTRGC; [101, 200]),
which contains essential thiol and amine groups, to polymer-coated magneto-fluorescent
nanoparticles. LyP- 1 binds to p32, a mitochondrial proteins that is both overexpressed and
aberrantly localized at the cell surface of tumor cells, macrophages and lymphatic endothelial
cells in certain experimental tumors and in human cancers [201-202]. We find that "click" LyP- 1
nanoparticles are able stably traverse the systemic circulation, extravasate into tumors, and
penetrate the tumor interstitium to specifically bind to receptors on p32-expressing cells in the
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tumors. Together, these results provide strong motivation for future use of "click"
functionalization as a strategy for developing nanoparticles for in vivo biomedical applications
(Figure 2.1).
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Figure 2.1. Design of a "click" nanoparticle that targets tumor cells in vitro and in vivo. Cross-
linked, fluorescent, superparamagnetic iron oxide nanoparticles are modified to display azido-PEG
groups. Conjugation of cyclic targeting peptides (purple circles) bearing pendant alkynes to azido-PEG
nanoparticles via the copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition ("click" reaction) allows
specific targeting of the nanoparticles to cells expressing the receptor (red).
2.2 Results and Discussion
In order for "click" chemistry to be applied to the development of peptide-targeted
nanomaterials, peptides must be able to harbor pendant alkyne or azide moieties without abating
peptide activity. To investigate the efficacy of targeting peptides harboring pendant alkyne
moieties, LyP- 1 peptide and untargeted cyclic control peptide, LyP- 1 CTL (CRVRTRSGC) in
which the essential NKRTR motif is replaced with RVRTR to maintain net charge but abate p32
targeting [200], were synthesized to incorporate either of two alkyne moieties (the unnatural
amino acid propargylglycine or 6-heptynoic acid) and a 5,6-carboxytetramethylrhodamine
fluorophore (TAMRA) (Figure 2.2).
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Figure 2.2. Fluorophore-labeled LyP-1 Peptide Spectra.UV-Vis spectra forLyP-1 and LyP-lCTL
peptides synthesized with varying pendant alkyne groups (prop= propargyiglycine; Hep=heptynoic acid)
Because the alkyne moieties provide molecularly small chemical handles that may be
incorporated in FMOC synthesis to either the N- or C-terminal of essential peptide sequences,
we hypothesized their presence could be tailored to allow chemical attachment to azido-
nanomaterials without interfering with LyP-1 peptide activity. In previous investigations, we
found that N-terminal addition of visible and near-infrared fluorophores do not disrupt peptide
binding to its receptors [101, 200]. Accordingly, we reasoned alkyne moieties located near the
N-terminus would be well-tolerated by the peptide.
To verify the specificity and efficacy of alkyne-LyP- 1 targeting, 10 gM of LyP-1, bearing
either propargylglycine, heptynoic, or no alkyne group were incubated for 45 minutes on
monolayers of MDA-MB-435 human tumor cells, which have been shown to bind and
internalize LyP-1 and express p32 at the cell surface [200-201], LyP-1CTL peptides were
included as a control sequence to verify targeted enhancement of uptake over non-specific cyclic
peptide structures. Cellular uptake of LyP- 1 was quantified via flow cytometry and plotted as the
populational fluorescent intensity, relative to cells incubated with vehicle alone. In vitro targeting
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of LyP- 1 peptides bearing either propargylglycine or 6-heptyoic acid was similar to that of native
LyP- 1 and control peptides, indicating that alkyne modifications N-terminal to targeting
sequences were innocuously chaperoned by peptides and did not affect cell binding (Figure 2.3).
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Figure 2.3. Native and alkyne-bearing LyP-1 peptides target p32-expressing MDA-MB-435 cells in
vitro.(A) Structures of LyP-1, propargylglycine-LyP-1, and Heptynoic acid-LyP-1, all labeled with a
TAMRA fluorophore (red). The cyclic nonapeptide is in blue. The pendant alkyne moieties were
conjugated to the N-terminus of the peptide during standard FMOC peptide synthesis. (B) Flow
cytometry shows that peptides bearing different alkyne groups target MDA-MB-435 cancer cells
similarly, while a scrambled control (LyP-1CTL) do not target (P=propargylglycine, H=6-heptynoic acid,
*p<0.01, unpaired Student's t-test ).(C) Flow cytometry histogram shows LyP-1, P-LyP-1, and H-LyP-1
peptides (in different shades of blue) target MDA-MB-435 cells in vitro, while LyP-1CTL peptide (green)
did not show targeting relative to peptide-free control cells (red).
We next probed the effect of three variables on "click" reaction conditions between our
peptides and an azido-PEG-amine (catalyst, catalyst concentration, and reaction time). Azido-
PEG-amine was chosen to emulate the azido-PEG surface of the nanoparticles to be used
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subsequently and to provide a model reaction amenable to HPLC quantitation of product
formation. Copper(I) catalyst was added either directly as an iodinated salt (Cu(I)l), or indirectly
as soluble copper sulfate (Cu(II)SO 4 ) and reduced by sodium ascorbate in situ. The degree of
product formation was measured via HPLC with mass spectrometric verification of product
identity. The addition of the azido-PEO-amine rendered peptides more hydrophilic and decreased
retention times compared to unconjugated peptides. Product formation proceeded more
completely in the tested reaction conditions for the heptynoic acid-LyP- 1, likely due to reduced
steric hindrance provided by the extended hydrocarbon chain (Table 2.1). Optimal reaction
conditions were found to be either: 1 mM CuSO4 / 5 mM Na ascorbate or 1 mM -100 mM Cul
for 72 h. Notably, the reaction yields with 10 mM CuSO 4 levels were dramatically lower than
1mM, likely due to global precipitation of reduced Cu(I) in solution. Nevertheless, we found
1mM CuSO 4 reactions to yield more reliable conjugations than 1 to100 mM Cul reactions,
possibly because the insolubility of Cul in aqueous solutions produced variations in the amount
of available catalyst. Therefore, the optimal conditions for subsequent nanoparticle modification
were determined to be 1 mM CuSO 4 and 5 mM Na ascorbate. Under these conditions we did not
observe any reduction of peptide disulfide bonds due to copper catalyst or Na ascorbate
reduction as determined by MALDI mass spectrometry and HPLC analysis.
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Table 2.1. Optimization of the "click" reaction. The rate of product conversion in the "click" reaction
is measured as a function of product formation in HPLC. The reaction is performed in various catalysts
(CuSO4 or Cul) and concentrations, in 24h or 72h reactions, using LyP- 1 peptides bearing either
propargylglycine or 6-heptynoic-acid.
Catalyst type [mM]
CuSO4 [1 mM]
CuSO4 [1 mM]
CuSO4 [10 mM]
CuSO4 [10 mM]
Cul [1 mM]
Cul [1 mM]
Cul [10 mM]
CuL [10 mM]
Cul [100 mM]
Cul [100 mM]
No Catalyst
Click reaction
time (h)
24
72
24
72
24
72
24
72
24
24
72
Propargylglycine-
LyP-1
44%
80%
0%
0%
70%
76%
68%
77%
75%
79%
0%
Heptynoic Acid-LyP-
1
48%
82%
0.5%
13%
70%
95%
76%
100%
83%
89%
0%
Having verified that alkyne-bearing LyP- 1 peptides could effectively target p32-
expressing MDA-MB-435 cancer cells and become linked to azido-bearing PEG polymers, we
next developed a protocol for linking these peptides onto azido-PEG bearing, near-infrared
fluorochrome-labeled (VivoTag 680) iron oxide nanoparticles. Dextran-caged iron oxide
nanoparticles were used as the parent formulation to provide a highly stable, relatively non-
cytotoxic, and in vivo-tested nanoparticle scaffold. Briefly, a heterobifunctional linker bearing an
azide on one end an N-hydroxysuccinimide leaving group on the other was synthesized and
attached to an amine-PEG-thiol polymer (MW 50000 Da) via its terminal amine.
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Azido-PEG-thiol polymers were subsequently linked to surface of cross-linked, aminated,
fluorochrome-labeled, and dextran-coated iron oxide nanoparticles via the linker N-[y-
maleimidobutyryloxy] succinimide ester (GMBS) (Figure 2.4). Long PEG polymers were
utilized to carry pendant azide groups in order to enhance particle circulation time in vivo and to
provide a generalizable nanoparticle surface, whereby optimized "click" attachment conditions
might be applicable to other PEG-coated organic and inorganic nanomaterials in the future.
Azido-PEG particles were purified from excess polymer and linked to alkyne-bearing peptides in
1 mM CuSO4 , 5 mM Na ascorbate. Finally, the conjugated nanoparticles were purified and
sterile filtered forin vitro and in vivo applications.
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Figure 2.4. Synthesis of LyP-1-coated nanoparticles using "click" chemistry. (A) Synthesis of
Succinimidyl 4-azidobutyrate. (B) Synthesis of azide-PEG-thiol by linking Succinimidyl 4-azidobutyrate
to a 5kDa thiol-PEG-amine. (C) Aminated, cross-linked, fluorochrome-labeled superparamagnetic iron-
oxide nanoparticles are activated with GMBS, filtered, and then reacted with the thiol-PEG-azide from
(B) to yield azido-PEG bearing nanoparticles. After purification, the particle solutions were reacted with
alkyne-bearing LyP- 1 peptides with CuSO 4/Na Ascorbate as catalysts to yield LyP- 1-coated nanoparticles
for in vitro and in vivo use.
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Peptide valency on nanoparticles was assessed spectrophotometrically by quantifying the
number of TAMRA dyes added onto nanoparticles following "click" reaction (Figure 2.5). In
the presence of catalyst, approximately 30 peptides were added per nanoparticle for both LyP- 1
and LyP- 1 CTL peptides, whereas no addition was observed in the absence of catalyst. LyP- 1
nanoparticles, LyP-1CTL nanoparticles, or azide nanoparticles were incubated over MDA-MB-
435 tumor cells for 2 hours and nanoparticle accumulation was quantified using flow cytometry.
LyP- 1 -nanoparticles showed significant tumor cell accumulation, while LyP- 1 CTL-nanoparticles
or azide-nanoparticles displayed minimal cell uptake (Figure 2.6). The effect of serum on
nanoparticle uptake was also studied, as low serum levels enhance the stress-induced expression
of the p32 receptor [200]. The slight increase in LyP-1-nanoparticle targeting in lower serum
levels provided further validation of receptor-specific targeting, as decreased serum protein
concentrations lowers the likelihood of non-specific serum protein mediated uptake (Figure 2.6).
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Figure 2.5. Spectrophotometric characterization of Click nanoparticles. The amount of peptide
bound per particle was quantified spectrophotometrically by measuring the absorbance of the TAMRA
dyes added following the click reaction. With the addition of catalyst CuSO 4/Na ascorbate (dark
circles), the TAMRA absorbance at 555nm was quantified to equal approximately 30 peptides per
particle, whereas no TAMRA signal was observed without catalyst (light circles).
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Figure 2.6. LyP-1-conjugated nanoparticles target p32-expressing MDA-MB-435 cells in vitro,
while nanoparticles conjugated to control cyclic peptides (LyP-1CTL) do not target. (A) LyP-1-
nanoparticles or control LyP-1CTL-nanoparticles (both at -30 peptides per particle), or parent azido-
bearing particles (N3), were added to MDA-43 5-MB cancer cells in normal 10% serum (dark green) and
0.1% serum-starved (light green) conditions. (B) Flow cytometry histogram shows marked increase in
uptake of LyP-1 -nanoparticles (blue) vs. LyP-ICTL-nanoparticles (green) and particle-free control cells
(red). Each error bar represents 6 parallel experiments.
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Figure 2.7. Effects of LyP-1 peptide on the cellular uptake of Click nanoparticles. Addition of free
LyP-1 peptides at concentrations from 10 to 100 uM inhibited cellular uptake of LyP-1-coated
nanoparticles, suggesting that the LyP-1 peptide and LyP- 1-labeled particles target the same receptor.
To further confirm the uptake specificity of LyP- 1 -nanoparticles, free LyP- 1 peptide was
added to cells along with LyP-1-particles. Dose-dependent inhibition of uptake was observed
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with LyP- 1 peptide concentrations from 10 to 100 .M, suggesting the free LyP- 1 and LyP- 1-
labeled particles share common cellular receptors (Figure 2.7). We attribute the large excess of
free peptide required for inhibition compared to the concentration of nanoparticles used (100
nM) to the presence of multiple copies of the LyP- 1 peptide on each nanoparticle, thus
improving nanoparticle avidity to receptors through polyvalent binding [203].
In order to visualize LyP- 1 peptide-mediated cell uptake, nanoparticles bearing LyP- 1
peptides, control LyP-1CTL peptides, or azides were incubated over MDA-MB-435 cells and
imaged via epifluorescence microscopy (Figure 2.8). LyP- 1 -nanoparticles were seen associated
with cells, while markedly less binding of azide-bearing or control peptide-bearing nanoparticles
was not observed. If the same staining procedure was instead performed at 24 hrs post
incubation, LyP- 1 -nanoparticles were seen in punctate locations consistent with sequestration in
endosome-like compartments (Figure 2.9). To assess the cytotoxicity of "click" nanoparticles,
NH 2-PEG-, azido-PEG- and peptide-conjugated nanoparticles were incubated for 24hrs of
incubation above HeLa cell cultures. In all three formulations, the TC50 is >7mM Fe, or over 16
times higher than maximal blood concentrations during in vivo experiments performed here and
32 times higher than concentrations used in vitro here (Figure 2.10).
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LyP-1CTL-Nanoparticles
Figure 2.8. Tumor cell targeting with LyP-1 nanoparticles. LyP-1-nanoparticles target MDA-MB-435
cancer cells (right). Fluorescence imaging of cells incubated with LyP-1 -nanoparticles showed increased
near-infrared fluorescence (red). Uptake of azido-bearing or scrambled control peptide (LyP-1CTL)-
bearing nanoparticles are not visible or show minor background (left and middle).
Figure 2.9. LyP-1-nanoparticles target MDA-MB-435 cancer cells and become localized in
endosome-like compartments. Cells were incubated with LyP-1-nanoparticles for 30min, washed,
and incubated for 24hrs before nuclear staining and imaging. PEG-LyP-1 nanoparticles no longer
show diffuse membranous staining, but have become localized into punctuate compartments, implying
endosomal sequestration away from cell surface
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Figure 2.10. Probing "Click" Nanoparticle Cytotoxicity to Human Cell Cultures. Human HeLa
cervical cancer cells were incubated with parent NH2-PEG-NPs, PEG-N3-NPs, or PEG-LyP-1CTL-NPs
at varying concentrations for 24 hrs. Quantitaion of cellular viability showed that all three NP peparations
have TC50 values of greater than 7mM, which is over 35-times that used in vitro here and greater than
sixteen times the maximum blood concentrations during in vivo experiments.
Having found that "click" attachment of homing peptides mediated nanoparticle targeting
in vitro, we evaluated the ability of "click" chemistry to direct nanoparticles to specific tumor
cells in vivo. Again, near-infrared fluorochrome-labeled (VivoTag 680) nanoparticles were
"clicked" to LyP-1 peptides, resulting on average of~-30 LyP-1 peptides per particle, while the
parent azido-PEG nanoparticles were used as a negative control. Each population of
nanoparticles was injected i.v. into mice bearing MDA-MB-435 melanoma xenografts.
Nanoparticles were allowed to circulate in mice for 24 hrs, after which the mice were sacrificed
and organs collected for immunohistochemical or whole organ fluorescence analysis. Vascular
staining with anti-CD31 antibodies showed that azide nanoparticles in tumors remained localized
within the immediate periphery of blood vessels. This perivascular distribution of untargeted
nanomaterials is in agreement with previous histological and intravital observations of passive
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liposomal accumulation in tumors [204-205]. By contrast, LyP- 1 "click" nanoparticles appeared
to have extravasated from the tumor vasculature, penetrated into the interstitial space of the
tumor, and bound to p32-expressing cells (Figure 2.11).
As a result, the fraction of LyP-1 nanoparticles that get sequestered beyond the
perivascular space was significantly higher than that of azido-nanoparticles (Figure 2.12)
(P<0.005). This pattern was observed in all injected mice and is characteristic of LyP- 1 peptide
and phage homing observed previously [101]. Interestingly, previous LyP-1 bacteriophage
experiments showed that the LyP- 1-expressing phage concentrate in non-vascularized sites of
tumors within minutes after injection while insertless phage do not reach these regions [101].
Thus, there may be unique transportation pathways within tumors that are exploited by this
ligand after extravasation that are not available to untargeted materials. In the future, the
localization of LyP- 1 nanoparticles in avascular tumor regions may be of use for directing
therapeutics into hypoxic regions of tumors, where most nanoparticle therapies do not reach.
Whole organ assessment of near-infrared tumor fluorescence demonstrated that, despite
the distinct microscopic behavior of LyP-1 nanoparticles, the macroscopic tumor accumulation
of LyP-1 nanoparticles and PEG-azide nanoparticles was similar (Figure 2.13), indicating that
the targeted accumulation of LyP- 1 -nanoparticles was on par with passive delivery, whereby
long-circulating materials accumulate in tumors via their hyper-porous vasculature over time
[206-207]. These results are in accordance with data showing that the development of targeted
nanoparticle formulations that amplify the macroscopic accumulation in tumors requires
systematic in vivo optimization of multiple material parameters, including target avidity,
circulation time, and particle size [129, 208]. Experiments of this kind are ongoing in order to
probe the power of the LyP- 1 targeting ligand for amplifying the accumulation and efficacy of
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nanoparticle-based imaging and therapeutic agents.
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Figure 2.11. "Click" LyP-1-nanoparticle targeting to tumor cells in vivo. Nanoparticles bearing only
azide groups (top) or labeled with LyP-1 peptides (bottom) that are matched in circulation time were
injected intravenously via the tail vein into mice bearing human MDA-MB-435 cancer xenografts.
Histological sections were obtained 24 hours post injection. (A) Light reflectance images of tumor
xenografts. (B) Fluorescent LyP-1-nanoparticles (green) did not co-localize with CD31, a blood vessel
marker (red) while untargeted azide-PEG nanoparticles remained localized to the blood vessels or their
immediate periphery. (C) LyP-1-nanoparticles (green) accumulated in regions of high p32 expression
(red), whereas untargeted, azido-bearing nanoparticles did not accumulate in these areas.
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Figure 2.12. Quantification of "Click" LyP-1-nanoparticle targeting to tumor cells in vivo.
Histological quantitation using CD31 stain to assess nanoparticle localization to immediate periphery
of blood vessels. (A) The fraction of LyP-1 nanoparticles outside of the perivascular space of CD3 1-
stained blood vessels is significantly higher than (B) azido-nanoparticles (P<0.005) as assessed from 3
randomly chosen views in each set of mice (n=3).
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Figure 2.13. Near-Infrared Fluorescence Analysis of Nanoparticle Accumulation. Near-infrared
fluorochrome-labeled nanoparticles bearing terminal azide (red) or LyP-1 (blue) were injected i.v.
into mice bearing MDA-MB-435 melanoma xenografts. After 24 h, tumor, liver, spleen, and kidneys
were fluorescently imaged for nanoparticle accumulation.
2.3 Conclusions
In this work, we have demonstrated that "click" chemistry may be used to develop
nanoparticles that seek out specific cells in vivo based on their surface expression of protein
markers. Ultimately, these findings suggest that "click" chemistry meets the criteria of being
applicable under aqueous conditions, efficient, orthogonal to thiol- and amine-containing
targeting motifs, and stable in the complex in vivo environments of the blood and tumor milieu.
In the future, this work may empower the development of "click" nanomaterials that seek out
specific tumor cell types, including tumor stem cells and angiogenic endothelial cells, or amplify
the macroscopic accumulation of imaging agents or therapeutics in tumors. Further, the
modularity of this "click" attachment strategy should allow it to be adapted to a diversity of in
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vivo nanoparticle platforms and both biological and synthetic ligands, potentially empowering
novel on-nanoparticle screen approaches to targeted nanomaterial development.
2.4 Materials and Methods
Unless otherwise stated all reagents were purchased from Sigma-Aldrich and all reactions were
performed at room temperature.
Iron-oxide nanoparticle synthesis. Cross-linked, aminated, fluorescent, superparamagnetic iron oxide
nanoparticles were synthesized according to the published protocol [209-2 10]. Briefly, dextran-coated
iron oxide nanoparticles were synthesized, purified, and subsequently cross-linked using epichlorohydrin.
After exhaustive dialysis, particles were aminated by adding 1:10 v/v ammonium hydroxide (30%) and
incubated on a shaker overnight. Aminated-nanoparticles were subsequently purified from excess
ammonia using a Sephadex G-50 column and concentrated using a high-gradient magnetic-field filtration
column (Miltenyi Biotec). The near infrared-fluorochrome VivoTag 680 was added to remotely detect
particle accumulation in vitro and in vivo by reacting in 0. 1M HEPES buffer with 0.1 5M NaCl at pH 7.2.
DMSO-solubilized fluorochromes were added into particle solutions at 4'C under mixing and allowed to
warm to room temperature to react for 2 hours. The yield was approximately 10 fluorochromes per
nanoparticle for all experiments.
Succinimidyl 4-azidobutyratesynthesis.
Ethyl 4-azidobutyrate (1). To a solution of ethyl 4-bromobutyrate (5.85 g, 30 mmol) in dimethyl sulfoxide
(DMSO, 20 ml), sodium azide (2.925 g, 45 mmol) was added with stirring. The reaction mixture was
stirred for 22 h at 55 0C, and cooled to room temperature. Water was added to the reaction mixture and
extracted with ethyl ether (3 x 30 ml). Combined organic layer was washed with water and brine, and
reduced in vacuuo to afford 3.80 g of the azido compound 1.
4-Azidobutyric acid (2). Ethyl 4-azidobutyrate 1 (3.14 g, 20 mmol) was dissolved in aqueous sodium
hydroxide solution (1 N, 24 ml) with minimum amount of methanol to make the solution homogeneous.
The reaction mixture was stirred for 3 hrs at room temperature. After removal of methanol in vacuo, the
aqueous solution was acidified to pH 0 with HCI and extracted with ethyl ether (3 x 50 ml). The ether
layer was then dried over sodium sulfate and filtered. Removal of solvent gave the acid 2 (2.25 g).
Succinimidyl 4-azidobutyrate (3). To a solution of N-hydroxyl succinimide (1.65 g, 14.3 mmol) in
methylene chloride (100 ml) was added acid 2 (1.68 g, 13 mmol) followed by 1-Ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride (EDAC, 2.74 g, 14.3 mmol). After stirring for 4 h at
room temperature, the mixture was washed with water and brine, dried over sodium sulfate, and filtered.
Solvent was removed under reduced pressure to yield 1.15 g of the succinimidyl 4-azidobutyrate 3.
Peptide synthesis. Peptides were synthesized in the MIT Biopolymers Lab and their composition was
confirmed via HPLC and mass spectrometry. The LyP- 1 and LyP- 1 CTL peptides were synthesized with
either heptynoic acid or propargylglycine at the N-terminus for conjugation. Each peptide is also labeled
with a TAMRA fluorophore (Anaspec) via a lysine residue separated by an aminohexanoic acid (Ahx)
spacer. (LyP-1: Heptynoic acid or propargylglycine - K(Tamra)[Ahx] - CGNKRTRGC; LyP-lCTL:
Heptynoic acid or propargylglycine - K(Tamra)[Ahx] - CRVRTRSGC). Peptides were cyclized by
bubbling air into 10 pM aqueous peptide solutions overnight and lyophilized for subsequent use.
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"Click" attachment of peptides to nanoparticles. Succinimidyl 4-azidobutyrate was linked to 5kDa
thiol-PEG-amine polymers in 0. 1M HEPES 0. 15M NaCl pH 7.2 for 1 hour at a 2:1 molar ratio between
linker and polymer. Simultaneously, amino-modified, fluorochrome-labeled nanoparticles were activated
with N-[y-maleimidobutyryloxy] succinimide ester (GMBS) (dissolved in DMSO) cross-linker under
similar conditions at a 200:1 molar ratio between cross-linker and nanoparticles. To remove excess
GMBS, nanoparticle samples were filtered on a G50 column into 50mM Na Phosphate buffer at pH 7.2
supplemented with 10mM EDTA. Purified nanoparticles were then combined with the polymer reaction
mixture and allowed to react at room temperature overnight. Azido-PEG-nanoparticles were then purified
from excess polymer and succinimidyl 4-azidobutyrateon a size exclusion column (ACA-44 media: Pall)
into 0.1 M HEPES pH 7.2 buffer. Finally, the azide-PEG-bearing particles were concentrated using
Amicon Ultra-4 (Millipore) filters and stored at 4'C.
To optimize catalyst concentrations for the "click" reaction by HPLC, a 10-fold excess of azido-
PEG-NH2 or O-(2-Aminoethyl)-O'-(2-azidoethyl) pentaethylene glycol (Polypure) was added to a 100
ptM peptide solution. CuSO4 and Na ascorbate were dissolved in H2 0 and added to the reaction mixture to
final concentrations of 1 mM/5 mM and 10 mM/50 mM CuSO4/Na Ascorbate. This mixture was shaken
at 37 0 C for various times (1 day to 3 days), after which it was characterized via HPLC.
Alkyne-bearing peptides (35:1 peptide:nanoparticle molar ratio), CuSO 4 (1 mM), and sodium
ascorbate (5 mM) in H20 were added to a solution of particles and the mixture was shaken at 370 C for 48
h. Following the reaction, nanoparticles were purified from copper catalyst and excess peptides by
filtration in ACA-44 size exclusion media into 0. 1M HEPES 0. 15M NaCl pH 7.2 buffer.
Cell culture. Cell uptake experiments were performed using a human MDA-MB-435 cancer cell line.
Grow media was minimum essential medium eagle (Invitrogen) with fetal bovine serum (10%;
Invitrogen). Cells were passaged into 96-well plates and used at 60-80% confluency.
For peptide uptake experiments, LyP- 1 or LyP- 1 CTL peptides were added to cell monolayers in serum-
containing media at a final concentration of 10 ptM. After 45 minutes of incubation at 37 'C, cells were
washed for flow cytometry (BD LSRII). Fluorescence data on 10,000 cells was collected for each sample.
For nanoparticle uptake, particles bearing LyP-1, LyP- 1 CTL, or terminal azides were added to the
cells. After 2 h of incubation, cells were trypsinized and assayed for particle fluorescence by flow
cytometry. For peptide inhibition experiments, free LyP-1 peptides (10 pM to 100 pM) were first
incubated with the cells for 1 h. The cells were then washed and 100 nM of LyP-1 -coated nanoparticles
were added to the cell culture. For imaging, cells were observed using a 20x objective. Images were
captured with a CCD camera mounted on a Nikon TE200 inverted epifluorescence microscope.
In vivo studies of nanoparticle targeting. Nude athymic mice were inoculated subcutaneously with
human cancer cells (MDA-MB-435). After tumors had reached -. 5 cm 3 in size, LyP-1 - and azide-bearing
nanoparticles were injected intravenously in the tail vein (1mgFe/kg). Twenty-four hours after the
injection, tumor tissues were excised, snap frozen, and cut into 15 ptm histological sections. Rat anti-
mouse CD-31 (1:50, BD Pharmingen) and polyclonal anti-p32 antibody (1:200; [201]) were used for
immunohistochemical staining of frozen tissue sections. The corresponding secondary antibodies were
added and incubated for 1 hour at room temperature: Alexa Fluor 594 goat anti-rat IgG (1:500,
Invitrogen) for CD-31 and Alexa Fluor 594 goat anti-rabbit IgG (1:500, Invitrogen) for p32 antibody.
The slides were washed three times with PBS and mounted in Vectashield Mounting Medium with DAPI
(Vector Labs). The stained tumor sections were observed with a fluorescence microscope (Nikon, Tokyo,
Japan). Histological quantitation of nanoparticles localization was done using ImageJ software. Stacks of
CD3 1-stained sections and nanoparticle fluorescence images were utilized for intra- and extravascular
particle distribution quantitation. Regions with CD3 1-staining were selected to denote intravascular
accumulation of nanoparticles and surrounding areas were classified as extravascular. The net
nanoparticle fluorescence signal above background was quantified for each of these regions to determine
the approximate percent of nanoparticle fluorescence localized to the vasculature vs the extravascular
space. Three sections from each set of mice were randomly chosen for analysis.
70
3 Development of targeted tumor-penetrating nanomaterials
for siRNA delivery
3.0 Abstract
Targeted delivery of therapeutics such as siRNA may improve tumor treatment by
increasing efficacy and minimizing side effects [211]. To date, siRNA targeting to the tumor
parenchyma in vivo has been challenging due to siRNA's rapid clearance, susceptibility to serum
nucleases, endosomal entrapment, and potential for innate immune stimulation [5]. Furthermore,
nanoparticle- and antibody-based approaches have suffered from low tumor penetration and
transvascular transit, thereby limiting the applicability to tumor parenchymal targets [128, 212].
Here, we provide a unifying technology that enables the precise homing of siRNA therapeutics
deep into regions of the tumor parenchyma that express specific receptors in vivo. We report a
siRNA delivery platform that is comprised of a tandem peptide structure, linking a cyclic tumor-
penetrating homing peptide identified via in vivo phage display to a membrane-penetrating and
siRNA-binding domain. Upon non-covalent complexation with siRNA, the resulting
nanocomplex is stable, non-immunostimulatory, displays homing peptides in a multivalent
fashion, and delivers siRNA payloads to the cytosol of tumor cells expressing p32 on the surface.
Upon systemic administration into mice bearing orthotopic ovarian tumors, the nanocomplex
penetrates into the tumor parenchyma to achieve gene silencing in a receptor-specific manner.
(Adapted with permission from [213])
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3.1 Introduction
RNA interference offers an attractive means to silence gene expression with
extraordinary specificity, particularly for the subset of "undruggable" gene targets [1]. This
capability is particularly appealing for diseases with complex genotypic and phenotypic
alterations such as cancer. Still, the translation of new insights on mechanisms underlying cancer
survival into new RNA-based therapeutics has been thwarted by an inability to efficiently reach
extravascular cancer cells in vivo. Among the fundamental transport challenges that hinder the
advancement of siRNA therapeutics are the requirements that intravenously-administered siRNA
delivery vehicles extravasate in tumor blood vessels, penetrate into the tumor interstitium, and
subsequently translocate into specific intracellular compartments such as the cytosol in order to
be active. To date, approaches to target the delivery of siRNA in vivo have focused on
development of carriers such as antibodies [128], lipids [126], and peptides [166, 212] which
passively escape blood vessels in order to reach target cells. These advances have illustrated the
potential of siRNA delivery in filtration organs, tumor endothelial cells, and cells in close
proximity to tumor vessels in vivo, yet have shown limited capacities to efficiently deliver
therapeutics to extravascular cancer cells located throughout the tumor parenchyma in vivo.
Recent work has identified new classes of peptides using in vivo phage display that are
capable of rapidly accessing sites deep in the tumor parenchyma following intravenous injection.
Two such tumor-penetrating ligands, LyP- 1 (CGNKRTRGC) and iRGD (CRGDKGPDC), have
demonstrated the ability to deliver large macromolecules and nanoparticles with diagnostic and
therapeutic potential deep into the tumor parenchyma within minutes after intravenous injection
[117, 169]. In some cases, tumor-penetrating peptides leverage consensus R/KXXR/K C-
terminal peptide motifs (CendR) as mediators of cell and tissue penetration [117-118, 214]. This
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process has been described as 'stimulated penetration' and involves neuropilin-1 binding that
stimulates vascular permeability in a VEGF-like manner, thereby enabling rapid extravasation of
therapeutics beyond the vascular barrier and through the tumor parenchyma. Separately, in vitro
evidence has emerged that cell penetrating peptide sequences, such as TAT and poly-Arg
domains, are capable of binding siRNA and penetrating the membrane of multiple cell types to
access the cytosol [151, 215].
Here, we hypothesized that the unique functions of tumor-penetrating and cell-
penetrating peptides could be integrated into tandem peptide sequences to direct siRNAs into the
tumor parenchyma and subsequently into the cytosol of tumor cells in vivo. We report the design
of a peptide-siRNA nanocomplex containing siRNA non-covalently bound to a tandem peptide
comprised of a cyclic homing domain and a membrane-translocating domain, which targets
tumors and efficiently delivers siRNA into the tumor parenchyma in vivo (Figure 3.1).
Payload Tandem Peptides Tumor Penetrating
(siRNA) Nanocomplexes (TPNs)
Figure 3.1. Design of tumor-penetrating nanocomplexes for siRNA delivery. Screening of tandem
peptides bearing distinct cell-penetrating domains and a fixed cyclic tumor-penetrating domain (LyP-1,
red) for ability to form tumor penetrating nanocomplexes (TPN) and deliver siRNA payloads in a cell
type-specific fashion
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3.2 Results and Discussion
3.2.1 Development of tumor-penetrating nanocomplexes
To begin, we synthesized a library of tandem peptides with a fixed cyclic domain for
tumor homing and penetration and variable linear domains to electrostatically bind siRNA and
cross cell membranes (Figure 3.2). Ideally, the resulting peptide-siRNA nanocomplex should not
only target receptors that are differentially expressed on tumor cells, but also overcome the
transport permeability barrier by penetrating into the tumor tissue. We selected the cyclic
nonapeptide, LyP-1, as the tumor-penetrating domain because: (1) it binds p32, a mitochondrial
protein whose expression is aberrantly elevated on the surface of stressed tumor cells in a variety
of tumor types, thus conferring its tumor homing properties [202, 216-217]; (2) once bound, it is
proteolytically processed by proteases to reveal a CendR motif that activates tissue penetration of
associated payloads [218]; and (3) LyP-1 peptide causes extravasation of phage, albumin, and
nanoparticles into tumors, and results in higher therapeutic accumulation [101, 169, 218-219].
In addition to receptor-specific binding, an effective siRNA delivery system must transfer
its payload into the cell cytoplasm. Cell penetrating peptides (CPP), such as TAT and poly-
Arginine, are short cationic peptide sequences capable of transducing macromolecular cargos
into cells. However, CPPs have no inherent cell type specificity; they are internalized
ubiquitously likely via binding to cell surface glycans [220]. We postulated that a tandem peptide
consisting of an N-terminal CPP with a C-terminal LyP- 1 separated by a 4-glycine linker domain
would retain membrane translocation and tissue penetrating properties, condense siRNA into
nanoparticles, and selectively target p32-expressing tumor cells. We created a library of 18 linear
membrane-translocation domains that contained both polycationic (oligoarginines, TAT (48-60),
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and the HSV-1 tegument protein VP22) and amphipathic sequences (penetratin derived from the
Antennapedia homeotic transcription factor and transportan). Inspired by the myristoylated
switch found in RNA viruses, we added a myristoyl group to the N-terminus to further stabilize
the nanocomplex and facilitate interactions with membrane lipids [221-222]. The homing and
membrane penetrating domains are separated by a four-glycine spacer to ensure that
complexation with siRNA does not interfere with tumor targeting.
We generated tandem peptides that conformed to these design principles and examined
their ability to condense siRNA into nanocomplexes that specifically target cells expressing
surface p32. We confirmed that peptides from the library bound siRNA electrostatically to form
stable nanocomplexes in water (diameter ~ 50nm), in phosphate-buffered saline (PBS, diameter
~ 200-400nm), and in mouse serum (diameter ~ 200-400nm) (Figure 3.3). The majority of
peptides were non-cytotoxic (Figure 3.4). A gel-shift assay was used to determine an optimal
complexation ratio of 1:20 (siRNA to peptide) and showed that 70% of the peptide-bound siRNA
remained intact after 24 h incubation in murine serum (Figure 3.5).
Membrane penetrating Homing
siRNA binding
...mmum Poly-(d)Arg: (dR) 3, 6, 9, 12, 15
TAT (48-60): GRKKRRQRRRGYK
Transportan: GWTLNSAGYLLGKINLKALAALAKKIL
Penetratin: RQIKIWFQNRRMKWKK
VP22: DAATATRGRSAASRPTERPRAPARSASRPRRPVD
Figure 3.2. Schematic of tumor-penetrating nanocomplexes with tandem peptides and siRNA
payloads. Schematic representation of a tandem peptide bearing a cyclic homing domain, a cell
penetrating domain, and a linker (gray).
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Figure 3.3. In vitro size characterization of nanocomplexes. Transmission electron micrograph
(TEM) of TPN in water. A higher magnification view is shown on the right. Scale bar, 100 nm.
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Figure 3.4. Cytotoxicity of nanocomplexes in vitro. Cytotoxicity assessments of TPN 48 h after
transfection in HeLa cells. Error bars indicate s.d. from 3 independent experiments. Total viability was
normalized to untreated cells.
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Figure 3.5. Characterization of nanocomplex formation and stability in vitro. (A) Agarose gel
analysis of free siRNA complexed to tandem peptide at various molar ratios. (B) Agarose gel analysis
of free or peptide-complexed siRNA in mouse serum at 37'C for up to 24 h. Naked, unmodified siRNA
is completed degraded by 12 h.
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3.2.2 Delivery of siRNA by nanocomplexes in vitro
We screened the library of nanocomplexes for uptake by p32-expressing HeLa cells and
found that nanocomplex uptake was dependent on the homing domain, as quantified by
monitoring tetramethylrhodamine-labeled peptides by flow cytometry. Internalization of
nanocomplexes occurred after 1 h. After 4 h, cells efficiently incorporated all targeted
nanocomplexes, whereas no uptake was seen with nanocomplexes formed from tandem peptides
harboring a control homing domain (Figure 3.6; Figure 3.7).
To evaluate TPN-mediated gene silencing, we treated HeLa cells expressing destabilized
green fluorescent protein (GFP) with GFP-specific siRNA bound to either tandem peptides or
lipofectamine. Three carriers: 6R, 9R, and Transportan (TP), silenced GFP expression by ~40-
60% (Figure 3.8). Flow cytometry analysis indicated that gene suppression was dose-dependent
and heterogeneous across the cell population (50-70% of cells exhibiting near-complete gene
suppression), likely due to the heterogeneity in surface p32 expression (Figure 3.9). In our
experience, GFP suppression can underreport the magnitude of silencing endogenous gene
targets, such as amplified oncogenes, thus we use this assay to compare TPNs but not as a
quantitative measure of efficiency in evaluation of oncogenes [223].
Next, we examined the specificity of receptor targeting and gene suppression. We failed
to detect altered GFP expression in HeLa cells exposed to untargeted TPNs carrying GFP-
specific siRNA or TP-LyP- 1 carrying a scrambled siRNA sequence. In contrast, when we used
TP-LyP- 1 carrying GFP siRNA, we observed over 40% suppression of GFP expression (Figure
3.10). In addition, we explored p32-receptor specificity by observing that MDA-MB-435 cells
expressing a p32-directed shRNA showed significantly reduced binding of TP-LyP- 1
nanocomplexes compared to cells expressing a control shRNA, whereas binding of
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nanocomplexes bearing a control homing domain (TP-ARAL) was unaffected (Figure 3.11).
Similar results were obtained with 6R-LyP-1 (data not shown).
To further confirm the uptake specificity of those nanocomplex candidates that showed
efficient GFP knockdown, free LyP-1 peptide was added to HeLa cells along with
nanocomplexes in a competitive binding assay. Dose-dependent inhibition of GFP silencing was
observed for TP-LyP- 1 and 6R-LyP- 1, suggesting that LyP- 1 and the nanocomplexes compete
for binding to the common p32 receptor (Figure 3.12). By contrast, the addition of LyP- 1 did not
interfere with lipofectamine. In addition, competition with a control peptide that has the same net
charge as LyP- 1, ARAL (ARALPSQRSR), had no effect. We attribute the excess of free peptide
required for inhibition to the presence of multiple copies of LyP- 1 on each nanocomplex, thereby
improving avidity through multivalent binding. In contrast, LyP- 1 did not inhibit functional
siGFP delivery by 9R-LyP- 1, suggesting this nanocomplex carrier failed to enter cells in a p32-
specific manner. Taken together, our results illustrated that 6R-LyP 1 and TP-LyP- 1
nanocomplexes enabled efficient and p32-dependent delivery of siRNA in vitro.
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microscopy analyses showed binding of LyP- 1 targeted nanocomplexes(TP-LyP- 1) but not controls (TP-
ARAL) to MDA-MB-435 cells.
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Figure 3.7. Cellular binding of LyP-1 targeted tandem peptides depends on p32 expression. (A)
Immunofluorescence staining showed that MDA-MB-435 and HeLa cell lines both express p32 on the
cell surface. Rabbit IgG or a polyclonal antibody against full-length p32 was applied to live cells and
detected with an Alexa 488-labeled secondary antibody. (B) Flow cytometry analysis of cellular uptake
of TP-LyP-1 versus TP-ARAL peptide labeled with a TAMRA fluorophore over time.
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Figure 3.8. Gene silencing by tandem peptide-mediated delivery of siRNA. HeLa cells stably
expressing destabilized GFP were transduced with nanocomplexes carrying siRNA against GFP. The
amount of gene silencing as determined by the geometric mean of cells undergoing RNAi was
determined by flow cytometry 48 h later. Lipofectamine was used as a positive control. Representative
histograms for 6R- and TP-LyP-1 peptides (inset) and cumulative data from three independent
experiments are shown.
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Figure 3.9. Gene silencing by tandem peptide-mediated siRNA delivery. Flow cytometry histograms
of HeLa cells expressing GFP 24 h after transfection with 3 tandem peptides (6R, 9R, and TP) carrying
GFP-siRNA (100 nM). Mock treated cells are shaded in gray. Geometric mean (GM) of the population is
indicated with a vertical line. The geometric mean of the mock treated cells is shown in black.
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Figure 3.10. Receptor- and sequence-specificity of nanocomplex siRNA delivery. Normalized GFP
knockdown by TP-LyP-1 nanocomplexes carrying siRNA against GFP (black bars), siRNA against an
irrelevant sequence (siUT, dashed bars), or by TP-ARAL carrying GFP siRNA (gray bars). Mean
values were normalized to percent of untreated control. Error bars indicate averages ± s.d.
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Figure 3.11. Nanocomplex binding is p32-specific. (A) Western blot on whole-cell lysates from MDA-
MB-435 tumor cells stably expressing shRNA for p32 or a base mismatch control shRNA (top). Flow
cytometry analysis of the same cell lines for surface levels of p32 using polyclonal anti-full-length/NH 2-
terminal p32 or IgG isotype control (bottom). (B) TAMRA-labeled tandem peptides bearing the LyP-1
homing domain or a control domain (ARALPSQRSR, ARAL) were incubated over p32 shRNA cells. TP-
LyP-1 binding was only observed in the control cells but not in p32 knockdown cells. TP-ARAL did not
bind to either cell line.
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Figure 3.12. A subset of tandem peptides are p32-specific. GFP silencing was re-examined in HeLa
cells treated with siRNA delivered using three different tandem peptide candidates: TP-LyP-1, 6R-LyP-1,
and 9R-LyP-1, in the presence of free LyP-1 peptide (5 to 20 pM) or control peptide (ARAL, 20 gM).
Transfection by lipofectamine was used as a positive control.
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3.2.3 In vivo siRNA delivery
For in vivo applications, an ideal carrier should stably circulate in the blood, extend the
half-life of siRNA in serum by protecting it from nuclease degradation, and yet readily dissociate
from siRNA once in the cytosol of target cells to allow for RISC incorporation. We found that
complexation by TP-LyP- 1 extended the stability of siRNA in the presence of serum to > 12 h
(Figure 3.5), and the size of nanocomplexes remained stable in serum (Figure 3.13).
Furthermore, we observed unpacking of nanocomplexes upon exposure to endolysosomal pH via
monitoring the intercalation of a nucleic acid-binding dye (TO-PRO-3) (Figure 3.14).
Collectively, these findings suggest that TP-LyP- 1 effectively condensed siRNA into stable
nanocomplexes that have the potential for in vivo applications.
We next set out to investigate the in vivo homing behavior of nanocomplexes after
systemic administration in mice. Near-infrared fluorochrome-labeled siRNA was complexed
with TP-LyP- 1, while siRNA complexed with untargeted peptides and naked siRNAs were used
as negative controls. After administration into immunodeficient mice bearing subcutaneous
MDA-MB-435 melanoma xenografts, a significant fraction of both naked siRNAs was rapidly
removed via renal clearance as indicated by bladder accumulation of siRNA owing to their small
size. By contrast, nanocomplexes were renally cleared more slowly and distributed to tumor
tissues over time (Figure 3.15). After clearance from circulation (4 h), the distribution of
nanocomplexes was examined via near-infrared imaging of the whole-animal and fluorescence
imaging of explanted organs. We found an over three-fold increase in the tumor accumulation of
LyP-1 targeted nanocomplexes compared to ARAL targeted control nanocomplexes (Figure
3.16; Figure 3.17).
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Histologically, TP-LyP- 1 targeted nanocomplexes carrying fluorescein-labeled siRNAs
accumulated in the interstitium of harvested tumors. Vascular staining with CD31 showed that
nanocomplexes extravasated from the vasculature. Tumor cell staining with anti-p32 showed that
p32 positive cells were also efficient at taking up targeted nanocomplexes (Figure 3.18). This
pattern of distribution was consistent with previously reported LyP- 1 peptide, Lyp- 1 phage and
LyP-1 targeted nanoparticle homing [200, 224]. Similar results in tumor targeting were also
obtained by injecting TPN intraperitoneally (Figure 3.19), suggesting the potential for multiple
routes of administration.
We sought to apply this approach to silence genes of interest in ovarian cancer, a disease
that is largely confined to the peritoneal cavity. Standard chemotherapy suffers from drawbacks
such as acute toxicity and emergence of drug resistance [225]; therefore, novel gene-based
approaches such as RNAi therapeutics may be beneficial in helping patients overcome the
disease. To establish a murine model of ovarian carcinoma, we implanted T22H mouse ovarian
tumor cells orthotopically in the peritoneal space of syngeneic nude mice. Total metastatic tumor
burden was assessed via non-invasive whole-animal bioluminescent imaging of luciferase
expression. Cohorts of mice with established tumors were treated intraperitoneally with
luciferase-targeting siRNA bound to TP-LyP- 1 (5 mg siRNA/kg). A significant reduction in the
bioluminescence was observed 48 h after treatment; the BLI signal was gradually restored in
mice over a 6-day period after a single TP-LyP-1/siRNA injection (Figure 3.20). By contrast, all
other cohorts, including those receiving untargeted nanocomplexes carrying siRNA targeting
luciferase, did not exhibit any significant luciferase knockdown (Figure 3.21).
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Figure 3.13. Nanocomplexation is stable in serum. Dynamic light scattering (DLS) measurements
of TPN in various concentrations of mouse serum at 37"C over time. The hydrodynamic diameter of
TPN measured in each serum concentration over time is normalized to the size of TPN in PBS at time
0. Error bars indicate s.d. from 6 independent measurements. n.s., not significant.
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Figure 3.14. Intercalation of a nucleic acid-binding dye into siRNAs packaged in nanocomplexes.
Binding of siRNA to TPN prevents intercalation of TO-PRO-3 into siRNA and results in decreased TO-
PRO-3 fluorescence. Upon exposure to endolysosomal pH, siRNA is released from TPN and results in
increased fluorescence. Error bars indicate s.d. from 4 independent experiments. **p<0.01; ***p<0.001.
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Figure 3.15. In vivo targeting of TP-LyP-1/siRNA nanocomplexes. (A) Peptide-bound siRNA has
greater circulation time in vivo compared with naked siRNA upon intravenous administration into mice.
Error bars indicate s.d. (n=3). (B) Whole-animal imaging of non-tumor bearing mice at multiple time
points after systemic administration of siRNA payloads labeled with a near-infrared fluorophore
(VivoTag-750) bound to either TP-LyP-1 or TP-ARAL, or naked siRNA without a carrier.
T T B K Li Sp
0.5 h
3.0 h
Lu
20051
15038
10026
5013
0
Figure 3.16. Biodistribution of systemically administered TP-LyP-1 nanocomplexes. At 30 min and 3
h post intravenous injection, organs and tumors were harvested from mice bearing OVCAR-8 flank
xenografts and imaged. Two representative sets of tissues are shown in pseudocolor. T-tumor, B-bladder,
K-kidney, Li-liver, Sp-spleen, Lu-lung.
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Figure 3.17. In vivo tumor targeting by TPNs. (A) Representative fluorescence images of tumor
explants harvested after injection of TPN carrying siRNA, untargeted nanocomplexes, or naked siRNA (5
nmols per mouse) i.v. or i.p. Tumors were harvested after TPN were cleared. (B) Quantification of near-
infrared fluorescence from tumor explants from A. Error bars indicate s.d. (n=3).
Figure 3.18. Intratumoral
fluorescein-labeled siRNA
nanocomplexes; Red: CD31
localization of TP-LyP-1 targeted nanocomplexes. Histological analysis of
distribution in MDA-MB-435 tumor sections (Green: TP-LyPl/siRNA
(left) and p32 (right); Blue: DAPI counterstain). Scale bar is 50 pm.
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Figure 3.19. In vivo homing of nanocomplexes after intraperitoneal administration. (A) Circulation
time of i.p. injected, fluorescently-labeled siRNA (5 nmols) either in its naked form or complexed to a
TPN. Error bars indicate s.d. (n = 3). (B) Whole-animal fluorescence imaging at multiple time points after
intraperitoneal injection in mice. Arrows indicate bladder accumulation.
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Figure 3.20. Duration of gene silencing by TPN. (A) Mice were injected intraperitoneally with tandem
peptide/siRNA nanocomplexes, and the duration of gene silencing was determined by whole-animal
bioluminescence imaging of luciferase expression on the indicated days. Error bars indicate s.d. (n=3);
(B) Representative bioluminescence images from mice in (A).
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Figure 3.21. In vivo siRNA delivery and gene knockdown by TPN. Top, mice bearing luciferase
expressing T22H tumors were injected i.p. with siRNA against luciferase bound to nanocomplexes.
The amount of gene silencing was measured by bioluminescence imaging 48 h later. Statistical
analyses were performed with ANOVA and Bonferroni post-test for pair-wise comparisons.
Horizontal lines, mean values. (n = 4-6); **p< 0.01, ***p< 0.001. Bottom, representative
bioluminescence images of luciferase activity of mice before and after treatment.
3.3 Conclusion
In this chapter, we described a novel nanotechnology-based system for tumor-targeted
delivery of siRNA payloads in vivo. The delivery system consists of a multifunctional, tandem
peptide that contains a tumor-penetrating motif (LyP-1) discovered via phage display, a nucleic-
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acid binding motif, and a domain for transporting siRNA cargoes into the cytosol of tumor cells
(Transportan, TP) that aberrantly express the mitochondrial protein p32. Potent and cell type-
specific suppression of several reporter genes was achieved using this delivery approach both in
established human cancer cell lines and in a syngeneic mouse model of ovarian carcinoma.
Our delivery platform may be modular in that both homing and cell penetrating domains
can be varied independently from each other to identify the best performing peptide, and be
easily adaptable to other homing domains and cancer models. By leveraging new discoveries in
amplified vascular transportation and tissue penetration of constitutive and cryptic CendR
ligands, this tandem peptide platform has the potential to enable broad access of parenchymal
tumor cells to RNAi-based therapeutics that would otherwise be inaccessible via vascular
targeting means. Such a capability may have broad utility for in vivo validation and clinical
translation of novel oncogene targets in parenchymal cancer cells that are identified from large-
scale genomic screens, which will be described in Chapters 4-5.
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4 Targeted tumor-penetrating siRNA nanocomplexes for
credentialing cancer targets
4.0 Abstract
The comprehensive characterization of a large number of cancer genomes will eventually
lead to a compendium of genetic alterations in specific cancers. Unfortunately, the number and
complexity of alterations identified by these efforts complicate endeavors to identify biologically
relevant mutations critical for tumor maintenance, since many of these targets are not amenable
to manipulation by small molecules or antibodies. Although RNAi provides a direct way to study
putative cancer targets, specific delivery of therapeutics to the tumor parenchyma remains an
intractable problem. We describe a platform for the discovery and initial validation of cancer
targets, composed of a systematic effort to identify amplified and essential genes in human
cancer cell lines and tumors partnered with a novel modular delivery technology. We developed
tumor penetrating nanocomplexes (TPN) comprised of siRNA complexed to a tandem tumor-
penetrating and membrane-translocating peptide, which enables the specific delivery of siRNA
deep into the tumor parenchyma. We employed TPNs in vivo to evaluate ID4, a novel oncogene
that induces tumorigenesis by disrupting both differentiation and proliferation through direct
regulation of CDKN1A and HOXA9 transcriptional programs. We show that treatment of tumor-
bearing mice with ID4-specific TPNs suppresses growth of established tumors and significantly
improves survival. These observations not only credential ID4 as an oncogene in a substantial
fraction of high grade ovarian cancers, but also provide a framework for the identification,
validation, and understanding of novel cancer targets.
(Adapted with permission from [213])
90
4.1 Introduction
Genome scale studies of cancer samples have begun to provide a global depiction of
genetic alterations in human cancers [34), but the complexity and sheer volume of data that
emerges from these efforts has made dissecting the underlying biology of cancer difficult, and
little is known about the functions of most of the candidates that emerge. For example, in studies
of 489 primary high-grade serous ovarian cancer genomes, 1825 genes were identified as
targeted by recurrent amplification events [226]. Systematic approaches to study the function of
genes in cancer cell lines, such as genome-scale, pooled short hairpin RNA screens, offer a
means to assess the consequences of the genetic alterations found in such genome
characterization efforts, and we recently used this approach to find genes that are both
overexpressed in primary tumors and also essential for the proliferation of ovarian cancer cells
[48]. However, this approach yielded a large number of candidate genes that required further
functional validation in vivo; for example, we identified 54 overexpressed and essential genes in
ovarian cancer and 16 genes in non-small cell lung cancer. Furthermore, many of these
candidates represent targets that are not amenable to antibody-based therapeutics or traditional
small molecule approaches. Thus, if one envisions a discovery pipeline that begins with cancer
genomes and ends with novel therapeutics, there is clearly a bottleneck at the point of in vivo
validation of novel targets.
RNA interference offers a potentially attractive means to silence gene expression of
candidates in vivo, particularly for "undruggable" gene products [1-3]. However, systemic
delivery of siRNA to tumors has been challenging due to their rapid clearance, susceptibility to
serum nucleases, and endosomal entrapment, in addition to their inherent inadequate tumor
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penetration [5, 7]. Achieving silencing in the epithelial cells in the tumor parenchyma is
especially critical to study the genetic alterations of interest.
Tumor penetration is a problem for the delivery of any cargo, including siRNA, and is
characterized by limited transport into the extravascular tumor tissue beyond the perivascular
region [227]. This low penetration is thought to arise from the combination of dysfunctional
blood vessels that are poorly perfused, and a high interstitial pressure, especially in solid tumors,
in part due to dysfunctional lymphatics [85, 228]. The leakiness of tumor vessels partially
counteracts the poor penetration (the enhanced permeability and retention [EPR] effect), but the
size dependency and variability of this property can limit its usefulness [92-93, 117].
Desmoplastic stromal barriers can further impede transport of therapeutics through tumors [115].
Recently, a new class of tumor-penetrating peptides were described which home to
tumors and leverage a consensus R/KXXR/K C-terminal peptide motif to stimulate transvascular
transport and rapidly deliver therapeutic cargo deep into the tumor parenchyma [117-118, 218].
These peptides are tumor-specific, unlike canonical cell-penetrating peptides that do not display
cell or tissue-type specificity [229-230]. The tumor-penetrating peptides were able to
significantly improve the delivery and efficacy of small molecules, antibodies, and even
nanoparticles [119]. Despite their promise, this class of peptides has not been successfully co-
opted for siRNA delivery, in part due to the additional challenges of delivering oligonucleotides
across cell membranes, out of endosomes, and into the cytosol in order to interact with RISC and
achieve gene silencing.
Here we sought to apply the siRNA delivery system developed in Chapter 3 that can
penetrate into the tissue parenchyma, target p32-expressing tumor cells, and easily accommodate
siRNA payloads to modulate gene targets of interest. We envision that such a technology would
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enable a platform wherein novel targets can be identified using structural and functional
genomics and subsequently rapidly credentialed in vitro and in vivo. Follow-up studies could
then identify the mechanism of action underlying the observations and establish (and ultimately
prioritize) novel oncogenes as therapeutic targets (Figure 4.1). To achieve this goal, we have
combined a systematic effort to identify genes that are both essential and genetically altered in
human cancer cell lines and tumors with the development and deployment of a novel tumor-
specific and tissue-penetrating siRNA delivery platform.
Patients
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Figure 4.1. An integrated platform enables high-throughput genomic discovery and in vivo
credentialing of cancer genes. Analyses of ovarian cancer genomes nominate genes that are amplified
and essential. The application of TPN system for siRNA delivery overcomes the in vivo validation
barrier (dotted line) by enabling rapid validation of candidate genes in animal models. Follow-up
studies could identify the mechanism of transformation to establish novel therapeutic targets that can
ultimately benefit patients.
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4.2 Results
4.2.1 Identification of ID4 as an Essential Oncogene in Ovarian Cancer
To facilitate the identification of genes that are essential in specific cancer types, we
initiated Project Achilles, a large scale effort involving genome-scale, pooled short hairpin RNA
(shRNA) screens in human cancer cell lines [48]. In our initial analysis of 102 cell lines
including 25 ovarian cancer cell lines, we identified lineage-specific essential genes, such as
PAX8 in ovarian cancer and NKX2.1 in non-small cell lung cancer, as genes that were both
overexpressed and required for proliferation in specific cell lineages [48].
Recent efforts to characterize the genomes of primary high grade serous ovarian cancer
[226] have revealed a large number of recurrent regions of copy number gain [63] and loss [50],
each containing a number of genes. To identify genes that are both recurrently amplified and
essential in ovarian cancers that harbored increased copy number of these genes, we quantified
the distribution of shRNA proliferation scores among all shRNAs for each amplified gene
(Figure 4.2). We identified 206 cases in which shRNAs targeting the amplified gene were
significantly depleted (p<0.05), including known ovarian cancer oncogenes KRAS [231-233],
AKT1 [226], BCL2L] [234] and ERBB3 [235], and novel candidates including the ID4
transcriptional regulatory protein and the SKP2 E3-ubiquitin ligase [236].
We selected ID4, a helix-loop-helix (HLH) transcriptional regulator, for further study
because recent genomic analyses indicate that it is frequently altered in ovarian cancer: the
chromosomal region containing ID4 (6p22) is amplified in 32% of high grade serous ovarian
cancers [226] (Figure 4.3), and ID4 is overexpressed in the majority of primary ovarian cancers
but not expressed in normal ovary and fallopian tube and other tissues (Figure 4.4). In addition,
by examining the transcript levels of ID4 in a large panel of cancer cell lines, we found that ID4
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was frequently overexpressed in the majority of ovarian cancer cell lines and cells derived from
other cancer lineages, such as endometrial cancer, breast cancer and glioblastomas (Figure 4.5).
With the identification of ID4 as a candidate oncogene from amongst the many hits that
resulted from the genome-wide studies of human samples, our next step was to establish
preclinical models to credential the oncogenic potential of ID4, specifically by investigating the
relationship between amplification, expression and essentiality of ID4 in a panel of human
cancer cell lines. First, we found that in vitro suppression of ID4 by multiple shRNAs that did
not alter the expression of the other ID family members (Figure 4.6) significantly inhibited the
proliferation of 9 of 11 ovarian cancer cell lines and 2 glioblastoma cell lines tested (Figure 4.8).
Cell lines that harbored increased copy number (Figure 4.7) and overexpression of ID4 (Figure
4.8) died by apoptosis after ID4 suppression (Figure 4.9). By contrast, 7 cell lines that express
comparatively lower ID4 levels were relatively insensitive to ID4 suppression (Figure 4.8).
Since we found that ID4 was both recurrently amplified and essential for the survival of
ovarian cancer cell lines that overexpress ID4, we tested whether ID4 was an oncogene by
investigating its ability to induce cell transformation. We previously showed that expression of
oncogenic HRASv2 or co-expression of known RAS effectors, such as MEK and AKT], suffices
to render immortalized human epithelial cells tumorigenic in vivo [36, 237-240]; therefore, to
investigate the role of ID4 in ovarian epithelial cells, we similarly created an ovarian surface
epithelial cell line expressing the SV40 Large T and small t antigens, hTERT and MEKDD
(IOSE-M) (Figure 4.10), and used this cell line to identify genes that promote tumorigenicity.
We found that expression of ID4at levels found in ovarian cancer cell lines dramatically
increased the rate of tumor formation in vivo; however, addition of either a mutant ID4_DM
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harboring mutations in the HLH domain, ID 1, ID2, or ID3 each failed to confer significant
tumorigenicity (Figure 4.11).
Since recent work suggests that the majority of ovarian cancers may arise from the
fallopian tube (FT) epithelium rather than the ovarian surface epithelium [31, 241], we used
immortalized FT epithelial cells (FTSEC)[242] and assessed whether ID4 expression also
induced cell transformation in these cells. As we found for ovarian epithelial cells, the expression
of ID4 induced anchorage independent growth in FT cells (Figure 4.12). These observations
show that ID4 is amplified, essential and transforming in ovarian epithelial cells and thus show
that ID4 is a novel ovarian cancer oncogene. Together, these observations identify ID4 as a
transforming oncogene recurrently amplified in, broadly overexpressed in, and essential for the
survival of high grade serous ovarian cancers.
Determine if amplified gene
is essential in amplified lines
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Figure 4.2. Schematic of shRNA analysis. Analysis of median shRNA depletion scores for each
amplified gene. Copy number analysis using GISTIC of primary high-grade serous ovarian cancers
identified 1825 recurrently amplified genes in 63 regions of genomic amplification. Schematic showing
the distribution (blue bars) of median shRNA scores in cell lines that harbor copy number gain (log2
copy number ratio > 0.3) of a given gene. shRNAs targeting the amplified gene (dots) are considered
significant (red) if p-value<0.05 (red line). Analysis is repeated for each of 1825 amplified genes in 63
recurrent regions of genomic amplification identified in primary serous ovarian cancer.
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Figure 4.3. Amplification of ID4 in primary high-grade serous ovarian tumors. SNP array
colorgram depicts genomic amplification of ID4 in subsets of primary ovarian tumors, sorted based on
the degree of amplification of 1D4. Regions of genomic amplification and deletion are denoted in red and
blue, respectively.
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Figure 4.4. ID4 expression in primary ovarian cancers. (A) Immunohistochemical analysis of ID4 in
primary ovarian cancers and normal tissues. Immunohistochemical staining of ID4 was performed on
sections from tissue microarrays composed of primary ovarian cancers (n=131) and normal tissues
(n=85). Percent of samples that were stained positive in ID4 is shown. (B) Representative micrograph of
a primary ovarian cancer stained with an anti-1D4 antibody.
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Figure 4.5. Boxplot showing D4 expression in cancer cell lines derived from different lineages
(http://www.broadinstitute.org/ccle). The black dot in each boxplot is the median expression value for
each lineage, boxes represent the 25th to 75th percentile of the data and whiskers span the most extreme
values of the group. Ovarian cancer cell lines are marked in red.
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Figure 4.6. 1D4 suppression by shRNAs did not affect other ID family members. Immunoblot of
ID 1, 1 D2, 1D3 and 1D4 in OVCAR-4 cells expressing a control shRNA targeting GFP or ID4-specific
shRNAs.
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Figure 4.7. FISH Analysis of ID4 in ovarian cancer cells. Four (4) ovarian cancer cell lines were
analyzed for amplification of ID4 by FISH. OV-90 cells, which do not harbor 6p22 amplifications, was
used as a negative control.
99
UControl shRNAs *shD4#1 ElshlD4#2
0
e
Ovarian cancer GBM NSCLC Breast Colon
cancer cancer
z
z
Figure 4.8. Effects of ID4 suppression in ovarian cancer cell lines. Top, Effects of ID4 suppression on
proliferation of human cancer cell lines. Cells were infected with a control shRNA targeting GFP or 2
shRNAs targeting ID4 and the proliferation was measured 6 d after infection. Error bars indicate s.d. of 6
replicate measurements. Bottom, The relative ID4 mRNA levels; 6p22-amplified lines are marked in red.
Error bars indicate s.d. of 6 replicate measurements.
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Figure 4.9. Induction of apoptosis by ID4 suppression in ovarian cancer cell
PARP and caspase-3 after suppressing ID4 in 6p22-amplified cell lines.
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Figure 4.10. Establishment of ID4-overexpressing immortalized ovarian surface epithelial
(IOSE) cells. Immunoblot of MEK, phospho-ERK1/2 and ID4 in immortalized ovarian surface
epithelial cells expressing indicated constructs.
101
4W mow 400M Law 1w I
P= 0.0001
on. 21/27 7/9
t40 3/9 3/9
4/21 2/9
020 2/18E
Figure 4.11. Potentiation of tumorigenicity in IOSEs overexpressing ID4 and other ID family
members. IOSE-M cells expressing the indicated constructs were implanted subcutaneously into
immunodeficient mice. The percent tumor formation is shown for each condition, and the number of
tumors formed/number of injections is indicated above each bar. H-RASv12 expressing IOSE cells were
used as a positive control.
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Figure 4.12. ID4 promotes anchorage independent growth. (A) ID4 promotes anchorage independent
growth of FTSEC-M cells. Error bars indicate s.d. (B) Anchorage independent growth of IOSE-M cells
expressing ID4 or control vector. Error bars indicate s.d.
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4.2.2 TPNs for ovarian cancer-specific siRNA delivery
To rapidly assess whether ID4 or any other candidate gene functions as a therapeutic
target for ovarian cancer, we required a modular siRNA delivery platform that will permit tumor-
penetrating access to specific cancer cells and manipulate the expression of any arbitrary gene in
those cells. Although we and others have previously used inducible shRNAs to evaluate potential
candidates, this approach is labor-intensive, time-consuming and requires extensive manipulation
of cell lines in vitro, which limits its utility to analyze more than a small number of candidates.
In addition, the ideal siRNA delivery vehicle should integrate unique functions of bulk tissue
penetration and cellular membrane translocation, thereby overcome the transport permeability
barrier by penetrating into the tumor tissue, and target receptors that are differentially expressed
on epithelial tumor cells. To accomplish this task, we utilized the delivery system developed in
Chapter 3 that conformed to these design principles, and generated tumor-penetrating
nanocomplexes (TPN) that consisted of siRNA bound to TP-LyP- 1 tandem peptides.
To apply TPN to assess the effects of suppressing ID4 in vivo, we first selected cell lines
that were both ID4-sensitive and compatible with TPN-targeted delivery of siRNA. Both
OVCAR-4 and OVCAR-8 ovarian cancer cells showed elevated surface p32 expression (Figure
4.13) and required ID4 expression as assessed by ID4-specific shRNAs and TPN/siID4in vitro
(Figure 4.14). Specifically, when ID4 was suppressed in these cell lines in vitro using TPNs, we
observed a decrease in cell viability (Figure 4.14) and an increased rate of apoptosis (Figure
4.15; Figure 4.16). We therefore selected the OVCAR-4 and OVCAR-8 ovarian cancer cell
lines for our preclinical in vivo evaluation of ID4.
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Before testing the functionality of TPNs on delivery of ID4-siRNA to orthotopic ovarian
tumors in vivo, we assessed whether TPNs enabled receptor-specific siRNA delivery to ovarian
tumor parenchyma. After intravenous administration to mice bearing subcutaneous OVCAR-8
tumor xenografts, we found an over five-fold increase in the tumor fluorescence of LyP- 1
targeted TPNs compared to ARAL targeted control TPNs (Figure 4.17).
Although bulk tumor accumulation provides a global measure of targeting, it does not
provide spatial information on the extravascular and tumor interstitial availability of TPNs,
which ultimately determines their efficacy. We thus performed histological characterization of
TPN penetration in subcutaneous OVCAR-8 tumors at various time points and found that TPN
exhibited an initial intravascular distribution and subsequently extravasated into the tumor
interstitium (Figure 4.18). The fraction of TPNs that were sequestered beyond the intravascular
space was significantly higher than that of untargeted controls (Figure 4.19). Furthermore, LyP-
1 targeted TPNs accumulated in the tumor parenchyma to a similar degree as TPNs bearing a
different tumor penetrating motif, iRGD (CRGDKGPDC) [117], whereas non-penetrating
nanocomplexes (TP-RGD4C) [100] or a commercial cationic lipid siRNA delivery reagent
(lipofectamine) failed to show a similar distribution (Figure 4.20). These observations
demonstrate that TPNs exhibit the desired tumor homing and parenchymal penetration properties
necessary for in vivo target validation.
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Figure 4.13. Surface expression of p32 in cancer cell lines. Six human cancer cell lines derived from
ovarian cancer (CaOV3, EFO21, OVCAR-8 and OVCAR-4), cervical cancer (HeLa), melanoma
(MDA-MB-435), and a mouse ovarian cancer cell line (T22H) were surveyed for surface expression of
p32 by flow cytometry with a polyclonal rabbit antibody directed against the full-length p32 peptide. A
rabbit IgG isotype control was used (black). Unstained cells are shaded in gray.
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Figure 4.14. ID4 suppression by TPN-mediated siRNA delivery in vitro. (A) Immunoblot of ID4 in
two 6p22-amplified ovarian cancer cell lines (OVCAR-4 and OVCAR-8) treated with TPNs containing
two ID4-specific siRNAs or a control siRNA targeting GFP. a-Tubulin is used as a loading control. (B)
Effects of ID4 suppression on cell proliferation. Proliferation of ovarian cancer cell lines treated with
TPNs containing GFP-siRNA (white bars), untargeted TPN (TP-ARAL) carrying ID4-siRNA (hashed
bars), and TPNs carrying ID4-siRNA (black bars). Error bars indicate s.d. from 4 independent
experiments. ***p<0.001.
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Figure 4.15. Effects of ID4 suppression on apoptosis. ID4 knockdown by TPNs carrying ID4-siRNA
in OVCAR-8 ovarian cancer cells led to an increased proportion of the population that binds Annexin-
V, relative to untreated cells (mock), cells treated with TP-LyP-1 (carrier) or with TPN carrying an
irrelevant siRNA (siUT).
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Figure 4.16. Summary of Annexin-V assays (white bars) and cells entering S-phase by the Click-
iT-EDU assay (red bars). The percentages of apoptotic and S-phase cells were calculated. Three
independent experiments were pooled and analyzed as a combined data set. Error bars indicate s.d.
from 3 independent experiments. n.s., not significant; ***p<0.001.
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Figure 4.17. Ovarian tumor targeting by TPNs. (A) Quantification of siRNA fluorescence per area
of subcutaneous OVCAR-8 ovarian tumor xenografts harvested 6 h after tail-vein injection of LyP-l
TPNs (red bar), untargeted nanocomplexes (ARAL TPNs, gray bar), or carrier-less siRNA (No carrier,
white bar) labeled with a near infrared fluorophore (VivoTag-750). Error bars indicated s.d. (n=4).
(B)Near-infrared fluorescence images of OVCAR-8 tumor xenografts.
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Figure 4.18. Time-course of tumor penenetration by TPN. Histological analysis of time-dependent
homing of TPN carrying FITC-labeled siRNA (pseudocolored green) in relation to cells (DAPI, blue) and
blood vessels (CD3 1, red) in mice bearing bilateral s.c. OVCAR-8 tumors. Scale bars, 50 im.
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Figure 4.20. Quantification of tumor parenchymal penetration by TPN. (A) Comparison of bulk
tumor parenchymal penetration of FITC-labeled siRNA in different TPN formulations: LyP-1 TPN
(LyP-1), iRGD TPN (iRGD), a non-penetrating nanocomplex (RGD4C), and lipofectamine (Lipo) in
OVCAR-8 tumors at 1 h or 3 h post i.v. injection (n = 6 per formulation). Scale bars, 50 Pm. (B)
Quantification of tumor fluorescence. Error bar indicates averages ± s.d. from 6 randomly selected
views per condition. n.s., not significant; **p<0.01; ***p<0.001.
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4.2.3 Loss of tumor maintenance after TPN-mediated suppression of ID4
Since suppression of ID4 by TPN inhibited the proliferation of ovarian cancer cell lines
that overexpress ID4 in vitro and TPN could deliver siRNA to the extravascular milieu of
ovarian tumors in vivo, we next tested whether ID4 was essential for tumor maintenance through
TPN-mediated delivery of ID4-siRNA in human ovarian cancer xenografts. Mice harboring
existing subcutaneous OVCAR-4 tumors were injected i.v. or i.p. with TPN/siID4
nanocomplexes every 3 days. We observed that repeated, systemic administration of the
nanocomplexes prevented additional growth of the tumors, and thus resulted in 80-90%
reduction in tumor burden relative to control animals (Figure 4.21; Figure 4.22).
Correspondingly, TPN/siJD4 treatments led to a significant suppression of ID4 mRNA in
the residual tumors. We also found that TPN/siID4 nanocomplexes induced CDKN1A
(p21 WAF1/CIP1) transcript levels (Figure 4.23), a known target of ID4 [243-244]. Residual
TPN/siJD4 treated tumors exhibited significant apoptosis (Figure 4.24). In contrast,
nanocomplexes carrying an unrelated siRNA (siUT) or tandem peptide alone (Carrier) had no
effect. We also observed that tumor growth was static in siID4-treated cohorts for an additional
30 d after the termination of TPN treatment (Figure 4.22). These observations demonstrated that
TPN/siID4 nanocomplexes induce specific tumor delivery and target suppression when
introduced systemically, and yield a functional impact on recipient cells.
We then tested whether TPNs could induce therapeutic activity in mice harboring
disseminated ovarian tumors. We established orthotopic OVCAR-8 tumors, confirmed intra-
abdominal dissemination three weeks post implantation, and then initiated intraperitoneal
injection of TPN every 3 days. We found that the tumor burden in mice that received TPN/siID4
regressed, and the recipients survived beyond 60 d, even after the nanocomplex treatments
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ceased (Figure 4.25; Figure 4.26). In contrast, control tumors continued to grow and recipient
mice developed hemorrhagic ascites, which may have attenuated tumor bioluminescence
resulting in an underestimation of tumor burden [245].
After 40 d, we found disseminated tumors in control cohorts but no visible tumor lesions
in 4 out of 5 TPN/siID4 treated mice upon necroscopy, indicating tumor regression (Figure 4.27;
Figure 4.28). Histological analysis of the single remnant tumor revealed significant reduction in
ID4 levels and increased apoptosis in the tumor parenchyma (Figure 4.29; Figure 4.30). We
noted that the level of p32 in the siID4 treated tumors was higher than that in the controls
(Figure 4.31). Since the surface expression of p32 is known to increase under stress [217, 219],
this finding is consistent with the potential that uptake of these TPNs may be enhanced upon
repeated exposures to tumoricidal siRNA.
In some cases, apparent therapeutic effects of RNAi may be confounded by non-sequence
specific innate immune responses mediated by toll-like receptors [70]. Therefore, we
independently measured serum levels of IFN-a, TNF-a, and IL-6 in immunocompetent mice
after TPN administration and failed to observe induction of these cytokines in treated animals
compared to mice that received a known immunostimulatory siRNA [69] (Figure 4.32).
Moreover, we failed to observe deleterious effects on animal weight in any of the cohorts
for both mouse models of ovarian cancer (Figure 4.33). Finally, histological examination of
numerous vital organs from TPN/siID4 treated mice, including the bladder, kidneys, liver,
spleen, heart, and ovaries, failed to reveal evidence of organ toxicity (Figure 4.34).
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Figure 4.21. Efficacy of TPN-mediated delivery of ID4-siRNA in in vivo.OVCAR-4 cells were
xenografted subcutaneously and allowed to form tumors of up to 5mm in diameter for 14 days before start
of treatment with indicated formulations every 3 d for 25 d (at 1mg siRNA/kg/injection, arrowheads).
Mice in the carrier group received TP-LyP-1 peptide without siRNA (at 6.5mg peptide/kg). Inset, the
timeline of the experiment. Tumor size was measured by digital caliper and the volume was calculated
based on the modified ellipsoidal formula volume = 2 (length x width2) and normalized to that at the start
of treatment (day 14). Treatment period is shaded in gray. n = 8-10 tumors per group. Error bars indicate
s.d.; n.s., not significant; ***p<0.001.
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Figure 4.23. Effects of TPN-mediated ID4 suppression in OVCAR-4
and p21 mRNA levels from tumors harvested from all cohorts at day 60.
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Figure 4.25. Therapeutic efficacy of TPNs in mice bearing disseminated tumors. Left, OVCAR-8
cells were xenografted intraperitoneally and allowed to form tumors over 20 d. On day 21, mice were
randomly divided into 4 groups with matching tumor burdens and treated every 3 d for 14 d and then
once weekly thereafter with: TPNs carrying ID4-specific siRNA (red circles); saline (black squares);
TPN carrying GFP-siRNA (green triangles); and untargeted TP-ARAL nanocomplexes carrying ID4-
specific siRNA (blue triangles), at 5mg siRNA/kg/injection (arrowheads). Inset, the timeline of the
OVCAR-8 tumor therapy experiment. Total tumor burden was followed by bioluminescence imaging
(BLI). n = 5 per group. Error bars indicate s.d.; n.s., not significant; *p<0.05 ; ***p<0.001. Right,
Representative whole-animal bioluminescence images of mice in the groups treated in D confirmed
disseminated intraperitoneal tumor burden. Images were taken on day 60.
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Figure 4.26. Kaplan-Meier plot of overall survival. Survival of animals bearing disseminated
orthotopic OVCAR-8 xenograft tumors from cohorts shown in Figure 4.25 (n = 5 per group).
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Figure 4.27. Bioluminescence imaging (BLI) of OVCAR-8
bearing orthotopic OVCAR-8 ovarian tumor xenografts were
obtained on day 40 of therapeutic trial.
TPN Saline siUT
6.0
-4.0 x 108
:2.0
tumor burden. All cohorts of mice
imaged serially. Images shown were
ARAL
Figure 4.28. Photographs of representative OVCAR-8 tumor bearing mice from each cohort upon
necropsy at day 60. Arrowheads indicate the presence of disseminated intraperitoneal ovarian tumor
nodules. No visible tumors were seen in the TPN/siID4 treated mice.
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Figure 4.29. Effects of TPN-mediated siID4 delivery in vivo. Tumor sections harvested from all 4
cohorts on day 40 were stained for p32 (pseudocolored red) and ID4 (pseudocolored green) (top) and for
induction of apoptotic cell death (bottom) by TUNEL (red). Scale bars, 50 pm.
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Figure 4.30. Downstream effects of ID4 suppression in OVCAR-8 tumors. Quantification of ID4 and
TUNEL intensities from OVCAR-8 tumors after TPN treatment. Statistical analyses were performed
using ANOVA; Error bars indicate s.d. **p<0.01.
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Figure 4.31. Quantification of p32 intensities from OVCAR-8 tumors after TPN treatment.
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Figure 4.32. Lack of immunostimulation by TPN. Immunocompetent Balb/c mice were injected
intraperitoneally with TPNs and 6 h later, serum samples were tested for levels of: (A) interferon-alpha
(IFN-a), (B) IL-6, and (C) TNF-a, by ELISA. The immunostimulatory siRNA sequence, sipgal-728, was
complexed to either lipofectamine or TP-LyP1 and these were used as positive controls for non-specific
immunostimulation. n = 4-8 per group. Error bars indicate s.d. *p<0.05; **p<0.01; ***p<0.001.
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Figure 4.33. Effects on body weight from TPN treatment. (A) Total body weight of OVCAR-4
subcutaneous tumor xenograft-bearing mice over the course of TPN treatment. Error bars indicate s.d. (B)
Total body weight of OVCAR-8 orthotopic tumor xenograft-bearing mice during TPN/siID4 treatment.
Error bars indicate s.d.
Figure 4.34. Absence of general toxicity after TPN treatment. Organs were harvested from OVCAR-8
tumor bearing mice after TPN treatment for 40 d (5 mg siRNA/kg) and stained with H&E: (A) bladder.
(B) kidney. (C) liver. (D) spleen. (E) heart. (F) ovary. No relevant histological or morphological evidence
of toxicity was observed in these organs. Scale bar is 50 im.
4.2.4 1D4 induces transformation by regulating HOXA9 and CDKN1A
To explore the mechanism of action by which ID4 induces transformation, we performed
gene expression profiling in immortalized ovarian surface epithelial (IOSE-M) cells that
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overexpress ID4or a control vector. Among the top 5 gene sets, we found highly significant
enrichment of 3 gene sets upregulated by expression of the oncogenic NUP98-HOXA9 fusion
protein [246] (Figure 4.35).
We confirmed that expression oflD4in IOSE-M cells consistently increased expression of
multiple HOXA genes, including HOXA9, HOXA 7 and HOXA3 (Figure 4.36) while suppression
of ID4led to significantly reduced levels of these same genes (Figure 4.37).To determine
whether HOXA9 was required for ID4-induced cell transformation, we introduced previously
validated HOXA9-specific shRNAs [247] or control shRNAs (targeting GFP) into ID4-
overexpressing IOSE-M cells (Figure 4.38). We found that suppression of HOXA9 only slightly
reduced cell proliferation (Figure 4.39) but significantly inhibited ID4-induced anchorage
independent growth and reduced the rate of tumor formation (Figure 4.40).
Finally, to confirm these observations in human ovarian cancers, we analyzed the
expression profiles from primary ovarian tumors[226] and found that many genes within the
HOXA9 expression signature were significantly downregulated in tumors that express low levels
of ID4 (Figure 4.41). We also found that tumors that harbor ID4 amplifications showed
significantly increased expression of the p2 1 WAFl/CIP1 target gene set (Figure 4.42). These
observations demonstrate that expression or amplification of ID4 induces the HOXA9 and
CDKN1A transcriptional programs to disrupt the normal regulation of proliferation and
differentiation.
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Figure 4.35. ID4 regulates HOXA9 activity. Gene expression profiling and GSEA were performed on
IOSE-M cells expressing ID4 or a control vector. Top, Enrichment plots show the running enrichment
score (y-axis) in green for the ranked list of genes (x-axis) based on their differential expression (signal to
noise value) between cells expressing ID4 or a control vector. Black bars at the bottom of the figure
indicate the location of genes in a gene set upregulated by expression of NUP98-HOXA9 fusion protein
generated 6 h (A), 3 d (B), and 8 d (C) after induction within the ranked list. Significant upregulation of
these genes (p=0.001) was observed in cells expressing [D4. Bottom, Heatmaps showing the expression
levels induced by ID4 overexpression (triplicate measurements) of a subset of genes within each of the
gene set. High and low expression levels are indicated by red and blue colors, respectively. Members of
the homeobox family of transcription factors are marked in red.
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Figure 4.36. Overexpression of ID4 in IOSE-M cells increases mRNA levels of HOXA9, HOXA 7
and HOXA3. Quantitative PCR analysis of HOXA9, HOXA7 and HOXA3 in IOSE-M cells
overexpressing ID4 or a control vector. Error bars indicate s.d. of 6 replicate measurements.
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Figure 4.37. Suppression of ID4 reduces HOXA9, HOXA7 and HOXA3. (A) Quantitative PCR
analysis of HOXA9, HOXA7 and HOXA3 in OVCAR-8 cells 3 days after infection with a control
shRNA targeting GFP or two shRNAs targeting ID4. Error bars indicate s.d. of 6 replicate measurements.
(B) Suppression of ID4 reduces expression of HOXA9 proteins. Immunoblot of ID4 or HOXA9 in
OVCAR-4, NIH:OVCAR-3 and OVCAR-8 cells expressing a control shRNA targeting GFP or 1D4-
specific shRNAs. Arrow indicates the specific HOXA9 band. p-actin included as a loading control.
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Figure 4.38. Suppression of HOXA9
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Figure 4.39. Effect of suppressing HOXA9 on proliferation of IOSE-M cells. Cells expressing
indicated constructs were plated in triplicate and counted daily. Suppression of HOXA9 by the most
effective HOXA9-specific shRNA (shHOXA9#2) resulted in 30% inhibition on cell proliferation 120 h
after plating.
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Figure 4.40. HOXA9 is necessary for ID4-mediated transformation. (A) HOXA9 is necessary for
1D4-mediated transformation. Suppression of HOXA9 by previously described shRNAs (54) inhibited
anchorage-independent growth of ID4-overexpressing IOSE-M cells. (B) Suppression of HOXA9
suppressed ID4-induced tumorigenicity in immunodeficient mice. ID4-overexpressing IOSE-M cells
expressing indicated shRNAs were subcutaneously implanted into immunodeficient mice. Tumors were
monitored for 5 months. Percent tumor formation based on number of injection sites is depicted.
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Figure 4.41. ID4 expression in ovarian tumors correlates with HOXA9 activity. Expression data
from primary ovarian tumors were used to perform GSEA on 44 samples with low ID4 expression levels
vs. 45 samples with high ID4 expression (thresholds were 1 s.d. below and above the mean expression of
all the samples). Enrichment plots are as described in C. Black bars at the bottom of the figure indicate
the location of genes in a NUP98-HOXA9 downregulated gene set
(TAKEDATARGETSOFNUP8_HOXA9_FUSIONlOD_DN). Significant enrichment of these genes
(p = 0.004) was observed in tumors with low ID4 levels.
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Figure 4.42. ID4 amplification in ovarian tumors correlates with decreased p21 activity. Expression
profiling of primary ovarian tumors with matched copy number data was used to perform GSEA on
amplified ID4 (log 2 copy number ratio >0.3) and non-amplified ID4 samples (log 2 copy number ratio <0).
All genes were ranked by their differential expression (signal to noise) between 81 non-amplified and
109 amplified ID4 primary tumors. Black bars at the bottom of the figure indicate the location of genes in
the p21 WAFI/CIPI target gene set (P21 P53 ANY DN); significant upregulation (p=0.016 ) of the gene set
was observed in amplified tumors.
4.3 Discussion
4.3.1 Integrated platform to credential oncogenes in vivo
Current genome characterization efforts will eventually provide insight into the genetic
alterations that occur in most cancers and identify statistically significant recurrent alterations
that define new cancer targets. However, most epithelial cancers harbor hundreds of genetic
alterations as a consequence of past or on-going genomic instability. For example, although
recent work from TCGA have demonstrated that recurrent somatic alterations occur in a small
number of genes in high-grade ovarian cancers, ovarian cancer genomes are instead
characterized by multiple regions of copy number gain and loss involving at least 1825 genes.
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This genomic chaos complicates efforts to identify biologically relevant mutations critical for
tumor maintenance.
One approach to identifying genes involved in cancer initiation, tumor maintenance
and/or metastasis is to analyze the function of genes recurrently altered in cancer genomes by the
systematic manipulation of the candidate oncogenes. Here we have used the information derived
from Project Achilles, a large scale effort to identify genes essential for proliferation and survival
in human cancer cell lines through the application of genome scale loss of function screens,
together with genome characterization data derived from the study of high grade ovarian cancers
to identify potential ovarian cancer oncogenes. Using this approach, we identified several known
oncogenes as well as ID4 and used the TPN system to efficiently demonstrate that ID4 is
essential for tumor maintenance. These observations provide proof-of-principle evidence that the
combination of functional genomics with TPN-mediated siRNA delivery constitute a highly
flexible and scalable platform for the discovery and validation of cancer targets (Figure 4.43).
4.3.2 Identification of 1D4 as an ovarian cancer oncogene
Mutations, amplifications and translocations involving transcription factors play a key
role in the pathogenesis of hematopoetic malignancies. Indeed, the paradigm of dysregulation of
differentiation, usually through the disruption of a lineage-specific transcription factor,
accompanied by a constitutive proliferative signal, such as those imparted by an activated kinase
oncogene, has provided a foundation for the discovery of a number of oncogenes in
leukemias[248]. Although the physiologic programs that regulate differentiation in most
epithelial tissues remain incompletely understood, recent work has identified a number of
transcription factors that are activated in the majority of specific types of cancers, including
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MJTF in melanoma [249], NKX2.1 in lung adenocarcinomas [250], SOX2 in squamous cell lung
cancers [251] and TMPRSS2-ERG fusions in prostate cancer [252].
Using integrated genomic approaches derived from the interrogation of hundreds of
primary ovarian tumors and cell lines, we identified ID4 as an oncogene, amplified in 32% of
high grade serous ovarian cancers. In addition, ID4 is overexpressed in a large fraction of high
grade serous ovarian cancers, and ovarian cancer cell lines that overexpress ID4 are highly
dependent on ID4 for survival and tumorigenicity. Expression of ID4 at levels corresponding to
those observed in patient derived samples in either immortalized ovarian epithelial or fallopian
tube epithelial cells induces cell transformation. These observations credential ID4 as a bona fide
ovarian cancer oncogene and suggest that ID4 is one of a growing class of lineage-restricted
transcriptional factor oncogenes in human epithelial cancers.
Like other ID family proteins, ID4 binds to and regulates the activity of E protein
transcription factors such as E2A and HEB. Indeed, we found that ID4 regulates cell
proliferation in part through its effects on p21 wAF/CIP1. In addition, when we generated an
expression signature corresponding to ID4 in ovarian epithelial cells, we found that the
transcriptional program induced by ID4 was similar to that induced by HOXA9. Although it is
clear that ID4 regulates the expression of many genes, we found that suppression of HOXA9
abrogated the cell transformation induced by ID4. ID4 has been reported to regulate
differentiation of neural progenitor cells, adipocyte cells and osteoblast cells [253-257]. As a
result, the majority of Id4-deficient mice died either in uteri and postnatally due to rapid weight
loss and only -20% of mice survived to adulthood with significantly smaller brain size due to
diminished fraction of neural progenitor cells [253-255, 257]. HOXA9 is known to regulate
normal hematopoiesis by controlling differentiation, proliferation and self-renewal [258], and
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overexpression of HOXA9 or HOXA9-NUP98 in hematopoietic precursors results in the
expansion of hematopoietic stem cells and promotes the development of leukemias in a
cooperative manner with MEIS 1 or RAS signaling [259-260]. HOXA9 is also required for
survival in the mixed lineage leukemia gene (MLL)-rearranged acute leukemias [247]. In
addition, HOXA genes have been shown to play essential roles in specifying regional
differentiation of mullerian duct into oviduct, uterus, cervix and vagina [261]. Therefore, our
observations suggest that ID4 expression may contribute to transformation by affecting both
p21WAF1/CIP1 and HOXA9 transcriptional programs that affect differentiation and proliferation
and contribute to the development of ovarian cancer.
Although prior work has shown that manipulation of the expression of ID 1, ID2 or ID3
induces compensatory changes in the expression of the other ID family members, we found that
expression of ID4 but not the other ID family members induced cell transformation in ovarian
epithelial cells. Since amplifications involving other ID family members have not been observed
in ovarian cancers, this observation suggests the ID4 has a unique role in the transformation of
this tissue type. Collectively, these observations suggest that inappropriate overexpression of
ID4, in part by regulating the transcriptional program of HOXA9, alters the physiologic
differentiation program of the ovary.
4.3.3 Development of tumor penetrating nanoparticles
To credential a novel oncogene as a therapeutic target, both in vitro and in vivo
perturbation of tumor cells harboring the gene product is required (Figure 4.43). Achieving this
goal, particularly in an established, disseminated tumor, is facilitated by efficient, targeted
delivery accompanied by significant tissue penetration. Here we show that a myristoylated
tandem peptide (TP-LyP- 1) with both a membrane-translocating domain and a tumor-penetrating
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domain condenses siRNA into nanocomplexes that, upon systemic administration into ovarian
tumor-bearing mice, penetrates the tumor parenchyma and silences a novel ovarian oncogene,
ID4, in a receptor-specific manner. Treatment with TPN/siID4 over time led to a complete
growth suppression of ovarian tumors and a significant survival improvement in mice.
The systematic delivery of siRNA to achieve suppression in animals continues to
represent a major barrier to the development of nucleic acid-based therapeutics. Many different
approaches have been explored extensively with a primary focus on developing strategies that
will achieve silencing in patients [7]. To enable the genomic discovery pipeline outlined (Figure
4.43), we favored a strategy that was modular, tumor-specific, and tumor-penetrating.
Importantly, the TPNs are biodegradable and did not elicit innate immune responses upon
systemic delivery, enabling repeated administration for tumor regression studies. Moreover, the
TPN system extravasates from the vasculature and moves through the tumor extracellular matrix
to delivery siRNA to specific parenchymal cancer cells.
Other methods for siRNA delivery include covalent coupling of siRNA to carriers and
therefore require specialized chemically-reactive siRNA and additional purification steps in the
formulation process, rendering this approach less amenable to the modular 'mix and dose'
paradigm motivated by the volume of emerging genomic targets [127, 132, 212]. Targeted
siRNA delivery approaches have been reported for specialized populations of cells such as
immune cells [134, 140, 165], neurons via viral mimicry [166], and hepatocytes by leveraging
LDL trafficking and vitamin A uptake [126, 142]; however, these methods cannot easily be
generalized across tissue types as would be necessary in the study of aberrant cancer genomes.
Elsewhere, siRNA has been targeted to tumors; however, not in a tumor-penetrating
fashion [151, 262]. As described earlier, tumor penetration is a longstanding challenge in cancer
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delivery. As an alternative to crossing the vascular wall to achieve tumor penetration, tumor
endothelium has instead been targeted using RGD-targeted nanoparticles [262]; however, this
approach does not enable silencing in parenchymal tumor cells, such as those identified with
genetic alterations in TCGA [34, 226]. Passive targeting (e.g. EPR) of siRNA in neutral
liposomes or transferrin-targeted cyclodextrin has also been described in mouse models and
recently in humans, but tumor penetration remains a challenge [145, 159]. The importance of
tumor penetration is not merely a theoretical constraint. In fact, studies with small molecules and
antibody-based therapeutics indicate that reducing tumor transport barriers via permeability
enhancement or inhibition of hedgehog signalling can have profound consequences on the
penetration, accumulation, and ultimately efficacy [107, 115, 119, 263].
The modularity in our siRNA delivery platform enables the potential for leveraging other
homing peptides selected from phage-displayed libraries, such as new discoveries in amplified
vascular transportation of CendR ligands, thereby expanding the number and type of
parenchymal tumor cells that can be accessed by TPNs. Herein, human ovarian cancer cells that
overexpress ID4 were highly sensitive to TPN-mediated suppression of ID4, and tumor-
penetrating delivery of ID4-siRNA produced powerful antitumor effects against orthotopically
implanted ovarian tumors. Since ID4 cannot be inhibited by means of small-molecule inhibitors
or monoclonal antibodies, this technology represents an important therapeutic paradigm for
systemic targeting of undruggable proteins that are essential in tumor maintenance.
4.3.4 Wider Implications
Although focused on ID4, the specific delivery technology reported here can be
generalized to other cancers. The surface expression of p32, the receptor targeted by our
nanocomplex, was examined in 81 different human tumors from 11 different tumor types.
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Approximately 60 of the 81 samples across 10 tumor types scored positive to p3 2 [217]. The
technology is also readily adaptable to other siRNA cargo, as we reproduced prior work on
another target, claudin-3 (CLDN-3), using this same experimental platform (data not shown).
This study provides evidence that TPN can be used as a facile system to evaluate the
consequences of manipulating putative oncogenes on tumor maintenance in vivo.
More generally, the integration of on-going cancer genome characterization efforts with
similarly comprehensive functional studies will narrow the number of potential cancer targets but
will still nominate a large number of genes that will require in vivo studies to validate their role
in tumor initiation or maintenance. These TPNs when combined with genomic studies illustrate
an efficient platform to functionally characterize the genes found to be altered in tumors and to
identify and validate the subset of such genes critical to cancer initiation and maintenance. As
such, these studies provide one path to bypassing a critical bottleneck in identifying and
credentialing genes involved in cancer.
Although it is clear that further mechanistic studies, such as those presented here that
identified HOXA9 as a target of ID4, will be necessary to understand the biology of new
oncogenes, only a fraction of such candidates will be amenable to target by traditional small
molecule chemistry or antibodies. Theoretically, RNAi provides a means to both assess and act
on novel candidate oncogenes but targeted delivery of siRNA remains a challenging barrier.
Although further work will be necessary to validate TPNs as a therapeutic delivery vehicle, these
studies demonstrate that these TPNs exhibit both specificity and pharmacokinetic properties that
may provide a platform for siRNA delivery in humans.
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Figure 4.43. An integrated platform to credential oncogenes in vivo. (A) Structural genomic analyses
of tumors from patients. (B) Schematic of ovarian-amplified gene analysis. Distribution (blue bars) of
median shRNA scores are shown in cell lines that harbor copy number gain of a given gene. shRNAs
targeting the amplified gene (dots) are considered significant (red) if z-score < -2. Analysis was repeated
for each of 1825 amplified genes. (C) Development of a tumor-penetrating siRNA nanocomplex (TPN)
to deliver siRNA to tumor cells in a receptor-specific manner and validates gene targets in mouse models.
(D) Follow-up studies to identify the mechanism of transformation and establish novel therapeutic targets
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4.4 Conclusion
In this work, we developed a targeted tumor-penetrating nanocomplex capable of
precisely delivering siRNA deep into the tumor parenchyma, and have combined this technology
with large scale methods to interrogate the function of genes in cancer genomes to credential ID4
as an oncogene target in ovarian cancer by studying preclinical disease models. Nanocomplexes
comprised of TP-LyP 1 tandem peptides and ID4 siRNA were able to potently impede the growth
of aggressive, metastatic ovarian tumors. The role of tumor homing in this system stands in
marked contrast to other in vivo siRNA delivery methods that lack tumor penetration domains
[128-129, 159, 264], systems that require direct conjugation and custom synthesis [162, 212],
and carriers where target cells cannot be molecularly specified [126, 151, 245]. Furthermore, by
leveraging new discoveries for amplification of transvascular transport through a diversity of
novel tumor-penetrating ligands, the tumor and membrane penetrating domains of this tandem
peptide platform can be varied independently, enabling broad access of parenchymal tumor cells
to RNA-based therapeutics. As large scale efforts to characterize all cancer genomes accelerate,
this capability illustrate a path to identify genes found to be altered in tumors, validate those that
are critical to cancer initiation and maintenance, and rapidly evaluate in vivo the subset of such
genes amenable to RNAi therapies and clinical translation.
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5 Cancer Vulnerabilities Unveiled by Genomic Loss
5.0 Abstract
Genome instability is a common feature of many cancers and leads to extensive somatic
copy number alterations. As a result, most cancers exhibit loss of substantial fractions of their
genomes, including regions containing known tumor suppressor genes and collateral loss of
many other genes. Here we performed an integrated genomic analysis to identify novel cancer-
specific vulnerabilities that result from copy number loss of genes irrespective of tumor
suppressor activity. For 6,085 genes, we correlated partial copy number loss to the anti-
proliferative effect of expressing shRNAs targeting that gene in 86 cancer cell lines. We
identified 102 genes for which suppression of the gene specifically inhibited the proliferation of
cells with partial copy loss of that gene. This class of CYCLOPS (Copy number alterations
Yielding Cancer Liabilities Owing to Partial losS) genes is enriched for multiple components of
the spliceosome and proteasome. One CYCLOPS gene, PSMC2, encodes an essential member of
the 19S proteasome regulatory complex, which is normally not limiting for 19S complex
assembly. The excess PSMC2 resides in a known complex that also contains PSMC1, PSMD2,
and PSMD5, and serves as a buffer that enables cells to maintain a functional 26S proteasome
after partial copy number loss or experimental suppression of PSMC2. Cells that harbor partial
PSMC2 copy number loss lack this reservoir and are exquisitely sensitive to further suppression
of PSMC2 both in vitro and in vivo. These observations define a new class of cancer specific
liabilities predicted by partial copy number loss and provide a novel strategy to target the
consequences of genome instability in cancer.
(Reprinted with permission from [265])
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5.1 Introduction
Cancers arise as the result of the accumulation of somatic genetic alterations within a
cell, including chromosome translocations, single base substitutions, and copy number
alterations [266-267]. Although a subset of these alterations ("driver events") promote
malignant transformation by activating oncogenes or inactivating tumor suppressor genes, most
somatic genetic alterations are the consequence of increased genomic instability that occurs in
cancer but do not contribute to tumor development ("passenger events"). The demonstration that
cancers are often dependent on specific driver oncogenes has stimulated efforts to find and
exploit these targets therapeutically. For example, cancers that harbor acquired translocations
(such as BCR-ABL or EML4-ALK) [268-269] or mutations (such as EGFR or BRAF) [270-271]
depend on the activity of these gene products for tumor maintenance. Therefore, the presence of
such an alteration often predicts response to drugs that inhibit the function of these proteins.
An alternative strategy to target cancers is to target genes that are not oncogenes, but
which cancers require to accommodate cancer-specific stress [272]. In comparison to normal
cells, cancer cells exhibit a variety of stress, including DNA damage replication stress,
proteotoxic stress, mitotic stress, metabolic stress, and oxidative stress. Therefore, cancers rely
inordinately on pathways that abrogate such stress [273]. Even though proteins within stress
support pathways may be essential in all cells, pharmacologic inhibition can still create a
therapeutic window as a result of a cancer stress phenotype [273-274].
The proteasome, which recognizes and degrades proteins that possess a poly-ubiquitin
post-translational modification, is one such target [275]. The 26S proteasome is responsible for
basal protein turnover, degradation of excess and unfolded proteins, and regulation of
concentrations of key regulatory proteins. The 26S proteasome is composed of a 20S catalytic
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complex and a 19S regulatory complex. One function of the 1 9S complex is to recognize poly-
ubiquitin modified substrates and regulate access to the 20S catalytic sites. The 19S complex
contains at least 19 proteins that are further divided into a base (9 proteins) and lid (10 proteins)
[276]. Prior to assembly, the 9 components of the base are divided into three modules, each
containing three components. Each module also contains a different chaperone protein that
catalyzes the hierarchical assembly of the 19S base. The chaperone proteins and each of the nine
19S complex base components are essential to form a functional 19S complex and reconstitute
the 26S proteasome [277]. Although proteasome function is essential in all cells, multiple
myeloma (MM) cells produce and secrete excessive amounts of immunoglobulin and are
especially dependent on effective protein turnover by the 26S proteasome. As a result, MM is
exquisitely sensitive to the 20S proteasome inhibitor, bortezomib (Velcade), which is now used
in the clinical treatment of MM [278].
Despite these advances, many non-kinase oncogenes (RAS, MYC) and tumor suppressors
(ARF, TP53) are still difficult to target with existing drugs. To identify new vulnerabilities in
cancer, an alternative approach is to target the effects of genomic alterations on non-cancer genes
that are the consequence of either driver or passenger events. For example, driver events such as
copy number losses of tumor suppressor genes often involve multiple neighboring genes that are
not necessarily involved in oncogenesis; the relative loss of essential genes could in turn cause a
deficiency in essential cellular processes, rendering cells highly vulnerable to further suppression
of those genes. Targeting such genes have been postulated to render cancer cells highly
vulnerable to further suppression or inhibition of those genes [279].
Here, we integrated both genome scale copy number and loss of function data on a panel
of 86 cancer cell lines to determine if partial copy number loss of specific genes renders cells
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highly dependent on the remaining copy. We identified a class of genes, enriched in proteasome
and spliceosome components that render cells that harbor copy number loss highly dependent on
the expression of the remaining copy.
5.2 Results
5.2.1 Identification of essential and haplosufficient genes
When we analyzed copy-number profiles from 3,131 cancers across several dozen
histologic types, we found that 50% of cancers exhibit copy-number loss affecting at least 11%
of the genome and many cancers exhibit much more extensive loss (Figure 5.1A). Much of this
widespread genomic disruption is due to copy number alterations of whole chromosomes or
chromosome arms (Figure 5.1B). As a consequence, most genes undergo copy-number loss in a
substantial fraction of cancers. While some of these are likely "driver" genes whose loss
contributes to malignant transformation, others are unlikely to contribute to cancer development.
Copy number loss of non-driver genes often results from involvement in a passenger event; in
other cases non-driver genes are recurrently lost because of their proximity to a frequently
deleted tumor suppressor gene (Figure 5.2). We therefore hypothesized that for a subset of non-
driver genes, hemizygous loss may be tolerated and frequent but complete loss would lead to cell
death. In some of these cases, hemizygous loss might lead to sensitivity to further inhibition of
the gene relative to cells that harbor two copies of these genes.
To identify genes whose loss correlated with a greater sensitivity to further gene
suppression, we integrated gene dependencies and copy-number data from 86 cell lines.
Specifically, we analyzed gene essentiality data from Project Achilles, a dataset derived from
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screening 102 cell lines with a shRNA library composed of 55,000 shRNAs targeting 11,194
genes [48]. In parallel, we determined DNA copy-numbers for these same cells. For each gene,
we classified each cell line as either copy-number loss or being copy-neutral, calculated the
mean gene dependency score among cell lines in each group, and determined the difference in
mean scores between the copy-loss and copy-neutral groups. Of the 102 candidate genes
identified (FDR p-value < 0.25) (Table 5.1), also known as Copy-number alterations Yielding
Cancer Liabilities Owing to Partial losS (CYCLOPS) genes, proteasome- and spliceosome-
related pathways were particularly enriched. Both of these pathways involve macromolecular
complexes that perform obligate cellular functions.
The highest ranked CYCOPS candidate was PSMC2, which encodes an ATPase AAA
domain containing protein that is an essential component of the 19S proteasome regulatory
complex. To study the effect of PSMC2 loss on PSMC2 protein levels, we evaluated PSMC2
levels in IOSE cells and ten ovarian cancer cell lines, including five PSMC2Neutral and five
PSMC2Loss lines. All five PSMC2Loss Cell lines expressed lower levels of PSMC2 than others
(Figure 5.3A). Since PSMC2 is essential for cell proliferation, we concluded that PSMC2Nural
cells either require more PSMC2, or produce more PSMC2 than is required. We therefore
investigated whether PSMC2Nea cells can tolerate greater suppression of PSMC2 expression.
We found that the anti-proliferative effect of suppressing PSMC2 was highly specific to
cells with copy number loss involving PSMC2 (PSMC2Loss), but not in cells that harbor both
copies of PSMC2 (PSMC2neutraI) (Figure 5.4). Specifically, in OVCAR-8 (PSMC2Loss) and
A2780 (PSMC2Nutral) cells that express PSMC2-specific shRNA under the control of a
doxycycline-regulated promoter (hereafter described as the PSMC2 inducible shRNA system)
(Figure 5.3B), the addition of doxycycline led to the suppression of PMSC2 in both OVCAR-8
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and A2780 cells, but only affected the viability of OVCAR-8 cells (Figure 5.4). The magnitude
of the anti-proliferative effect is dependent on the amount of PSMC2 suppression: A2780 cells
proliferated until 60% of PSMCS2 was depleted while OVCAR8 cells exhibited cell death when
we achieved only 20% suppression of PSMC2 (Figure 5.4). Based on these observations, we
concluded that higher levels of PSMC2 in A2780 cells do not reflect an increased requirement
for PSMC2, but instead constitute a "reservoir" of PSMC2.
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Figure 5.1. The identification of CYCLOPS genes amongst the genes that undergo copy number loss
in cancer. (A) The percentage of the cancer genome that undergoes copy number loss. (B) The size of
genomic deletions that result in copy number loss in cancer genomes. The length of individual deletions
(as a fraction of the chromosome arm where they occur) was determined as previously described.
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Figure 5.2. Schematic describing one mechanism by which tumor suppressor gene inactivation
results in partial loss of non-driver genes. Tumor suppressors often require bi-allelic inactivation for
tumor initiation or maintenance. Here, one allele is lost as a result of an alteration that affects a small
genomic region that includes the tumor suppressor gene (in red). The second allele is lost as a result of
chromosome arm loss, leading to complete tumor suppressor inactivation.
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(B) PSMC2 levels in cells that express an inducible shRNA that targets PSMC2.
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Figure 5.4. A non-linear relationship between PSMC2 levels and proliferation of ovarian cancer
cells. A2780 (Left) and OVCAR-8 (Right) cells were cultured in varying concentrations of
doxycycline. Cells were collected three days after to assess the levels of PSMC2 mRNA by qPCR. In
parallel, cell proliferation was determined and normalized to the untreated samples.
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Table 5.1. A list of genes that exhibit "Copy-number alterations
to Partial losS".
Yielding Cancer Liabilities Owing
Rank
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
Gene
PSMC2
TXN
RPS15
PHF5A
PABPN1
SMU1
POLR2A
NUP54
PAFAHIBi
ATP6VOA1
RBX1
CKAP5
USPLI
PRSS23
PCNA
TXNRD2
SF3A2
EEF1A1
SMC2
GUCYlA2
PSMD11
FOXD4L4
POLR2F
OR5212
USP8
PRPF8
FBXO7
CTDSPL
ANAPC1O
LSM6
COPS8
RIOKI
ALDH2
PSMD13
ZNF25
CSF3R
NUTF2
EIF2B2
BMP8A
NUPLI
EEF2
SNRPD3
CPTIB
LSM7
PRPSAP2
MADILI
PREP
Mean Difference
-2.07
-1.12
-1.12
-0.76
-0.87
-1.09
-0.93
-0.61
-1.29
-1.01
-0.57
-1.37
-0.86
-0.44
-1.19
-0.39
-0.62
-1.01
-0.89
-0.91
-1.15
-0.96
-0.76
-0.50
-0.63
-0.57
-0.25
-0.56
-0.38
-0.99
-0.94
-0.96
-0.49
-0.70
-0.52
-0.56
-0.84
-0.68
-0.55
-0.62
-0.63
-0.91
-0.43
-0.52
-0.37
-0.59
-0.30
P value (FDR)
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.02
0.02
0.03
0.03
0.03
0.03
0.03
0.04
0.05
0.05
0.06
0.06
0.06
0.06
0.06
0.08
0.09
0.11
0.11
0.13
0.15
0.15
0.15
0.15
0.16
0.16
0.16
0.16
0.16
0.16
0.16
0.16
0.17
0.18
0.19
0.19
0.22
0.23
0.25
0.25
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5.2.2 The reduction of PSMC2 levels inhibits tumor growth
To explore the therapeutic potential of PSMC2 suppression in vivo, we tested the
consequences of suppressing PSMC2 in xenograft ovarian tumors. Specifically, we utilized a
nanoparticle-based delivery system developed in Chapter 3 that can penetrate into the tumor
parenchyma and deliver siRNA payloads to select tumor cells expressing p32 [213]. We
generated tumor-penetrating nanocomplexes (TPN) consisting of PSMC2-specific siRNAs non-
covalently bound to TP-LyP- 1 tandem peptides.
We first assessed the compatibility of cell lines with TPN-targeted delivery of siRNA by
surveying cells for surface expression of p32, the cognate receptor for the tumor-specific
domain, LyP-1. Both OVCAR8 (PSMC2Loss) and A2780 (PSMC2Neur) cells, but not a normal
ovarian epithelial cell line (IOSE), exhibited elevated cell surface p32 expression as assessed by
flow cytometry (Figure 5.5). To ascertain whether p32 expression correlated with selective TPN
uptake, we quantified by flow cytometry TPN-mediated delivery of fluorescently-labeled siRNA
into the cytosol. We observed significant accumulation of siRNA in both OVCAR8 and A2780
cells, but not in IOSE. Further, TPN-mediated siRNA delivery is p32 receptor-specific; a
monoclonal antibody directed against p32 (mAb 60.11) abrogated TPN uptake (Figure 5.6),
whereas an isotype-matched control antibody had no effect. To confirm suppression of PSMC2
using TPN in vitro, we investigated the effects of PSMC2-specific siRNA on the proliferation of
PSMC2Loss and PSMC2Neta cells. Treatment with TPN carrying siRNAs targeting non-
overlapping exons of PSMC2 mRNA resulted in reduction of PSMC2 protein levels in both
OVCAR8 and A2780 cells. This reduction was associated with a corresponding decrease in
proliferation only in OVCAR8 cells (Figure 5.7).
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To probe the therapeutic effects of PSMC2 inhibition in vivo, mice harboring orthotopic
OVCAR8 (PSMC2Loss) tumor xenografts expressing firefly luciferase were injected with TPN
carrying PSMC2-siRNA (1 mg siRNA/kg/injection) intraperitoneally every 3 days for 14 days.
Repeated administrations of PSMC2-siRNA, but not a scrambled control siRNA (siCtrl), led to a
significant reduction in PSMC2 levels in the tumor (Figure 5.8), resulting in over 75%
suppression of the overall growth of OVCAR8 (PSMC2Lo ) tumors over time (Figure 5.9A). To
confirm that the therapeutic effect were due to sequence-specific RNAi, we performed an in vivo
therapeutic rescue experiment using orthotopic tumor xenografts from OVCAR8 cells expressing
an N-terminal V5-tagged form of PSMC2. V5-PSMC2 expression in OVCAR8 cells rescued the
expression of PSMC2 after in vivo treatment of nanocomplexes targeting the p32 receptor and
carrying PSMC2-specific siRNA. In the setting of ectopic PSMC2 expression, TPN/siPSMC2
injections every 3 days for 21 days (1 mg siRNA/kg/injection) failed to suppress tumor growth,
confirming that the therapeutic benefits in the presence of TPN/siPSMC2 was due to the
reduction of PSMC2 levels in PSMC2 tumor cells (Figure 5.9B).
To directly assess whether the sensitivity in PSMC2 Los to TPN/siPSMC2 in vivo is the
direct result of decreased PSMC2 expression, we measured their efficacy in isogenic xenografts
generated from PSMC2N"al cells engineered to inducibly express PSMC2-shRNAs.
Specifically, we established orthotopic A2780 (PSMC2Neutral) tumors expressing PSMC2-specific
shRNAs under the control of a doxycycline regulated promoter, confirmed tumor establishment
by bioluminescence imaging, and initiated twice weekly treatments of TPN/siPSMC2 for 2
weeks (1 mg siRNA/kg/injection). In contrast to OVCAR-8 tumors, PSMC2 suppression in vivo
did not show efficacy in A2780 cells without doxycycline induction, consistent with the in vitro
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finding that A2780 cell proliferation is insensitive to PSMC2 suppression, owing to the presence
of a buffer from excess PSMC2 protein (Figure 5.10).
The induction of PSMC2-shRNAs by doxycycline in A2780 (PSMC2Neutral) tumors did
not significantly abolish tumor initiation or growth, consistent with the model that a reduced
PSMC2 level is still sufficient for tumorigenesis. However, doxycycline does sensitize A2780
(PSMC2Neutal) tumors to further PSMC2 reduction. The combination of doxycycline and
TPN/siPSMC2 reduced tumor growth and significantly improved overall survival (median
survival = 33 d), with 3 out of 7 mice surviving after 42 days (Figure 5.11). In contrast, mice
that received doxycycline but TPN carrying a control siRNA (TPN/siGFP) grew uninhibited,
with all 6 animals of the cohort succumbed to tumors within 20 days (median survival = 16 d).
Collectively, these findings validate the therapeutic efficacy of PSMC2 suppression in vivo, and
support the theory that PSMC2Loss cells are specifically sensitive to suppression of PSMC2
through decreased basal levels of PSMC2 mRNA.
IOSE A2780 OVCAR-8
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Figure 5.5. Surface expression of p32, the cognate receptor for TPN. Immortalized ovarian surface
epithelial (IOSE) cells and two ovarian cancer cell lines (A2780 and OVCAR-8) were examined by flow
cytometry for overexpression of p32 receptor on the surface. Isotype-matched control are shown in gray.
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Figure 5.6. Uptake of TPN in A2780 and OVCAR-8 cells. Ovarian cancer cell lines are incubated with
TPN carrying siRNA labeled with a near-infrared fluorophore (VivoTag750) and cellular uptake was
assessed by flow cytometry. To probe the receptor-specificity of TPN uptake, a monoclonal antibody
against p32 (p3 2 mAb) was added along with TPN (red). Control cells received an isotype-matched
antibody (gray).
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Figure 5.7. TPN suppression of PSMC2 in ovarian cancer cell lines impact their viability. (A)
Immunoblots of PSMC2 levels after treatment with TPN carrying a pool of PSMC2-specific siRNAs.
Control cells received TPN carrying a control siRNA (GFP), lipofectamine carrying PSMC2-siRNA,
or untargeted control nanocomplexes (ARAL) carrying PSMC2-siRNA. (B) A2780 and OVCAR-8
cellular proliferation measured by total ATP content after treatment with indicated TPN formulations.
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Figure 5.9. Therapeutic effects of PSMC2 suppression in mice bearing orthotopic OVCAR-8
xenograft tumors. (A) Tumor burden over time in mice treated with TPN/siPSMC2. *p<0.05,
***p<0.001, by one-way ANOVA. (B) Tumor burden over time in mice bearing orthotopic tumors
derived from OVCAR-8 cells expressing a V5-tagged PSMC2.
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Figure 5.10. Therapeutic effects of PSMC2 suppression in mice bearing A2780 orthotopic ovarian
tumor xenografts. Mice with existing tumors were treated with TPN carrying PSMC2-specific siRNA
and tumor burden was monitored overtime via non-invasive whole-animal bioluminescence imaging.
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Figure 5.11. Therapeutic effects of PSMC2 suppression by TPN in the dox-inducible shRNA
system. (A) Mice bearing A2780 orthotopic tumor xenografts were fed with doxycycline and treated
with TPN carrying PSMC2-specific siRNA every 3 days for 20 days (n = 5). Control cohorts of received
either TPN carrying GFP-specific siRNA (n= 5) or phosphate-buffered saline (PBS, n = 5). (B) Overall
survival of mice that were fed with doxycycline and treated with TPN/siPSMC2 (sh7183 + Dox, n = 8),
compared against mice that were only treated with TPN/siPSMC2 (sh7183 - Dox, n = 6).
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5.3 Discussion
The resulted presented here suggest that hemizygous loss of PSMC2 in particular, and
CYCLOPS genes in general, represent a new class of cancer specific vulnerabilities. More
importantly, direct inhibition of PSMC2 by RNAi suppressed the growth of ovarian tumors,
suggesting that PSMC2 may be a potential therapeutic target for clinical translation.
Existing approaches to identify targeted therapeutics tend to focus on genes that drive
cancer growth or diminish cancer's response to specific stresses. The suppression of CYCLOPS
genes such as PSMC2 does not fit into either of these categories. The partial loss of CYCLOPS
genes, while frequently observed in cancer, is unlikely to directly promote oncogenesis. Ectopic
expression of PSMC2 did not inhibit proliferation in vitro or tumor progression in vivo.
Nevertheless, the copy number loss phenotype could be maintained in cancer due to mechanisms
such as a "Founder" effect or inherent proximity to nearby tumor suppressors.
Targeting CYCLOPS genes represents an alternative approach to synthetic lethality, in
which a genomic event can be identified as a non-driver vulnerability, even if no specific
pathway has been negatively affected. For example, in breast and ovarian cancer cells with
BRCA 1 or BRCA2 loss, repair of damaged DNA by homologous recombination is impaired,
thereby making them dependent exclusively on nucleotide-excision repair of DNA damage [280-
281]. Inhibition of the DNA repair enzyme Poly (ADP-ribose) polymerase 1 (PARP 1) by small
molecules or siRNA [282] is effective against these BRCA-deficient cancers via synthetic
lethality. If two events are synthetic lethal, one would expect not to find them in the same
cancers. Indeed, our results show that loss of both alleles of CYCLOPS genes is rarely observed.
Conversely, partial loss of CYCLOPS genes is frequently observed, indicating such partial loss is
tolerated. This suggests a potential alternative path to identify CYCLOPS and similar
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vulnerabilities in cancer cells: investigate cancer genomes for combinations of events that are
significantly underrepresented, under the hypothesis that the low frequencies of these
combinations reflect the effects of negative selection.
PSMC2 is an essential component of the 19S regulatory proteasome. Standard
proteasome inhibitors such as bortezomib have shown significant clinical activity and low
toxicity in several cancers, suggesting that a therapeutic window exists in targeting CYCLOPS
genes that are also part of the proteasome complex. Furthermore, standard proteasome inhibitors
do not fully take advantage of CYCLOPS -associated vulnerabilities, as PSMC2 copy number
loss does not dramatically affect the amount or activity of the 26S proteasome. In contrast,
inhibition of PSMC2 by small interfering RNAs exhausted a surplus of a requisite precursor and
inhibited proteasome function in vitro and in vivo. Recently, siRNAs have also been recently
utilized to discriminate and target closely related isoforms of an essential glycolytic enzyme to
induce tumor regression [283]. Together, RNAi provides a tool to assess and act on candidates
that not only include classic oncogenes, but also genes that result from unstable genomes that do
not necessarily contribute to a malignant phenotype.
In this work, the tumor-penetrating delivery of siRNA targeting PSMC2 resulted in a
significant reduction of PSMC2 in vivo and inhibited the growth of tumors that harbored copy
number loss of PSMC2. Importantly, a preclinical therapeutic trial with systemic administrations
of TPN/siPSMC2 over 20 days was associated with minimal toxicity in animals. The delivery
system is highly modular; other tumor-penetrating ligands and siRNA cargo can be varied with
ease. Therefore, as genomic efforts unveil more CYCLOPS genes in the future, this siRNA
delivery system could be easily adapted to discover and validate additional cancer-specific
vulnerabilities.
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5.4 Materials and Methods
Pooled shRNA Library Screen. Genome-scale pooled shRNA screens [284] in 102 cancer cell lines
were performed using a lentivirally delivered pool of 54,020 shRNAs targeting 11,194 genes. Each cell
line was infected in quadruplicate and propagated for at least 16 population doublings[48]. The
abundance of shRNAs relative to the initial DNA plasmids was measured by microarray hybridization
and normalized using dCHIP and GenePattern modules before identifying essential genes (See Extended
Experimental Procedures for details).
Analysis of shRNA screening data. Raw .CEL files from custom Affymetrix barcode arrays were
processed with a modified version of dCHIP software [284]. The GenePattern module 'HPscores' was
used to calculate the log fold change scores derived from replicate measurements of the shRNA
abundance in each cell line at the conclusion of the screening relative to initial DNA reference pool. This
score was adjusted to de-emphasize shRNAs that showed high variability among replicates of the DNA
pool. This log fold change score was divided by the s.d. of the DNA pool after it had been mean centered
at 1 and floored at 1 to de-emphasize shRNAs that showed high variability among replicates of the DNA
pool, which likely arises from technical artifacts including shRNA under-representation in the initial
DNA pool or sub-optimal array probe performance. The Gene Pattern module 'NormLines' was then used
to normalize the adjusted log fold change scores among cell lines by scaling and centering these scores
with Peak median absolute deviation (PMAD) normalization, a variation of ZMAD. PMAD
normalization consisted of, first, centering the shRNA scores per cell line at 0 by subtracting the value of
each shRNA from the modeled peak value of the distribution of each cell line. The shRNA scores for
each cell line were then rescaled so that each line had similar data ranges by dividing the centered data for
each shRNA by the median absolute deviation (MAD).
To identify genes that were both amplified in ovarian tumors and essential in amplified cell lines,
each gene identified as amplified in primary ovarian tumors [82] were tested one by one across the entire
panel of 102 cell lines screened. For those genes that have 5 or more lines with an amplification of the
gene, the median shRNA score for each shRNA in the pool was calculated and used to convert shRNA
scores to z-scores. Amplified genes that had mapped shRNAs with a z-score<-2.0 were identified. All
data files can be accessed at the Integrative Genomics portal (http://www.broadinstitute.org/IGP/home).
Please utilize Login: reviewer, Password: achilles to browse data.
Analysis of TCGA Data
All primary high grade serous ovarian cancer data were downloaded from the TCGA portal (http://tcga-
data.nci.nih.gov/tcga). TCGA has characterized copy number alterations in 489 primary high grade serous
ovarian tumors using Illumina 1MDUO arrays. 63 recurrent regions of amplification were identified using
GISTIC 2.0. The boundaries of these regions were set with at least 95% confidence to include the target
gene(s), resulting in the identification of 1270 amplified genes. The frequency of amplification for ID4,
KRAS, ERBB3 and SKP2 genes was determined by using a threshold of log 2 copy number ratio > 0.3
within a subset of tumors in TCGA project (345 tumors). Screenshots of the same tumor data were taken
using the Integrative Genome Browser (IGV; http://www.broadinstitute.org/igv).
Cell culture and generation of stable cell lines. All human cancer cell lines are cultured as described
[48]. Immortalized human ovarian surface epithelial cells (IOSE)[238] were maintained in 1:1 Medium
199:DMEM supplemented with 10% fetal bovine serum (FBS, Sigma). HeLa, MDA-MB-435, and T22H
cells were cultured in Dulbecco's modification of Eagle's medium (Invitrogen) with 10% bovine serum
(Invitrogen). OVCAR-8 cell line stably expressing firefly luciferase was generously provided by Dr.
Joyce Liu. Retroviruses were generated by transfection of 293T packaging cells with pBabe/pWzl and
pCL-Ampho plasmids [36].Lentiviruses were produced by transfection of 293T packaging cells with a
three-plasmid system [284]. To generate stable cell lines, cells were seeded into 10-cm dishes for 24 h
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before infection with either 5 ml of retroviruses or 0.3 ml of lentivirusesfor 3 h in the presence of 4 ptg/ml
polybrene. After the incubation, medium was replaced with fresh medium for another 24 h before
selection in media containing 2 tg/ml of puromycin for 2 d, 10 tg/ml of blasticidin for 4 d or 800 pg/ml
of neomycin for 5 d.
Plasmids. Human ID1, ID2, ID3 (obtained from the CCSB human ORFeome collection,Dana-Farber
Cancer Institute) and ID4 (obtained from Origene) were cloned into pLenti6.3-blast (BamHI and BsrGI
sites).The ID 4 S7 3PL 94 P(or ID4_DM) mutant was generated using the Quikchange Site-Directed
Mutagenesis kit (Stratagene). The pLenti6.2-LacZ was used as a control vector. Human HOXA9 was
provided by Anna Schinzel at Dana-Farber Cancer Institute and cloned into pWzl-blast (BamHI and
EcoRI). The human HRASV1 2 and KRASv12 in pBabe-puro vectors have been described[285]. The human
MEKD2 18,D 22 2 (or MEKDD) fragment was removed from pBabe-puro-MEKDD plasmid[36]with BamHI and
SalI and inserted into pBabe-neomycin.Lentiviral pLKO. 1 -puro-shRNA constructs were obtained from
The RNAi Consortium. The shRNA constructs used are as follows: control shRNA targeting GFP
(TRCN0000072181), ID4-specific shRNAs (shID4#1: TRCN0000017323, shID4#2: TRCN0000017325
and shID4#3: TRCN0000071444) and HOXA9-specific shRNAs (shHOXA9#1: TRCN0000012509,
shHOXA9#2: TRCN0000012510, shHOXA9#3: TRCCO019251728, shHOXA9#4: TRCCO019251729).
Peptides and siRNAs. The tandem peptide library was synthesized via standard FMOC solid-phase
peptide synthesis and purified by high-performance liquid chromatography at the MIT Biopolymers Core,
Tufts University Core Facility or CPC Scientific, Inc. The tandem peptides were then cyclicized by
bubbling air into 3 pM aqueous peptide solutions for 24 h, followed by lyophilisation and storage at -80
'C for later use. All siRNAs were obtained from Dharmacon, Inc. The sequences of siRNAs (5'-3') are as
follows: siGFP (GGCUACGUCCAGGAGCGCA),
siL UC(CUUACGCUGAGUACUUCGA), siBgal- 728 (CUACACAAAUCAGCGAUUU),
siID4_568(GAUAUGAACGACUGCUAUA), si1D4_62](CAACAAGAAAGUCAGCAAA),
siID4_564(GUGCGAUAUGAACGACUGCUA), and siID4_1195(CCGACUUUAGAAGCCUACUUU).
Fluorescent labelling of siRNA. siRNAs bearing 3'-amine on the sense strand was reacted in PBS with
twenty-fold molar excess of Vivotag S-750 amine-reactive dye (Visen Medical, Inc.) for 1 h at 37'C. The
reaction mixture was then precipitated overnight at-20'C in 0.5 M NaCl and 40% ethanol. Precipitated
siRNA was pelleted through centrifugation at 8000xg for 20 minutes at 4C, washed once with 70%
ethanol, and centrifuged again before being air-dried. This labelling process was repeated to yield
approximately 3.5 fluorophores per siRNA duplex.
Gene expression profiling. OVCAR-8 cells (2x 105) were infected with lentiviruses expressing a control
shRNA targeting GFP (shGFP) or two ID4-specific shRNAs (TRCN0000017323 and
TRCN0000071443)for 24 h. Cells were then cultured in fresh medium containing puromycin for 48 h to
select transduced cells (the pLKO. 1 vector also encodes the puromycin resistance gene). Total RNA was
extracted by Trizol reagent (Invitrogen) followed by RNeasy column purification (Qiagen). For
overexpression experiments, immortalize ovarian serous epithelial cells expressing activated MEK(IOSE-
M) cells were subjected to a 3 h infection with lentiviruses expressing control vector or ID4. Cells were
then cultured in medium containing blasticidin (blasticidin resistance gene encoded in the pLenti6.3-blast
vector) for 4 d togenerate polyclonal populations of stable lines and passaged twice before set-up for total
RNA extraction. Cells (4x 105 ) expressing the indicated constructs were plated onto 10-cm dishes for 48 h
and total RNA was extracted as described above. Gene expression profiling was then performed on
Affymetrix HG-U 1 33A_2 GeneChips by the Microarray Core at the Dana-Farber Cancer Institute. Probes
were aligned to a transcript database consisting of RefSeq (36.1) and complete coding sequences from
GenBank (v. 161). Gene-centric expression values were generated for every gene with at least 5 probes.
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Data for each experiment was normalized and summarized using robust multichip average (RMA), then
logged and row normalized.
Gene Set Enrichment Analysis (GSEA) [286]. Processed expression data from either the ID4 shRNA or
ID4 overexpression experiments was analyzed using GSEA v2.06(http://www.broadinstitute.org/gsea/).
For the shRNA experiments, we compared expression profiles derived from OVCAR-8 cellsinfected with
a control shRNA targeting GFP (shGFP) and OVCAR-8 cells infected with ID4-specific shRNAs. For
overexpression experiments, IOSE-M cells expressing a control vector were compared to cells
overexpressing ID4. GSEA was run using the default settings, except for the following; permutations
were based on the gene sets, not on phenotype and data was not collapsed to gene symbols (this was done
prior to GSEA). We additionally identified gene sets enriched in particular populations of ovarian tumor
samples. GSEA comparing 109 samples with amplified ID4 (log 2 copy number ratio > 0.3) vs. 81 non-
amplified ID4 samples (log 2 copy number ratio < 0) was performed using expression data from primary
ovarian samples with matched copy number from TCGA. GSEA was also performed with the same
dataset, using 44 samples with low ID4 expression levels vs. 45 samples with high ID4 expression
(thresholds were 1 standard deviation below and above the mean ID4 expression of all the samples).
Fluorescence in situ hybridization (FISH). BAC RPll-72111 clone containing ID4 (Invitrogen) was
labeled with Digoxigenin (Roche) using BioPrime labeling mix (Invitrogen). A reference probe specific
for the centromeric region of Chromosome 6 (CEP6 SpectrumOrange Probe, #06J36-016) was purchased
from Abbott Molecular. Labeled DNA was precipitated at -80'C for 2 h with 1 Il of glycogen (20 pg/pl),
pelleted by centrifugation at 18,000 xg for 15 min at 40C, air-dried for 10 min, and resuspended in 50 pl
of hybridization buffer (50% deionized formamide, 10% dextran sulfate, 2x SSC).
Slides containing metaphase chromosomes were pretreated with 1:25 Digest-All III (Invitrogen)
at 37 0C for 6 min before fixation in 10% buffered formalin for 1 min at room temperature. Slides were
dehydrated for 2 min each in 70%, 85%, 95% and 100% ethanol at room temperature. Probes were
prepared by mixing 2 pl of each labeled probe, 1 pl Cot-I DNA (1 mg/ml; Invitrogen), and 11 pl of
hybridization buffer. Probes were applied to air-dried slides; coverslips were applied and sealed with
rubber cement. These preparations were denatured at 72'C for 5 min. Hybridization was performed for 18
h at 37 0 C in a dark humid chamber. Coverslips were gently removed and slides were washed in 0.5x SSC
at 72C for 5 min, rinsed at room temperature in lx PBS containing 0.025% Tween-20. Slides were
blocked with CAS-Block containing 10% normal goat serum (Invitrogen) and then incubated with FITC-
anti-Digoxigenin (Roche). Slides were washed in 1x PBS containing 0.025% Tween-20 and
counterstained with DAPI (Invitrogen). Images were captured by using Zeiss Axio Observer Z1
microscope (Zeiss) and AxioVision digital imaging software (Zeiss).
Gel-shift and stability assays. For the gel-shift assay, siRNA was mixed with tandem peptide at
specified molar ratios in phosphate buffered saline (PBS) for 10 - 15 min at room temperature. The
mixture was analyzed by non-denaturing gel electrophoresis using a 15% acrylamide gel for siRNA,
stained with SYBR-Gold, and visualized under UV light. For the siRNA stability assay, siRNA (100
pmol) was mixed with TP-LyP1 or 6R-LyP1 (2 nmol) in PBS for 10 - 15 min at room temperature.
Naked siRNA or peptide-complexed siRNA was then added to 100% murine serum (10:1 v/v) and
incubated at 37 'C up to 24 h, after which the RNA is extracted and precipitated according to established
protocols, separated on a 15% TBE gel, stained with SYBR-Gold, and visualized under UV light.
Peptide uptake and gene silencing. For the initial screen, HeLa cells expressing GFP were cultured in
96-well plates to ~40-60% confluence. siRNA (0-100 nM) was incubated with 20-fold molar excess of
tetramethylrhodamine-labeled tandem peptides in PBS for 10-15 min at room temperature, incubated over
cells for 4 h at 37 'C, after which the medium was replaced. Transfection with Lipofectamine RNAiMAX
was used as a positive control. The cells were cultured for an additional 24-48 h before being examined
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by flow cytometry on a BD LSRII instrument. % Knockdown based on the geometric mean of GFP
fluorescence of the entire population was normalized to GFP signal of mock treated cells. For competition
experiments with free LyP1 peptide, cells were pre-incubated with unlabeled LyP1 or ARAL control
peptide at specified concentrations from 5 to 20 pMfor 1 h at 37 'C before nanocomplex treatment.
For ID4 silencing, siRNAs targeting different exons of the ID4 mRNA (100 pmol) were mixed
with TP-LyP1 at a molar ratio of 1:20 in PBS. The mixture was added to OVCAR-8 or OVCAR-4 cell
cultures (plated at 0.2 x 106 cells in 6-well plates 48 h prior) for 4-6 h at 37 'C and was then replaced with
fresh serum-containing media. Cell lysates were collected 48 h later for immunoblotting.
Cell proliferation assay. A total of 800-2000 Cells were seeded into each well of 96-well plates 24 h
prior to infection. Six replicate infections were performed for control shRNAs and each gene-specific
shRNA in the presence of 4 pg/ml polybrene for 24 h followed by selection with2 pg/ml of puromycin.
The ATP content was measured at 6 d post-infection by using CellTiter-Glo luminescent cell viability
assay (Promega). To measure the toxicity of nanocomplexes in vitro, HeLa cells grown in 96-well plates
at 40-60% confluency were incubated in triplicate with nanocomplex formulations for 24 h. Viability was
measured using CellTiter-Glo luminescent viability assay (Promega). To measure the cytotoxicity of ID4
suppression, OVCAR-8 and OVCAR-4 cells grown in 6-well plates at 40-60% confluence were
transfected twice on two consecutive days with nanocomplexes containing siRNA against ID4 (100 pmol)
or containing siRNA against GFP. Twenty-four (24) h after the second transfection, cells were trypsinized
and plated in 96-well plates in quadruplicate. The plateswere analyzed 24 h later using Celltiter-Glo
assays (Promega) according to manufacturer's instructions.
Anchorage-independent growth assay. Growth in soft agar was determined by plating 1x104 cells in
triplicate in 5 ml of medium containing 0.35% Noble agar (BD Biosciences) which was placed on top of 4
ml of solidified 0.7% agar [285]. Colonies greater than 100 pm in diameter were counted 4 weeks after
plating. Data represent mean ± s.d. from three independent experiments.
Flow Cytometry. Fluorescence-activated cell sorting (FACS) analysis of cell-surface p32 was done on
live cells. Approximately 2.5 x 105 cells were stained with a polyclonal anti-full-length/NH2-terminal p32
or rabbit IgG isotype control (1 pig per 1 x 106 cells) and Alexa-647 goat anti-rabbit secondary antibody,
each for 45 min at 4 'C, analyzed by gating for propidium iodide-negative (live) cells. For analysis of
apoptosis, cells were resuspended in 1x Annexin-V binding Buffer (BD Biosciences, San Jose, CA). Cells
were incubated with Annexin V - FITC and propidium iodide for 15 minutes in the dark according to the
manufacturer's recommendation. % of cells in S-phase was determined using the Click-iT EdU cell
proliferation assay (Invitrogen) according to manufacturer's instructions.
Immunoblotting. Cell lysates were prepared by scraping cells in lysis buffer [50 mM Tris HCl (pH 8),
150 mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate and 0.1% SDS] containing complete
protease inhibitors (Roche) and phosphatase inhibitors (10 mM Sodium Floride and 5 mM Sodium
Orthovanadate). Protein concentration was measured by using BCA Protein Assay kit (Pierce). An equal
amount of protein (30 tg) was separated by NuPAGE Novex Bis-Tris 4-12% gradient gels (Invitrogen)
and then transferred onto a polyvinylidene difluoride membrane (Amersham). The membrane was then
incubated with primary antibody for 1 h at room temperature. Antibodies againstID1 (sc-488), ID2 (sc-
489), ID3 (sc-490), ID4 (sc-13047), K-RAS (sc-30) and H-RAS (sc-29) were purchased from Santa Cruz
Biotechnology. Antibodies specific for Caspase-3 (#9665), MEK (#9122), PARP (#9532) and phospho-
ERKl/2 (#9101) were from Cell Signaling Technology. Antibody specific for HOXA9 (#07-178) was
from Millipore. Antibody specific for a-tubulin (#13-8000)was from Invitrogen. After incubation with the
appropriate horseradishperoxidase-linked secondary antibodies (Bio-Rad), signals werevisualized by
enhanced chemiluminescence plus Western blottingdetection reagents (Amersham). Expression of p-actin
wasalso assessed as an internal loading control by using a specific antibody (sc-8432-HRP,Santa Cruz).
Immunoblots of cell lysates after TPN treatment were incubated with IRDye 680 goat anti-mouse IgG or
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IRDye 800 goat anti-rabbit IgG (Li-COR) and scanned using the Odyssey infrared imaging system (Li-
COR). Intensities ofbands were quantified by LabWorks image analysis software (UVP) or ImageJ
(http://rsbweb.nih.gov/ii/).
Real-time quantitative Reverse-Transcription PCR. Total RNA was extracted with Trizol reagent
(Invitrogen). 4 pg of total RNA for each sample was used to synthesize the first-strand cDNA by using
Oligo(dT) 20/random hexamer primer cocktails and SuperScript III reverse transcriptase (Invitrogen).
Quantitative PCR reactions were performed using SYBR green PCR Master Mix (Applied Biosystems).
The primer sequences used are as follows: ID4 (forward: 5'-CCGAGCCAGGAGCACTAGAG-3';
reverse: 5'-CTTGGAATGACGAATGAAAACG-3'), HOXA3
(forward:5'-TGCTTTGTGTTTTGTCGAGACTC-3'; reverse: 5'-CAACCCTACCCCTGCCAAC-3'),
HOXA 7 (forward: 5'-TATGTGAACGCGCTTTTTAGCA-3'; reverse:
5'-TTGTATAAGCCCGGAACGGTC-3'), HOXA9 (forward: 5'-GAGTGGAGCGCGCATGAAG-3';
reverse: 5'-GGTGACTGTCCCACGCTTGAC-3') and GAPDH (forward: 5'-
CCTGTTCGACAGTCAGCCG-3'; reverse: 5'-CGACCAAATCCGTTGACTCC-3').Triplicate reactions
for the gene of interest and the endogenous control, (GAPDH) were performed separately on the same
cDNA samples by using the ABI 7900HT real time PCR instrument (Applied Biosystems).The mean
cycle threshold (Ct) was used for the AACt analysis method (ABI User Bulletin #2).
Tumorigenicity assay. Female Balb/c and NCR/nude mice (Charles River Laboratories) were obtained at
4-6 weeks of age. All animal experiments were approved by the MIT Committee on Animal Care under
approved protocols. Tumor xenograft experiments were performed as described[238]. IOSE cell lines
expressing indicated constructs were trypsinized and collected in media supplemented with 10% FBS.
Cells (8x 106) were resuspended in 400 pl of lx PBS and mixed with 400 pl of BD MatrigelTM -Basement
Membrane Matrix, LDEV-free (BD Biosciences) prior to injection. 200 pl of the cell mixture (containing
2x 106 cells) was injected subcutaneously into 8-week-old female BALB/c nude mice. Tumor injection
sites were monitored for 5 months for tumor formation. Mice were euthanized when tumors reached 1.5
cm in diameter. For HOXA9 experiments, ID4-overexpressing IOSE-M cells were infected with
lentiviruses expressing control shRNAs or two previously described HOXA9-specific
shRNAs[247](shHOXA9#1: TRCN0000012509 and shHOXA9#2: TRCN0000012510). Cells were then
cultured in fresh medium for 24 h before selection in 2 tg/ml of puromycin for another 2 d. Infected cells
were then passaged once before injection into immunodeficient mice as described above.
Systemic administration and in vivo characterization of TPNs. Female NCR/nude mice were injected
subcutaneously on the bilateral flanks with 2x10 6 MDA-MB-435 melanoma or 2x10 6 OVCAR-8 ovarian
cancer cells mixed with Matrigel and allowed tumors to form over two weeks. For circulation
experiments, 5 nmols of near-infrared fluorophore (Vivotag-750) labeled siRNA was complexed to
tandem peptides (at a molar ratio of 1:20 siRNA to peptide) in 5% glucose and injected either
intravenously or intraperitoneally into mice bearing bilateral subcutaneous MDA-MB-435 tumors. The
mice were imaged at specified times using the IVIS 200 imaging system (Caliper Life Sciences). Blood
was periodically drawn retroorbitally and near-infrared fluorescence from circulating siRNAs was
measured using the Odyssey imaging system (Li-COR Biosciences). The organs were harvested 6 h after
injection and were also imaged using IVIS. Tumor explants were examined at higher resolution (84 gm)
using the Odyssey imager with an excitation wavelength of 785 nm. To study time-dependent homing and
tumor penetration in OVCAR-8 tumors, TPNs carrying FITC labeled-siRNA were administered
intravenously to tumor bearing mice (5 nmols siRNA/injection). Tumors and tissues were collected 6 h
later for subsequent analyses by immunofluorescence or quantification of total injected dose.
To determine the % injected dose accumulated in the tissue, organs and tumors harvested from
mice were pulverized under liquid nitrogen and homogenized in 10 mM Tris buffer with 1% SDS. The
homogenate was heated at 95'C for 10 minutes and centrifuged at 14,000xg. Fluorescence of the lysate
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was measured using the Odyssey imager. To generate a standard curve for each organ, organs and tumors
from uninjected animals were processed and known amounts of fluorescent siRNAs were spiked into the
lysates. The lysates were imaged under the same settings, and the integrated fluorescence intensities
versus siRNA concentrations were fitted with a 3-parameter exponential equation (f=y0+a*(1 -exp(-b*x));
SigmaPlot).
To test knockdown of luciferase expression in vivo, mice bearing orthotopic luciferase-expressing
T22H tumors were injected i.p. with nanocomplexes (2.5 and 5 mg/kg). Control groups received saline,
peptide alone, nanocomplexes containing siRNA against GFP, or untargeted nanocomplexes containing
siL UC (all 5 mg/kg). Whole-animal imaging of luciferase activity was performed 48 h later. To measure
the duration of luciferase silencing, bioluminescence imaging was performed at specified time points.
Animal model of metastatic ovarian cancer. For the OVCAR-4 tumor model, 3x 1 O6 OVCAR-4 cells
mixed with Matrigel were implanted in the subcutaneous space on the bilateral flanks of 4- to 6-week-old
NCr/nude mice (Charles River Laboratories). Once tumors were established, animals were divided into
cohorts of five mice each and were treated with saline, or TP-LyP-1 carrier only without siRNA (6.5mg
peptide/kg body weight, Carrier), TPNs carrying GFP-specific siRNA (siUT), or TPNs containing ID4-
specific siRNA injected either intravenously (siID4(IV)) or intraperitoneally (siID4(IP)) all at 1mg
siRNA/kg body weight/injection, every 3 days for 25 days. For the OVCAR-8 tumor model, OVCAR-8
cells stably expressing firefly luciferase were injected intraperitoneally into 4- to 6-week-old NCr/nude
mice (Charles River Laboratories) at 106 cells per mouse. Three weeks after injection, tumor
establishment was confirmed by an increase in total bioluminescence signal. The animals were then
randomly divided into cohorts of five mice each. The first cohort received nanocomplexes containing TP-
LyPI and siRNA against ID4 (siJD4_568 and siID4_621, 5 mg siRNA/kg body weight). The other
control cohorts received saline, TP-LyPl/GFP-siRNA (siUT, 5 mg/kg), or TP-ARAL/ID4-siRNA
(ARAL/siID4, 5 mg/kg). For all treatments, siRNA was mixed with peptide at a molar ratio of 1:20
(siRNA to peptide) in 500 ptL of PBS with 5% glucose, and injected intraperitoneally. Treatments were
repeated twice weekly for 14 days, after which the dose was reduced to once weekly for 3 more weeks.
On day 60, tumors/organs were harvested for immunohistochemical analyses. Whole-animal optical
imaging was performed every 3 days. Mice were anesthetized using isofluorane, injected with 150 mg/kg
D-luciferin (Promega), and imaged 10-15 min after injection once the signal peaked.
Immunostaining and analysis. For histological analysis, harvested tumors were fixed in 4%
paraformaldehyde at 4'C overnight, soaked in 30% sucrose (w/v) for 24 h, then snap frozen. Rat anti-
mouse CD31 (1:50, BD PharMingen) and a polyclonal anti-full length p32 antibody were used for
immunohistochemical staining. Rat or rabbit IgGs were used as isotype controls. Sections were washed
and detected with AlexaFluor-488 goat anti-rat or anti-rabbit IgG (1:1000; Invitrogen). The slides were
counterstained with DAPI and mounted on glass slides for microscopic analysis. At least three images
from representative microscopic fields were analyzed for each tumor sample using the ImageJ software.
Immunogenicity studies in mice. Balb/c immunocompetent mice were injected intraperitoneally with
TP-LyP1 complexed to siRNAs against ID4, GFP, firefly luciferase, and sipgal-728 (5mg siRNA/kg body
weight). siBgal-728 encapsulated in Lipofectamine RNAiMAX was used as a positive control. Serum
samples obtained 6 h after injection were processed for measurements of IFN-U, TNF-U, and IL-6 by
ELISA (PBL Biomedical Laboratories and BD Biosciences) in accordance with the manufacturer's
instructions.
Statistical Analysis. Statistical analyses were performed using built-in statistical functions in GraphPad
Prism (GraphPad Software). Tumor burden between different cohorts and averaged fluorescence
intensities from immunofluorescence staining, and Western blots were analyzed using one-way ANOVA
and appropriate post-hoc tests.
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6 Characterization of receptor-specific cell-penetrating
peptides for siRNA delivery
6.0 Abstract
Tumor-targeted delivery of siRNA remains to be a major barrier in fully realizing the
therapeutic potential of RNA interference. While cell-penetrating peptides (CPP) are promising
as carriers of siRNA, they are universal internalizers that lack cell-type specificity. In Chapter 3,
we have developed tandem tumor-targeting and cell-penetrating peptides that condense siRNA
into stable nanocomplexes for cell type-specific siRNA delivery. In Chapters 4 &5, we utilized
tumor-penetrating nanocomplexes as a platform to validate cancer targets identified from large-
scale genomic efforts. Here, we present follow-up physiochemical and biological analyses of
nanocomplexes uptake, endosomal escape, carrier unpacking, and ultimately delivery of siRNA
to the cytosol in a receptor-specific fashion. To better understand the structure-activity
relationships that govern receptor-specific siRNA delivery, we employ computational regression
analysis and identify a set of key convergent structural properties, namely the valence of the
targeting ligand and the charge of the peptide, that help transform ubiquitously internalizing cell-
penetrating peptides into cell type-specific siRNA delivery systems.
(Reprinted with permission from [287])
6.1 Introduction
RNA interference (RNAi) offers an attractive means to silence gene expression with
extraordinary specificity, particularly for the subset of "undruggable" gene targets [1]. This
capability is particularly appealing for diseases with complex genotypic alterations such as
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cancer. However, siRNA molecules are large (~14 kDa), highly anionic, hydrophilic, and
susceptible to degradation by nucleases. Upon systemic administration, naked siRNAs cannot
penetrate into tumor tissue, target extravascular cancer cells, and cross cellular membranes to act
in the cytosol. Therefore, to bring RNA-based therapeutics into the clinic, one must improve the
pharmacokinetic properties of siRNA and overcome several delivery barriers [5, 7].
Approaches to target the delivery of siRNA to tumor cells include lipophilic conjugations
such as cholesterol [131], attachment to targeting moieties such as antibodies or aptamers [127-
128], or encapsulation in polymer-based or liposomal carriers targeting tumor-specific markers
[126]. Nonetheless, to date, none of the approaches enable active penetration into the tumor
parenchyma to achieve gene silencing in epithelial tumor cells where genetic alterations reside.
Elsewhere, cell penetrating peptides (CPP, also known as protein transduction domains) such as
TAT and poly-Arginine have been shown to bring DNA- and RNA-based payloads into the
cytosol [230]. While CPPs are a class of promising siRNA carriers that rapidly penetrates the cell
membrane, they lack receptor specificity; they bind to and are internalized by cells via heparan
sulfates and other glycosaminoglycans in nearly all cell types in vitro and in vivo [288-289].
Thus, an ideal siRNA delivery system should possess two complementary characteristics: it
should efficiently penetrate tissues and cross cellular membranes, but it should also be cell type-
specific by targeting only tumor cells while sparing normal cells. Efforts to enhance the
specificity of CPPs include attachment to homing peptides or restriction of cargo activity to
specific cells [290-292]. However, the development of receptor-specific CPPs has been highly
empirical: peptides were tested one at a time without systematic optimization of functional
properties. Consequently, tumor-specific delivery of siRNA by CPPs is not routinely achieved.
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Recently, a new class of cell-internalizing and tumor-penetrating peptides has been
described which leverage a consensus C-terminal (R/K)XX(R/K) motif (the CendR rule) to
activate transvascular transport, cell internalization, and parenchyma penetration [117, 119]. Two
peptides that both contain tumor-homing and cryptic CendR motifs, iRGD (CRGDKGPDC) and
LyP-1 (CGNKRTRGC), have been shown to significantly improve the delivery of small
molecules, antibodies, and nanoparticles to tumors [218]. Leveraging this discovery, we have
previously developed tandem peptide sequences bearing a constant tumor-penetrating domain
(LyP-1) and variable cell-penetrating/siRNA-binding domains to chaperone siRNA cargo deep
into the parenchyma of ovarian tumors in vivo and suppress a novel ovarian oncogene [213].
However, the intracellular trafficking mechanism by which siRNAs are delivered to tumor cells
expressing specific receptors remain incompletely understood. Furthermore, the structure-
activity relationships that favored cell internalization and maximized gene silencing, while
maintained receptor-specificity and cell type-specific penetration and have yet to be determined.
Here, we present an analysis of tandem peptides developed in Chapters 3 to better
understand the properties that govern receptor-specific siRNA delivery. We characterized a
library of nanocomplexes formed by siRNAs non-covalently bound to tumor-specific peptides
bearing structurally distinct cell-penetrating domains. A subset of nanocomplexes achieved
functional delivery of siRNA in a cell type-specific manner. To gain quantitative mechanistic
insights, we studied the intracellular trafficking mechanisms of peptide-siRNA nanocomplexes
by measuring cellular siRNA uptake, escape from endosomal entrapment, and dissociation of
siRNA from the carrier. To understand the relationship between peptide material properties and
receptor-specific siRNA delivery, we fused data from physiochemical characterizations with
regression modeling to derive structure-activity relationships. Two structural properties, the
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valence of the tumor-specific ligand on the nanocomplex and peptide charge, are key
considerations when designing a siRNA delivery system that is both membrane-penetrating and
receptor-specific. Specifically, we found that myr-TP-LyP- 1 met the desired material properties,
condensed siRNA into nanocomplexes that are multivalent, and delivered siRNA to human
cancer cell lines in a receptor-specific fashion.
6.2 Results and Discussion
6.2.1 Characterization and in vitro cellular uptake of tandem peptides
To develop tumor-specific and cell-penetrating peptides for siRNA delivery, we set the
following design criteria: the delivery system should non-covalently condense siRNA in a single
step, remain stable in physiologic conditions, multivalently display homing peptides for tumor-
targeting, and readily dissociate once inside the cytosol to enable siRNA incorporation into the
RNA-induced silencing complex (RISC). Towards this goal, we synthesized a library of 9
tandem peptide carriers composed of distinct cell penetrating domains at the NH 2-terminus and a
tumor-specific CendR peptide, LyP- 1, at the C-terminus (Figure 6.1;Table 6.1). LyP- 1 homes to
tumor cells and tumor lymphatics via binding to its receptor p32, a mitochondrial protein that is
aberrantly expressed on the surface of tumor cells and tumor-associated macrophages [101, 217].
We generated N-terminally myristoylated versions of each of the 9 tandem peptides, since
myristoylation has been shown to enhance hydrophobic interactions and peptide affinity to lipid
bilayers such as the cell membrane [221]. The selection of cell-penetrating domains included
representatives of polycationic sequences including oligoarginines, the HIV TAT protein [293],
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and the HSV-l tegument protein VP22 [294]; as well as amphipathic CPPs such as penetratin
[295] and transportan [161].
We found that tandem peptides readily condensed siRNA into tumor-penetrating
nanocomplexes (TPNs) in a one-step procedure, without the need for exogenous stabilizing
lipids. To determine the amount of peptide needed to fully encapsulate free siRNAs into stable
nanocomplexes, we mixed siRNA with each tandem peptide at increasing molar ratios in the
presence of a dye (TO-PRO-3) that fluoresces when intercalated into double-stranded nucleic
acids. Upon particle formation, we observed a decrease in dye fluorescence likely due to steric
exclusion of dye binding to siRNA by peptides in the nanocomplex (Figure 6.2). Near-maximal
(> 95%) encapsulation of siRNA occurred consistently at molar ratios between 1.6:1 and 20:1
(peptide-to-siRNA) for all peptides in the library. Since the positively-charged CPP domain
binds the negatively charged backbone of the siRNA, this variation in encapsulation ratio can
lead to differences in the valence of the LyP- 1 ligand of the nanocomplex, which in turn can
affect the affinity of binding to the p32 receptor on the cell surface.
Using TEM and dynamic light scattering (DLS), we observed that the majority of TPNs
have hydrodynamic diameters ranging from 50 to 100 nm in water and from 200 to 400 nm in
PBS, with a narrow size distribution (polydispersity index < 0.2) (Figure 6.3; Figure 6.5). The
zeta potential of TPNs ranges from +20 to +40 mV (Table 6.1). No significant changes in TPN
size was observed when placed in mouse serum at 37'C (Figure 6.4). Moreover, TPNs remained
intact for at least 24 h in phosphate-buffered saline (pH 7.1) at 37'C as indicated by minimal
change in TO-PRO-3 fluorescence (Figure 6.5). To ensure that TO-PRO-3 fluorescence indeed
corresponded to the presence of intact nanocomplexes, we disrupted TPNs with a detergent and
observed restoration of dye fluorescence (Figure 6.5). These results collectively suggest that
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tandem peptides can non-covalently condense siRNA into stable nanocomplexes at defined
molar ratios.
Polycationic CPP:
3R, 6R, 9R, 12R,
15R, TAT, VP22
Amphipathic CPP:
PEN, TP
CendR peptide:
LyP-1
+ pgdpqf
Cargo:
siRNA
Figure 6.1. Schematic representation of the tumor penetrating nanocomplex (TPN). siRNA (blue) is
non-covalently bound to tandem peptides composed of a cyclic tumor-specific domain (LyP-1, green) and
various cell-penetrating peptide domains (purple) separated by a 4-glycine spacer (gray). A subset of the
tandem peptides tested were N-myristoylated (myr, orange). Cell-penetrating peptide domains tested
include representatives from both polycationic and amphipathic CPPs.
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Figure 6.2. Encapsulation of siRNA by tandem peptides.Tandem peptides were mixed with siRNA at
varying molar ratios, and the amount of siRNA encapsulated in nanocomplexes was determined by
measuring the fluorescence of a nucleic-acid intercalating dye (TO-PRO-3) normalized to dye
fluorescence with siRNA alone.
159
cell-penetrating tumor-specific
100 na
Figure 6.3. Representative TEM of a tandem peptide/siRNA nanocomplex formed in water and
negatively stained with uranyl acetate; scale bar = 100 nm.
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Figure 6.5. Characterization and stability of TPNs. (A) Hydrodynamic size histograms of TPN from
dynamic light scattering measurements. (B) Stability of TPNs in saline at 37 'C, as measured by
intercalation of TO-PRO-3 dye. The final data point (red, marked with A) represents disruption with 0.1%
Triton-X 100 detergent. Error bars indicate s.d. from three independent experiments.
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Table 6.1. Structural properties of nanocomplexes. (A) The myr- prefix denotes NH2-terminal
myristoylation. (dR)n = oligoarginine where n is the number of d-Arginine residues; PEN = penetratin;
TAT = HIV TAT (48-60); TP = transportan; VP22 = HSV-1 VP22 protein. (B) Mean hydrodynamic size
based on dynamic light scattering measurements. Errors indicate s.d. from at least 3 separate
measurements. (C) Zeta-potential of nanocomplexes. Errors indicate s.d. from at least 3 independent
measurements. ND, not determined.
161
[A]
Name Sequence
3R (dR) 3GGGGK(TAMRA)CGNKRTRGC
6R (dR) 6 GGGGK(TAMRA)CGNKRTRGC
9R (dR) 9GGGGK(TAMRA)CGNKRTRGC
12R (dR) 12GGGGK(TAMRA)CGNKRTRGC
15R (dR) 15GGGGK(TAMRA)CGNKRTRGC
PEN RQIKIWFQNRRMKWKKGGGGK(TAMRA)CGNKRTRGC
TAT GRKKRRQRRRGYKGGGGK(TAMRA)CGNKRTRGC
TP GWTLNSAGYLLGKINLKALAALAKKILGGGGK(TAMRA)CGNKRTRGC
VP22 DAATATRGRSAASRPTERPRAPARSASRPRRPVDGGGGK(TAMRA)CGNKRTRGC
m3R myr-(dR) 3 GGGGK(TAMRA)CGNKRTRGC
m6R myr-(dR) 6 GGGGK(TAMRA)CGNKRTRGC
m9R myr-(dR) 9 GGGGK(TAMRA)CGNKRTRGC
m12R myr-(dR) 1 2GGGGK(TAMRA)CGNKRTRGC
m15R myr-(dR) 1 5GGGGK(TAMRA)CGNKRTRGC
mPEN myr-RQIKIWFQNRRMKWKKGGGGK(TAMRA)CGNKRTRGC
mTAT myr-GRKKRRQRRRGYKGGGGK(TAMRA)CGNKRTRGC
myr-
mTP GWTLNSAGYLLGKINLKALAALAKKILGGGGK(TAMRA)CGNKRTR
GC
myr-
mVP22 DAATATRGRSAASRPTERPRAPARSASRPRRPVDGGGGK(TAMRA)C
GNKRTRGC
Diameter
[b](nm)
517.0 ± 33.9
364.3 ± 42.0
291.7 ± 21.2
175.5 ± 42.3
211.4± 18.9
259.0 ± 36.1
175.3 ± 5.5
310.5 ± 61.2
253.5 ± 6.5
209.0 ± 40.5
151.0± 11.1
207.8 ± 19.6
191.2± 17.9
377.2 ± 49.4
337.6 ± 54.9
194.6 ± 43.6
343.6 ± 32.3
233.0 ± 58.8
C-Potential
(m V) [C]
7.8 ± 5.6
11.6± 8.6
ND
ND
ND
ND
ND
ND
ND
21.8 ± 5.0
27.3 ± 4.0
36.6 ± 7.1
27.6± 15.0
36.0 ± 7.5
29.0 ± 5.1
35.8 ± 8.0
31.9 ± 3.7
30.8 ± 4.8
6.2.2 Cellular uptake of TPNs
To effectively deliver siRNA, the carrier should exhibit high cellular uptake with
minimal cytotoxicity. We examined a panel of established, human cancer cell lines and identified
three (HeLa, MDA-MB-435, and OVCAR-8) that overexpress p32, the cognate receptor for the
tumor-specific domain, LyP-1, on the cell surface. Viability of HeLa cells was not affected after
TPN treatment for the majority of tandem peptides with the exception of 12R and 15R, whose
excess cationic charges may have contributed to disruption of membrane integrity and reduction
in cell viability (Figure 6.6).
To gain insight into the siRNA delivery capabilities of TPNs, we first assessed by flow
cytometry the effect of NH2-terminal myristoylation of the carrier on the cellular uptake of
siRNA. In OVCAR-8 human ovarian cancer cells, the myristoylated species of the tandem
peptides were significantly more efficacious in delivering fluorescently-labeled siRNA relative
to their non-myristoylated counterparts (Figure 6.7). This may be due to enhanced particle
stability due to hydrophobic interactions between myristoyl moieties, or enhanced interactions
between myristoylated peptides and membrane lipids. To confirm that siRNA delivery was
indeed correlated with uptake of the carrier, we repeated the experiments with tandem peptides
singly labeled with tetramethylrhodamine (TAMRA) and compared intracellular peptide
fluorescence with siRNA fluorescence for each peptide (Figure 6.8). In general, the relative
cellular uptake of the carrier correlated linearly with that of the siRNA cargo. Short oligo-
arginine CPPs such as 3R and 6R showed poor siRNA delivery in comparison to longer poly-
arginines such as 12R and 15R, likely due to the lower number of cationic charges available to
bind the negatively-charged siRNA backbone and provide sufficient charge shielding for
membrane translocation. Similar patterns in cellular uptake were observed in MDA-MB-435 and
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HeLa cells (not shown). Collectively, these results indicate that a subset of tandem peptides can
effectively carry siRNA payloads into cell linesthat express p32 on the surface; additionally, N-
terminal myristoylation of the peptide carrier can further enhance siRNA delivery into the cell.
Next, we assessed whether siRNA delivery by nanocomplexes is cell type-specific. To
confirm p32 receptor-specificity, we examined by flow cytometry siRNA uptake in the presence
of a monoclonal antibody (mAb 60.11) directed against the NH2-terminus of p32 polypeptide. In
OVCAR-8 cells, uptake of nanocomplexes bearing CPP domains such as TAT, 9R, 12R, and
15R was unaltered in the presence of the antibody. In contrast, the p32 antibody reduced siRNA
delivery by TP, 3R, 6R, and PEN nanocomplexes in a dose-dependent manner by up to 80%
(Figure 6.9). Compared to cationic CPPs such as 12R and 15R that formed nanocomplexes at a
peptide-to-siRNA molar ratio of nearly 1:1, TP-, 3R-, and 6R-LyP- 1 nanocomplexes were
formed at a ratio of at least 9:1. This difference in encapsulation likely resulted in
nanocomplexes with a varying apparent valence of the LyP- 1 ligand. Since multivalent receptor-
ligand interactions enhance specificity through avidity effects [170, 203], the higher p32-affinity
(lower IC50 of mAb) observed for the subset of nanocomplexes (TP, 3R, 6R) is attributable to
multivalency effects.
163
B3R 12R
6R + 15R
9R 0 PEN
(U
.5
a,
(U
ii:
0 TAT
* TP
9 VP22
Peptide Concentration (pM)
+ m3R
* m6R
m9R
-- m12R 0 mTAT N
4 m15R * mTP
* mPEN r mVP22
Pt 2 4
Peptide Concentration (p.M)
Figure 6.6. Cytotoxicity of TPNs. (A) Viability of HeLa cells after 4 h treatment with myristoylated
tandem peptides at varying concentrations as determined by the MTT assay. Total viability was
normalized to cells mock treated with media. (B) Viability of HeLa cells after 4 h treatment with
unmyristoylated tandem peptide carriers. Error bars indicate s.d. from at least 4 independent
measurements.
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Figure 6.7. Cellular uptake of TPNs. OVCAR-8 ovarian
aL E
0z
cancer cells were incubated with TPNs
carrying siRNA labeled with a near infrared fluorophore (VivoTag-S750). Cellular uptake is assessed by
flow cytometry for both non-myristoylated and myristoylated tandem peptides. Error bars indicate
s.d.from 4-6 independent experiments.
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Figure 6.9. p32-specificity of TPN uptake. LeftTPN uptake by OVCAR-8 cells in the presence of
increasing concentrations of a p32-specific monoclonal antibody (mAb 60.11) directed against the NH2-
terminus of p32 polypeptide. Uptake of nanocomplexes was normalized to that without antibody
inhibition. Error bars indicate s.d. from 6 independent experiments. Right, Representative histograms
from flow cytometry for cellular uptake of myr-12R-LyP-1 (top, m12R) and myr-TP-LyP-1 (bottom,
mTP), in the presence of indicated concentrations of mAb 60.11 (black and gray) or a IgG control (red).
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6.2.3 Gene silencing with TPNs
We next set out to determine in vitrogene silencing activity of siRNAs delivered by
TPNs. HeLa cells stably expressing a destabilized green fluorescence protein reporter (dGFP)
was used as a model system for direct quantification of the RNAi response. Cells were treated
with siRNA against GFP bound to either tandem peptides or lipofectamine and analyzed by flow
cytometry for GFP knockdown. Consistent with previous findings that myristoylation improves
cellular uptake, myrisoylated carriers were more efficient in delivering siRNA and suppressing
GFP expression than non-myristoylated ones (Figure 6.10; Figure 6.11). Six (6) of 9 tandem
peptide carriers were able to silence GFP expression by over 50%, as determined by comparing
the geometric means of the entire cell population. The amount of GFP suppression was
correlated with the dose of siRNA (Figure 6.12A), was detectable starting at 24 h, and was
maintained through at least 48 h after transfection (Figure 6.12B).
For tumor-specific siRNA delivery, an ideal system should target the delivery of siRNA
to tumor cells while sparing non-tumor or essential cells, thereby achieving gene knockdown in a
cell type-specific manner. To quantitatively assess the ability of nanocomplexes to deliver
siRNA in a receptor-specific fashion, we measured the "fitness" of each candidate nanocomplex
as the normalized sum of gene silencing efficiency and p32-receptor specificity (normalized
1/IC5 0 of mAb 60.11) (Figure 6.13). In particular, VP22 has low fitness because cellular uptake
was non cell-type specific and gene knockdown was also poor. By contrast, nanocomplexes
bearing polycationic CPP domains (1 2R and 15R) readily penetrated cellular membranes and
carried siRNA into the cytosol; however, they do so in a non-cell type-specific manner as the
presence of excess cationic charges likely abrogated receptor-specificity, resulting in low fitness.
In comparison, cellular uptake by amphipathic CPPs such as PEN and TP is blocked by a p32-
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specific antibody, suggesting that the receptor-specificity of the LyP- 1 domain is retained;
nevertheless, TP nanocomplexes are much efficient than PEN in suppressing gene expression.
Indeed, the nanocomplex formed with myr-TP-LyP- 1 has the highest fitness value of all carriers,
owing to both potency in knockdown (> 50% suppression of GFP) and p32 receptor specificity
(lowest IC5 0 of mAb 60.11).
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Figure 6.10. TPN-mediated receptor-specific gene silencing in vitro. (A) HeLa cells stably expressing
destabilized GFP were transfected with TPNs carrying siRNA against GFP. The amount of GFP
knockdown was determined by flow cytometry24 h later. Lipofectamine was used as a positive control.
Error bars represent s.d. from cumulative data of three independent experiments. (B) Representative
histograms for myr-TP-LyP1 nanocomplexes carrying GFP-specific siRNA. Mock treated cells are
shaded in gray.
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Figure 6.11. Gene silencing by unmyristoylated TPNs. (A) HeLa cells expressing destabilized GFP
were transfected with non-myristoylated tandem peptides complexed to siRNA against GFP and analyzed
by flow cytometry 24 h later. Lipofectamine was used as a positive control. Error bars indicate s.d. from 3
separate experiments.
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Figure 6.12. Gene suppression by TPN-mediated siRNA delivery. (A) GFP suppression by
myristoylated TPNs carrying different concentrations of siRNA (100 nM, 50 nM, or 25 nM). For each
siRNA concentration, the percent GFP knockdown for a particular TPN was shown after normalizing by
the mean GFP knockdown of all TPN candidates at that siRNA concentration. The heat map is
pseudocolored to indicate high efficiency in GFP knockdown (red) and low efficiency in knockdown
(green). (B) Kinetics of GFP suppression by TPN candidates as determined by flow cytometry
measurements at the indicated time points (24 h, 48 h, and 72 h) post transfection.
168
A
B
..
.-WC
0o
O -
0
-
U-
LL(.
C
0
A B
1000- 1.25
v 7501
C: 1 .00
50
E (00.75-
250
Figure 6.13. Fitness of nanocomplex candidates. (A) TPN receptor-specificity quantified as the
concentration of p32-specific monoclonal antibody to inhibit TPN uptake by 50% (ICso). Increasing
concentrations of mAb 60.11 was added to cells for 1 h without TPN and subsequently in the presence of
TPN for 4 h. Percent inhibition of TPN uptake was determined by flow cytometry. ICso values were
derived by fitting a standard normalized dose-response curve for inhibitory binding effects. (B) The
fitness of each tandem peptide, as determined by the sum of knockdown efficiency and p32-specificity.
6.2.4 Intracellular trafficking of TPNs
Our results thus far have demonstrated that the tandem presentation of a tumor-homing
ligand with various CPP domains can lead to varying degrees of fitness. To better understand the
properties that favored the conversion of a ubiquitously internalizing CPP into a receptor-specific
siRNA delivery system, we next investigated the intracellular trafficking mechanisms by which
nanocomplexes carry siRNA into the cytosol.
We applied myr-TP-LyP-1 nanocomplexes carrying siRNAs labeled with a near-infrared
fluorophore to HeLa cells and visualized intracellular trafficking via microscopy. Fluorescent
siRNAs were present in punctate vesicular structures consistent with sequestration in endosomes
(Figure 6.14). To directly confirm the intracellular localization of siRNAs, TPNs were applied to
HeLa cells either expressing a marker of early endosomes (Rab5a) or pre-labeled with a pH-
sensitive marker of endolysosomes (Lysotracker) (Figure 6.14). Fluorescently labeled siRNAs
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showed co-localization with both markers, suggesting that nanocomplexes carried siRNA
payloads into the cell via endocytosis and were initially sequestered in endosomes.
We next sought to directly evaluate the ability of nanocomplexes to disrupt the
endosomal membrane of HeLa cells and trigger the cytosolic release of cargo by co-delivery
with Calcein, a membrane-impermeable fluorophore [296]. In the presence of Calcein alone or
with LyP- 1 peptide without the CPP domain, a vesicular distribution indicative of little or no
endosomal escape was observed. By contrast, diffuse Calcein staining in up to 30% of cells
suggestive of endosomal escape was seen with 12R, 15R, and TP tandem peptides. Endosomal
escape was carrier dose-dependent (Figure 6.15; Figure 6.16) and was partially dependent on
the proton sponge effect [297], as the escape efficiency correlated linearly with the number of
arginines. In addition, N-myristoylated peptides were generally more efficient in enabling
Calcein entry into the cytosol than their non-myristoylated counterparts, consistent with
enhanced interactions between myristic acid and membrane lipids on the endosome that likely
generate transient pores to allow leakage of molecules [222]. Similar results in endosomal escape
were observed in OVCAR-8 cells (Figure 6.17).
To identify the trafficking pathways by which nanocomplexes undertake after
endocytosis, we examined the uptake of myr-TP-LyP-1 nanocomplexes in the presence of small
molecule inhibitors that each blocks a component of the endocytosis pathway [152]. Uptake of
TPN was significantly decreased when treated with amiloride, an inhibitor of macropinocytosis;
and with PDMP, an inhibitor of lipid-raft mediated endocytosis; but not with inhibitors of actin
polymerization, clathrin-mediated endocytosis, or caveolae-mediated endocytosis.
Deoxyglucose, an inhibitor of ATP biosynthesis, also inhibited GFP knockdown (Figure 6.18).
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In order to achieve gene knockdown, the carrier must ultimately dissociate from the
siRNA cargo after escaping from the endosome to allow the incorporation of siRNA into the
RISC machinery. To ascertain whether TPNs de-complex and release siRNA subsequent to
escaping from the endosome, we measured the relative amount of siRNA that dissociated from
the carrier upon exposure to endolysosomal pH (pH 4-6) via monitoring the intercalation of TO-
PRO-3 dye (Figure 6.19). We observed that long poly-Arginine peptides such as 12R and 15R
did not readily release siRNA at low pH, likely due to the large number of positively-charged
Arginines that retarded the unpacking of siRNA. In comparison, amphipathic CPP species that
are less cationic, such as PEN and TP, readily unpacked and dissociated from siRNA at acidic
pH. Taken together, these observations support a siRNA delivery mechanism that consisted of
receptor-mediated endocytosis mediated by macropinocytosis and lipid-rafts, followed by escape
from endosomal entrapment, and release of siRNA at acidic pH.
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Figure 6.14. Intracellular trafficking mechanisms of TPNs.Top, Fluorescence microscopy images of
human ovarian cancer cell line (OVCAR-8) transfected with Rab5a (CellLightTM Early Endosomes-GFP)
24 h prior (Early), and subsequently incubated with TPN carrying near infrared fluorophore-labeled
siRNAs for 1 h. Images were pseudocolored for visualization: blue = DAPI; red = Rab5a; green =
TPN/VivoTag-S750-siRNA. Co-localization of TPN with the early endosomal marker is shown in
yellow. Scale bar, 1 Opm. Bottom, Fluorescence microscopy images of HeLa cells after 4 h treatment with
100 nM FITC-siRNA encapsulated in myr-TP-LyP-1 nanocomplexes, in the presence of 50 nM
Lysotracker@ dye to label late endosomes and endolysosomes (Late). Images are pseudocolored for
visualization of co-localization: blue = DAPI; red = Lysotracker; green = FITC-siRNA. Scale bar, 10 im.
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Figure 6.15. TPNs trigger endosomal escape. TPNs formed with myr-TP-LyP-1 peptides and siRNA
trigger endosomal escape of siRNA in a carrier dose-dependent fashion (Black and shaded gray bars).
TP-ARAL (white bar) did not trigger any significant escape beyond the negative control (no carrier,
light gray). As a positive control, lipofectamine-mediated delivery resulted in -40% cells showing
endosomal escape of Calcein (hashed bar). Error bars indicate s.d. from 6 separate experiments.
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Figure 6.16. Tandem peptide carriers enable the delivery of Calcein, a membrane impermeant dye,
into the cytosol of HeLa cells. (A) The mean percentage of cells displaying a uniform, cytosolic
distribution of Calcein per each field of view was determined (n = 500-800 cells counted for each
carrier). Error bars indicate s.d. from 3 independent experiments. *p< 0.05; ***p< 0.001. (B)
Representative fluorescence microscopy images of HeLa cells treated with TPN + Calcein (top) or
Calcein alone (bottom) (Green = Calcein).
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Figure 6.17. TPNs trigger endosomal escape of co-delivered cargo in
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Figure 6.18. Intracellular trafficking of TPNs. Cellular uptake of myr-TP-LyP-1 nanocomplexes
carrying FITC-labeled siRNA in the presence of small molecule inhibitors at the indicated
concentrations. Scale bar, 50 pm.
173
IMEhEMpEEA
"4;\z
20.
15.
10.
5.
0.
37 C, 5 Jpg/miL
Nipin
37 C 25g/L
nystatin
3 I 11mM
Amlar" Iide
37 C, 5 tg/mL
chlorpr omiazinie
37 C. 10 ptg/miL
cytochalasin) D
37C10 mM'
deoxyglu cose
500 + 3R
40 -- 6R400. 9R
U) 
+ 12R;5 300-
+ 15R
200 0 PEN
STAT
100. TP
'9 VP22
0 . .. . . . .
4.0 5.0 6.0 7.0 8.0
pH
Figure 6.19. Quantification of the relative amount of siRNA dissociated from the nanocomplex
carriers at endolysosomal pH (pH = 4-6).
6.2.5 Understanding structure-activity relationships
Nevertheless, the different fitness of nanocomplex candidates could only be partially
explained by differences in cellular uptake, endosomal escape, and rate of nanocomplex
dissociation. For example, the low fitness of PEN and VP22 peptides can be attributed to low
cellular uptake and endosomal escape activity, which resulted in poor siRNA. In contrast, 12R,
15R, and TP showed high cellular uptake and endosomal escape activity; however, they differ
significantly in fitness owing to differences in receptor-specificity. Therefore, other features of
TP nanocomplexes lacking in 12R or 15R dictate the efficiency and specificity of siRNA
transfection. As the optimized TPN formulation likely resides within a much broader and more
complex structural and functional space, a systematic screening of carrier structural parameters is
needed to identify and understand key properties that could impact fitness.
To this end, we took a quantitative computational approach to systematically identify carrier
properties that favored cell-type specific gene knockdown. We hypothesized that the relationship
between carrier properties and fitness is likely to be linear; therefore, a linear regression
approach that could establish a list of relative weights of significant model parameters was used
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[298]. Specifically, we chose a regression model to generate relationships between carrier fitness
- the efficiency of cell type-specific gene knockdown taken at two different siRNA
concentrations (1OOnM and 50nM) and at two time points (24h and 48h) - and carrier structural
properties, including diameter, zeta potential, valence of LyP- 1, peptide charge at physiologic
pH, percent of Lysine's or Arginine's and charge density (Table 6.2). To generate the data for
the model, we screened every combination of structural parameters to select ones that were
linearly independent and individually significant (T-test with p<0.05). Measurements for each
parameter were centered and scaled to ensure that the value of the associated regression
coefficient is a direct measure of parameter importance. The parameter subset that resulted in a
model that best matched the measured fitness for each individual nanocomplex was selected for
further analysis (R 2=0.7 4 , p<0.001) (Figure 6.20).
Two structural properties, namely the valence of the targeting ligand and the peptide
charge, were found to be significant variables for explaining differences in nanocomplex fitness
(Figure 6.21). Namely, alterations in the valence of the targeting ligand or in peptide charge
could exert the largest influence on cell type-specific knockdown by that nanocomplex. The
regression coefficient for peptide charge was the most negative, suggesting that lowering peptide
charge could enhance nanocomplex fitness. Consistent with our previous observations that
multivalency favored high receptor-specificity; the regression coefficient for valence was the
most positive, suggesting that increasing LyP- 1 valence could also improve fitness.
To further validate the importance of LyP- 1 valence and peptide charge in influencing
cell type-specific gene knockdown, we separated all nanocomplex candidates into two groups
based on their measured fitness values. Accordingly, nanocomplexes with high fitness (best
fitness group) exhibited significantly higher peptide valence and lower peptide charge than those
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with low fitness (p<9.7e-5 and p< 0.01 by F statistic, respectively), trends that were consistent
with regression coefficients determined from the model (Figure 6.22). Similar analysis for other
selected parameters (concentration, diameter, zeta error and charge density) did not yield
statistically significant differences (data not shown). In aggregate, quantitative regression
analysis enabled us to identify and validate two carrier structural properties - the valence of the
targeting ligand and the peptide charge - that explained differences in nanocomplex fitness.
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Figure 6.20. Computational modeling to identify carrier structural properties that influence
fitness.Least square regression model used to predict carrier fitness versus measured fitness. The model is
able to fit the data with R2=0.74. Each data point represents the normalized fitness of a particular
nanocomplex candidate at a specific siRNA concentration and time point post transfection.
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Figure 6.21. Regression coefficients of the structural properties determined to be significant in
predicting fitness. The nanocomplex valence of the targeting ligand and the peptide charge (black)
havethe highest impact on nanocomplex fitness.
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Figure 6.22. Nanocomplex populations were separated into two groups based on individual fitness
(best fitness and worst fitness). The average LyP- 1 valence of the nanocomplex (left) and peptide charge
(right) are calculated for each group and compared. Consistent with regression results, significant
separations between the groups confirmed the positive impact of valence and the negative impact of
peptide charge on fitness. **p< 0.01; ****p<0.0001.
Table 6.2. Parameters used in the computational analysis. For linear regression analysis of fitness, the
input parameters included: concentration of TPNs, time of transfection, hydrodynamic size, zeta potential,
valence of the tumor-specific ligand, charge of the peptide at neutral pH, percent of amino acids that is
either Lysine or Arginine, and the overall charge normalized by number of amino acids.
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Conc Time Diameter Diam. err. Zeta
(nM) (h) (nm)
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
209
151
207.8
191.2
377.2
337.6
194.6
343.6
233
209
151
207.8
191.2
377.2
337.6
194.6
343.6
233
209
151
207.8
191.2
377.2
337.6
194.6
343.6
233
209
151
207.8
191.2
377.2
337.6
194.6
343.6
233
(nm)
40.5
11.1
19.6
17.9
49.4
54.9
43.6
32.3
58.8
40.5
11.1
19.6
17.9
49.4
54.9
43.6
32.3
58.8
40.5
11.1
19.6
17.9
49.4
54.9
43.6
32.3
58.8
40.5
11.1
19.6
17.9
49.4
54.9
43.6
32.3
58.8
(mV)
21.8
27.3
36.6
27.6
36
29
35.8
31.9
30.8
21.8
27.3
36.6
27.6
36
29
35.8
31.9
30.8
21.8
27.3
36.6
27.6
36
29
35.8
31.9
30.8
21.8
27.3
36.6
27.6
36
29
35.8
31.9
30.8
Zeta err. LyP-1 Peptide
(mV) valence charge
5
4
7.1
15
7.5
5.1
8
3.7
4.8
5
4
7.1
15
7.5
5.1
8
3.7
4.8
5
4
7.1
15
7.5
5.1
8
3.7
4.8
5
4
7.1
15
7.5
5.1
8
3.7
4.8
11.03
31.16
2.732
1.186
1.912
5.604
1.843
35.68
1.457
11.03
31.16
2.732
1.186
1.912
5.604
1.843
35.68
1.457
11.03
31.16
2.732
1.186
1.912
5.604
1.843
35.68
1.457
11.03
31.16
2.732
1.186
1.912
5.604
1.843
35.68
1.457
6.6
9.6
12.6
15.6
18.6
10.6
12.6
7.6
9.6
6.6
9.6
12.6
15.6
18.6
10.6
12.6
7.6
9.6
6.6
9.6
12.6
15.6
18.6
10.6
12.6
7.6
9.6
6.6
9.6
12.6
15.6
18.6
10.6
12.6
7.6
9.6
% K and/or Charge
R
41.18
50
56.52
61.54
65.52
36.67
48.15
19.51
27.08
41.18
50
56.52
61.54
65.52
36.67
48.15
19.51
27.08
41.18
50
56.52
61.54
65.52
36.67
48.15
19.51
27.08
41.18
50
56.52
61.54
65.52
36.67
48.15
19.51
27.08
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density
0.39
0.48
0.55
0.6
0.64
0.35
0.47
0.19
0.2
0.39
0.48
0.55
0.6
0.64
0.35
0.47
0.19
0.2
0.39
0.48
0.55
0.6
0.64
0.35
0.47
0.19
0.2
0.39
0.48
0.55
0.6
0.64
0.35
0.47
0.19
0.2
6.2.6 Quantifying the multivalency effect
Guided by the computational results, we further quantified the receptor-specificity and
multivalency effects of myr-TP-LyP-1 nanocomplexes. In four (4) human cancer cell lines with
varying p32 expression, we found that the uptake of TP nanocomplexes was enhanced relative to
TPNs bearing a scrambled peptide (TP-ARAL), while remained linearly correlated with surface
p32 levels across different cell lines (Figure 6.23).
In contrast to monovalent LyP-1 peptides, TP-LyP-1 nanocomplexes have higher affinity
to cell surface p32, as demonstrated by the lower measured EC50 (concentration to produce 50%
of maximal cellular binding) in two p32-expressing cell lines (Figure 6.24). The apparent
dissociation constant (KD) of TPNs was found to be 10-20 fold higher than that of free LyP- 1
peptide (KD,TPN= 215 nM; KD,LyPI = 5.6 pM), consistent with multivalent nanoparticle systems
reported elsewhere [203]. TPN cellular uptake was saturated at higher concentrations, which
further supports that TPN was taken up in a receptor-mediated manner (Figure 6.25).
To better understand how the number of LyP- 1 peptides displayed on the nanocomplex
influenced cellular binding, we synthesized TPNs with a mixture of TP-LyP- 1 and TP-ARAL
peptides. Mixed TPNs exhibited saturated uptake at a peptide-to-siRNA ratio of at least 10:1
(Figure 6.26). As the density of LyP-1 ligands exceeds the amount of p32 available for binding,
additional LyP-1 peptides will likely not engage in receptor-mediated endocytosis and uptake
will likely be saturated. Taken together, these results confirmed that p32 expression dictated
siRNA delivery by multivalent nanocomplexes formed with myr-TP-LyP- 1 tandem peptides.
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Figure 6.23. The myr-TP-LyP-1 nanocomplex delivers siRNA in a p32-specific manner and is
multivalent. (A) Flow cytometry analysis showing cellular uptake of TP-LyP-1/siRNA-VivoTag-S750
nanocomplexes (LyP-1 TPN, black) in cancer cell lines. Uptake of scrambled TPNs consisted of TP-
ARAL/siRNA-VivoTag-S750 (ARAL TPN, gray) was used as a negative control.(B) The relationship
between surface p32 levels and the cellular uptake of TPNs carrying siRNA-VivoTag750 in four (4)
human cancer cell lines that express varying amounts of p132, including cervical (HeLa), melanoma
cytometry and normalized to that of a scrambled peptide control, TP-ARAL.
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Figure 6.25. Uptake of nanocomplexes in HeLa cells over time. LyP-1 TPNs or ARAL TPNs are
incubated over cells at various concentrations for the indicated times and cellular TPN fluorescence was
determined by flow cytometry. Error bars represent s.d. from 3 separate experiments.
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Figure 6.26. Uptake of TPNs bearing a mixture of TP-LyP-1
MDA-MB-435 and Caov-3 cells measured by flow cytometry.
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6.3 Conclusion
To design vehicles for cell type-specific siRNA delivery, there are several barriers the
delivery system must negotiate before achieving gene knockdown. These include receptor-
mediated cellular binding, internalization by endocytosis, escape from endosomal sequestration
into the cytosol, and ultimately, dissociation of siRNA from the carrier for RISC incorporation.
Each step can influence the fate of the intracellular cargo, which in turn affects the receptor-
specificity and efficiency of gene knockdown. Here, we have taken a systematic, quantitative
approach to designing and understanding peptides for cell type-specific siRNA delivery. To this
end, we synthesized a library of tandem peptides bearing a tumor-specific domain and distinct
cell-penetrating domains, and formed nanocomplexes with siRNA through non-covalent
interactions. A subset of nanocomplexes delivered siRNA to human cancer cell lines that express
the cognate p32 receptor on the surface. We further evaluated the mechanism by which
nanocomplexes delivered siRNA to the cytosol by characterizing cellular uptake, endosomal
escape, and siRNA dissociation.
Comparative analysis of 18 tandem peptides revealed that variations in structural
properties had a significant impact on receptor-specificity and gene silencing efficiency.
Powered by linear regression modeling, we identified the valence of the targeting ligand on the
nanocomplex and the overall peptide charge as key structural properties that favored cell-type
specific gene silencing. The analysis led to the identification of the myristoylated tandem
peptide, myr-TP-LyP- 1, which condensed siRNA into multivalent nanocomplexes and
effectively delivered siRNA in a cell-type specific manner. This advancement suggests that a
systematic approach to the design of cell-penetrating peptides is essential for optimizing tumor-
specific delivery of siRNA therapeutics for therapeutic applications.
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6.4 Materials and Methods
DLS and Zeta Potential. Peptide-siRNA nanocomplexes were prepared by mixing siRNA in nuclease-
free H20 (20ptM) with each tandem peptide carrier (400gM) at a molar ratio of 1:20 (siRNA:peptide) in
1/5 of final volume in PBS for 10-15 min at room temperature. The hydrodynamic radii and zeta potential
of nanocomplexes were determined using the zeta-potential and dynamic light scattering (DLS)
instrument (Zetasizer-Nano, Malvern, Inc.).
Nanocomplex library gene silencing and uptake. To measure the cellular uptake of the TP-
LyPI/siRNA nanocomplex, OVCAR-4, OVCAR-8, CaOV-3, and MDA-MB-435 cells were plated 48 h
prior in 96-well plates and allowed to reach at least 70% in confluency. Nanocomplexes were added at
1 OOnM siRNA/2 uM peptide for 2 h at 37 'C in serum-free DMEM. Cells were then washed with
PBS/heparin, trypsinized, and analyzed by flow cytometry (LSR II). For TP-LyP1 nanocomplex blocking
experiments with anti-p32 antibody, OVCAR-8 cellswere pre-incubated with anti-p32 polyclonal
antibodyat specified concentrations for 1 h at 37 'C before nanocomplex treatment.
Endosomal Escape. HeLa and OVCAR-8 cells were plated 48 h prior in 96-well plates and allowed to
reach at least 70% in confluency. Calcein (0.25mM) dye was added with or without various nanocomplex
formulations (1 OOnM siRNA, 2uM of carrier) in complete medium (DMEM with 10% bovine serum) for
1 h at 37 'C. The cells were then washed three times with PBS and visualized live with a fluorescence
microscope using the FITC filter. The number of cells with efficient endosomal escape as indicated by a
diffuse cytoplasmic FITC fluorescence was counted from at least 8 randomly selected fields of view and
normalized to the total number of cells (n = 500-800 cells per carrier in each experiment).
Inhibition of endocytosis and imaging. HeLa cells grown in 96-well plates at -70% confluence were
incubated with small molecule inhibitors for 1 h at 37 'C, followed by incubation with
nanocomplexescontaining both labeled peptide (2 gM) and GFP siRNA (100 nM) for an additional hour
at 37 'C. The cells were washed three times with cold PBS and were subsequently trypsinized for flow
cytometry analysis. To visualize the intracellular trafficking of nanocomplexes along with endosomal
markers, Lysotracker Red DND-99 (Invitrogen) or CellLight Early Endosomes-RFP (Invitrogen) was
prior to the addition of nanocomplexes according to manufacturer's instructions.
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7 Receptor down-regulation improves the microdistribution
of tumor-targeted theranostics
7.0 Abstract
Nanotechnology is an emerging field that has tremendous potential for developing new
diagnostics and therapeutics for cancer. However, delivery of tumor-targeted nanoparticles into
tumors is challenging due to the presence of so-called "binding site barrier"; spatial
heterogeneities in receptor expression can lead to a non-uniform intratumoral distribution of
nanoparticles. Here, we present a strategy to improve the tumor microdistribution and
penetration of targeted nanoprobes through the systematic down-regulation of their cognate
receptors in the tumor. We utilized tumor-penetrating nanocomplexes (TPN) developed in
Chapters 3 through 5 that target p32, a receptor overexpressed on the surface of cancer cells, and
deliver siRNA payloads directed against p32 to suppress its surface expression. We find that
TPN suppressed p32 expression in multiple human cancer cell lines in vitro. In mice bearing
tumor xenografts that express p32, down-regulation of p32 in perivascular tumor cells led to
mitigation of the binding barrier, improved tumor penetration of successively administered TPN,
and upregulation of glycolytic metabolism in tumors that is exploitable by PET imaging. Thus,
strategies to modulate receptor expression should enhance the tumor microdistribution of
targeted nanoparticles for diagnostic and therapeutic applications.
(Reprinted with permission from [299])
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7.1 Introduction
Nanometer-sized carriers are an attractive platform for cancer drug delivery due to their
ability to stabilize and protect drugs from degradation, prolong drug in vivo half-life by
decreasing renal clearance, and enhance tumor accumulation via targeting. Since tumor blood
vessels are malformed and leaky, long-circulating nanoparticles decorated with polyethylene
glycol (PEG) can selectively extravasate from pores within the fenestrated endothelium. While
some nanoparticle therapeutics such as Doxil and Myocet exploit this enhanced permeability and
retention (EPR) effect for passive tumor targeting, EPR is not a constant feature of the tumor
endothelium [300]. Moreover, additional barriers such as the highly pressurized tumor interstitial
matrix must be negotiated before nanoparticles can reach the tumor cells [79, 89].
Elsewhere, nanocarriers have been decorated with homing ligands that specifically bind
to markers that distinguish cancer cells from normal counterparts. High-throughput screening
technologies using libraries of aptamers and bacteriophage-displayed peptides have enabled the
identification of a wealth of ligands with extraordinary tumor specificity [118, 172, 200, 211].
For example, peptides containing the Arg-Gly-Asp (RGD) motif have been shown to enhance
tumor drug delivery by binding to avp3 and avp5 integrins that are overexpressed in tumor
endothelium [301]. Nonetheless, recent studies suggested that active targeting does not increase
overall tumor accumulation, as the rate limiting step in tumor targeting is typically during
extravasation through vascular pores [129, 302-303]. Furthermore, uniform tumor delivery is
hampered by heterogeneities in tumor blood supply and hindered diffusion [304]. Therefore,
strategies are still needed to improve the tumor penetration and distribution of nano-therapeutics.
In Chapters 3 through 5, we have described system of tumor-penetrating nanocomplexes
(TPN) that could overcome these tumor transport barriers by chaperoning nucleic acid
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therapeutics such as siRNA deep into the parenchyma of disseminated ovarian tumors in mice
[213]. The homing peptide domain, LyP-1 (CGNKRTRGC), is tumor-specific and binds p32, a
mitochondrial protein aberrantly expressed on the surface of cancer cells. While this approach is
promising, histological examination of tumors repeatedly dosed with TPN revealed a
heterogeneous TPN distribution that is mostly concentrated around the vasculature, likely owing
to the presence of the so-called "binding site barrier" for nanoparticles directed by tumor-
targeting probes. Namely, if the targeted probe cannot initially saturate the receptor binding
capacity and the receptors can regenerate before the next dose of nanoparticles is introduced,
successive TPN will bind to unoccupied receptors near the vasculature and will not diffuse
further into the tumor. Indeed, experimental and theoretical analyses on antibody targeting have
shown that low affinity antibodies or antibodies targeting antigens with low expression levels
show improved penetration and distribution, due to their ability to dissociate from the receptor
after binding and subsequently penetrate further into the tissue [305-307]. While antibody
engineering approaches have enabled the precise tuning of antigen affinity for enhanced
penetration [308], similar methods to optimize nanoparticle penetration has yet to be achieved.
In this work, we hypothesize that down-regulation of receptor expression in a temporal-
and spatial-specific manner can improve the tumor microdistribution of targeted nanoprobes.
Specifically, we investigated whether reducing the perivascular interactions between TPN and
p32, its cognate receptor, can improve the in vivo tumor uptake and penetration of successively
administered TPNs (Figure 7.1). First, TPN delivery ofp32-specific siRNA was evaluated in
cancer cell lines. Next, the effects of in vivo p32 receptor knockdown on tumor uptake,
penetration and microdistribution of TPN are studied mice bearing tumor xenografts. Finally, the
utility of p32 suppression for functional tumor imaging via PET/CT is also explored.
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Figure 7.1. Schematic demonstrating the improvement in TPN microdistribution via modulation of
receptor expression in the tumor microenvironment. A time-dependent analysis showing TPN
penetration into the tumor parenchyma subsequent to extravasation from blood vessels. Top, TPN
intratumoral diffusion is limited by the binding barrier located in regions immediately adjacent to the
vasculature. Middle, TPN deliver y of siRNA can suppress receptor expression in tumor cells located near
the vasculature. Bottom, Successive TPN administrations can now diffuse further into the tumor and
bypass the binding barrier, which are ultimately taken up by receptors located on the surface of tumor
cells further away from vasculature.
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7.2 Results
7.2.1 Down-regulation of p32 in p32-expressing cancer cell lines
p32 (p33/HABP1/gClqR), a protein primarily located in the mitochondrial matrix, is
located on the cell surface of tumor cells and is expressed at higher levels than in their
nonmalignant counterparts [217, 309]. The homing domain of tumor-penetrating siRNA
nanocomplexes, LyP-1, is a cyclic nonapeptide shown to bind p32 in human cancer cell lines
from several tumor types, including melanoma, cervical cancer, and ovarian cancer [200, 217].
Previously, stable p32 knockdown by shRNA in MDA-MB-435 human melanoma cells and
MDA-MB-321 human breast cancer cells resulted in a shift in cellular metabolism from
oxidative phosphorylation (OXPHOS) to glycolysis, decreased synthesis of mitochondrial
OXPHOS proteins, and reduced tumorigenicity in vivo [309]. To investigate the effects of
transient, siRNA-mediated p32 suppression in cancer cell lines that express p32, we generated
TPN carrying three p32-specific siRNAs targeting non-overlapping regions of the exon. In
OVCAR-8 human ovarian cancer cells, delivery ofp32-specific siRNA (siP32 #2) reduced p32
mRNA by over 90% compared to a control siRNA, with a corresponding reduction in p32
protein (Figure 7.2). Gene knockdown is dependent on LyP-1-mediated cellular uptake, as
untargeted control nanocomplex (UCN) bearing a scrambled homing peptide (ARAL,
ARALPSQRSR) did not suppress p32 (Figure 7.3). To determine whether p32 knockdown is
generalizable across cell lines derived from distinct tumor types, we further evaluated the
efficacy of TPN-mediated siRNA delivery in cells from ovarian (OVCAR-4), cervical (HeLa),
and skin cancers (MDA-MB-435). All showed reduction ofp32 mRNA and protein levels 48 h
after TPN/siP32 treatment but not with TPN/siGFP (Figure 7.4).
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The affinity of the LyP-1/p32 interaction dictates the cellular uptake of TPN in vitro and
tumor retention in vivo. According to the binding barrier model of antibodies [308, 310], the
local concentration of free antibodies that is dissociated from the receptor determines the amount
available to diffuse into the tumor. The importance of antibody availability was further
underscored in studies that showed antigen expression can profoundly affect antibody
penetration [311-312]. Therefore, we postulated that reducing p32 expression on the cell surface
can effectively decrease the binding sink for TPN, thereby allowing further extravasation and
creating a more uniform intratumoral distribution. In two ovarian cancer cell lines (OVCAR-4
and OVCAR-8) and a cervical cancer cell line (HeLa), TPN delivery ofp32-siRNA reduced cell
surface p32 levels by over 50% as determined by flow cytometry, compared to cells treated with
a scrambled, GFP-targeted siRNA (Figure 7.5). Taken together, TPN can transiently suppresses
p32 expression in a receptor- and siRNA sequence-specific manner in multiple cell lines.
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Figure 7.2. Suppression of p32 in vitro. (A) qPCR of p32 mRNA extracted from OVCAR-8 human
ovarian cancer cells 48 h after treatment with TPN carrying three (3) distinct p32-specific siRNAs
targeting non-overlapping regions of the p32 exon. TPN carrying a scrambled siRNA targeting GFP
(siGFP) was used as a negative control. All p32 mRNA levels were normalized to an internal loading
control (GAPDH). Data are averages ± s.d. ***p<0.001 by one-way ANOVA. (B) Immunoblotting of
lysates from OVCAR-8 cells treated as in (A). a-Tubulin was used as the loading control. Quantification
of band intensities are listed below the blot.
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Figure 7.3. TPN-mediated suppression of p32 in vitro. (A) OVCAR-4 human ovarian carcinoma cells
were treated with indicated TPN formulations carrying p32-siRNA or GFP-siRNA. Untargeted control
nanocomplex (UCN) consists of TP-ARAL non-covalently bound to siRNA. At 48 h and 72 h post
transfection, lysates were harvested and subjected to immunoblotting. a-Tubulin was used as a loading
control. (B) Immunoblot of OVCAR-8 cells treated with either TPN carrying siP32 or UCN carrying
siP32. A scrambled siRNA targeting GFP was used as a negative control.
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Figure 7.4. p3 2 suppression in human cancer cell lines. Human cancer cell lines derived from ovarian
cancer (OVCAR-4), melanoma (MDA-MB-435) and cervical cancer (HeLa) were treated with TPN-
bound p32-siRNA (siP32) or GFP-siRNA (siGFP), and p32 mRNA and protein levels were analyzed 48 h
later by qPCR and immunoblotting, respectively. Data are averages ± s.d. (n = 3 independent
experiments). *p<0.05; ***p<0.001 by unpaired Student's t-test.
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Figure 7.5. Suppression of cell surface p32 by TPN. (A) Summary of cell surface p32 levels 24 h and
72 h after treatment with p32-specific siRNA using TPN. A scrambled siRNA targeting GFP (siGFP)
was used as a negative control. (B) Representative flow cytometry histograms from each cell line.
7.2.2 Metabolic consequences of p32 suppression
In MDA-MB-435 melanoma cells that harbored stable p32 knockdown, it was observed
that they exhibited altered metabolism including elevated glycolysis and decreased oxidative
phosphorylation[309]. A shift towards utilizing glycolytic pathways for ATP generation is
associated with anaerobic conditions, higher glucose uptake and consumption, and increased
lactic acid production, as glycolysis is less efficient than oxidative phosphorylation in ATP
production. To ascertain whether transient, TPN-mediated, p32 knockdown can preferentially
bias cells towards a more glycolytic phenotype, we measured the rate of glucose consumption
and lactate production, two features that correlate with glycolysis, in cells treated with
TPN/siP32. Suppression ofp32 did not significantly affect cell viability (> 80% viable cells),
even in doses up to an order of magnitude higher than that required to knockdown p32 by over
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90% (Figure 7.7A; Figure 7.8A; Figure 7.9A). Glucose consumption was consistently elevated
in OVCAR-8 and HeLa cells from 24 h up to 72 h after TPN/siP32 treatment (Figure 7.9B and
Figure 7.7B) but was not altered in OVCAR-4 cells (Figure 7.8B), suggesting that factors other
than p32 suppression can co-regulate glucose uptake. Furthermore, cells that consumed more
glucose also exhibited higher production of lactic acid, a by-product of anaerobic glycolysis
(Figure 7.6; Figure 7.7C; Figure 7.8C; Figure 7.9C).
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Figure 7.6. Effects of p32 suppression on lactate production in vitro. Left, Measurements of lactate
concentration in the media of HeLa cells over time after TPN treatment with p32-siRNA. Right, Color of
media from HeLa cells after TPN treatment.
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Figure 7.7. In vitro phenotype of p32-suppressed HeLa cells. (A) Cellular viability of HeLa cells after
TPN delivery of p32-specific siRNA or a control siRNA (siGFP). The dotted line indicate >80% viability.
(B) Glucose consumption rates of HeLa cells treated with TPN/siP32 compared to TPN/siGFP. **p<0.01,
unpaired Student's t-test.Data are averages + s.d. (n = 3 independent experiments). (C) Lactate production
rates of HeLa cells treated with TPN/siP32. *p<0.05, unpaired Student's t-test. Data are averages ± s.d. (n =
3 independent experiments).
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Figure 7.8. In vitro phenotype of p32-suppressed OVCAR-4 ovarian cancer cells. (A) Cellular viability of
OVCAR-4 cells after TPN delivery of p32-specific siRNA or a control siRNA (siGFP). The dotted line
indicate >80% viability. (B) Glucose consumption rates of OVCAR-8 cells treated with TPN/siP32 compared
to TPN/siGFP. n.s, not significant, unpaired Student's t-test.Data are averages ± s.d. (n = 3 independent
experiments). (C) Lactate production rates of OVCAR-8 cells treated with TPN/siP32. n.s, not significant,
unpaired Student's t-test.Data are averages ± s.d. (n = 3 independent experiments).
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Figure 7.9. In vitro phenotype of p32-suppressed cells. (A) Cellular viability of OVCAR-8 cells after
TPN delivery of p32-specific siRNA or a control siRNA (siGFP). The dotted line indicate >80% viability.
(B) Glucose consumption rates of OVCAR-8 cells treated with TPN/siP32 compared to TPN/siGFP.
*p<0.05, unpaired Student's t-test.Data are averages ±s.d. (n =3 independent experiments). (C) Lactate
production rates of OVCAR-8 cells treated with TPN/siP32. **p<0.01, unpaired Student's t-test. Data are
averages ±bs.d. (n 3 independent experiments).
7.2.3 Suppression of p32 receptor expression in vivo
Having established that TPN can target p32-expressing cancer cell lines and deliver
siRNA to suppress p32 levels in vitro, we next investigated whether TPN can a) suppress p32
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receptor expression in vivo, and if so, b) a reduction in p32 in perivascular tumor cells can
improve the uptake and spatial distribution of successive TPN. We generated SCID mice bearing
bilateral subcutaneous OVCAR-8 human ovarian carcinoma xenografts, and injected via the tail
vein on two consecutive days (with TPN carrying either GFP- or p32-specific siRNA (1 mg of
siRNA/kg/injection), respectively. Two days after the second injection, TPN encapsulated with
siRNA labeled with a near-infrared fluorophore (VivoTag750-siRNA) were administered i.v.
into both cohorts (1.5 nmols/injection), and tumors were harvested after TPNs were cleared (6 h)
for histological assessment of p32 knockdown and nanoparticle accumulation (Figure 7.10A).
Immunofluorescence studies revealed over 80 % reduction in p32 expression in tumors
that received TPN/siP32 (Figure 7.10B, C). To gain more insight into the spatial distribution of
p32 expression, whole-tumor sections were dual stained with p32 and an endothelial cell surface
marker and examined for their co-localization. We found that p32 expression was reduced by
over 85% in areas of the tumor where blood supply was abundant but remained high near
avascular areas, indicating that the efficacy of TPN delivery was limited to perivascular zones
where tumor cells highly express p32 (Figure 7.11). Together, the data suggest that
intravenously administered TPNs achieved functional delivery of p32-specific siRNA; however,
knockdown of p32 was heterogeneous and was restricted to perivascular tumor cells.
To determine whether the modulation of p32 expression in the tumor microenvironment
can influence the tumor uptake of successive TPNs, we quantified the amount of fluorescently-
labeled TPNs that is present in the tumor xenografts by measuring bulk tumor fluorescence 6 h
after TPN injection (Figure 7.12A). Prior studies showed that intravenously administered TPNs
were cleared from circulation after 4 h [213]. Tumors that were pre-treated with p32-specific
siRNA showed slightly enhanced accumulation of TPNs compared to control tumors that
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received a scrambled siRNA (siGFP). However, the difference was not statistically significant
(Figure 7.12B), consistent with previous studies that suggest extravasation from blood vessels is
the rate-limiting step in tumor targeting [313].
Although bulk uptake measurements revealed varying levels of nanoparticle
accumulation due to alterations in the distribution of p32, it does not provide information on
nanoparticle localization within the tumor. To gain a better understanding of the heterogeneity of
TPN targeting on a microscopic scale, we adopted a method to unbiasedly quantify the
distribution of extravasated antibodies in tumor sections [314]. Briefly, histological sections
containing CD3 1-positive areas were isolated to generate a map of the vasculature. This mask
was combined with tumor sections devoid of necrotic areas to create a Euclidean distance map
between blood vessels and cell that took up TPNs. Finally, an intensity profile as a function of
distance from the nearest vessel was created (Figure 7.13). To enable facile comparison between
cohorts, the distance at which 50% of TPN/VivoTag-750-siRNA fluorescence remains
(d12 TPN) was measured and averaged for each cohort.
In tumors that received GFP-siRNA followed by successive administration of TPN
carrying fluorescent siRNA, delivery of TPN was primarily localized to perivascular regions
(Figure 7.14). The limited extravasation into the tumor parenchyma suggests the presence of a
TPN binding sink created by p32-expressing tumor cells near the vasculature. In contrast, TPN
penetration was significantly enhanced in tumors where p32-expression is suppressed from pre-
treatments with p32-specific siRNA. Fluorescence intensity was high in the vasculature,
perivascular cancer cells, as well as cells distant from blood vessels. Quantitative analysis of
tumor cross-sections revealed that the average diffusion distance of TPN from the tumor blood
vessels was improved by nearly five-fold, from 17 jim (range: 3.75 ptm - 41 jim) to 83 pm
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(range: 4 pm - 188 pm). Alternatively, the reduction of the p32 binding barrier enhanced TPN
penetration from 1-2 cell layers to 4-6 cell layers away from vasculature (Figure 7.15).
Consistent with evidence from literature that suggests antigen abundance can negatively
affect antibody penetration into tumors, these data collectively suggest that the TPN binding
barrier can be overcome by reducing p32 receptor expression. Stochastic models based on
microenvironmental parameters and measured nanoparticle properties (Table 7.1) are currently
under development to reproduce experimental outcomes and establish guidelines to further
improve TPN tumor penetration.
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Figure 7.10. p3 2 knockdown by TPN. (A) Schematic of the experiment. Mice bearing s.c. OVCAR-8
human ovarian carcinoma xenografts were injected i.v. on day 0 and day 1 with TPN carrying either
siGFP or siP32. Two days later, both cohorts of mice were injected i.v. with TPN carrying a
fluorescently-labeled siRNA (VivoTag750). Tumors were harvest 6 h after injection. (B)
Immunofluorescence staining of p32 (pseudocolored in red). (C) Quantification of p32
immunofluorescence intensities from tumor cross sections from (B). Data represent averages ± s.d. (n = 8-
10 randomly selected tumor sections from each cohort). *p<0.05, unpaired Student's t-test.
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Figure 7.11. Whole-tumor immunofluorescence images from tumor xenografts harvested from mice
treated with either TPN/siP32 or TPN/siGFP. Sections are stained with antibodies against CD31
(pseducolored red) and overlaid with fluorescence from the near-infrared channel to indicate localization
of TPN carrying VivoTag750-siRNA. Scale bar, 500 pim.
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Figure 7.12. Tumor uptake of TPN after suppression of p32. (A) Near-infrared fluorescence imaging
of TPN uptake in explanted tumors after suppression of p32 by TPN/siP32. (B) Quantification of
VivoTag-750-siRNA fluorescenc intensity from (A). n.s., not significant, unpaired Student's t-test.
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Figure 7.13. Schematic of quantitative image analysis of tumor penetration. Fluorescent images
containing signal from CD31 are thresholded to generate a map of vasculature. Tumor sections are
outlined manually to delineate regions of the tumor parenchyma for analysis. The vasculature map is
applied to tumor sections to generate a Euclidean distance map of siRNA fluorescence as a function of
distance from the nearest vascular structure. Finally, the distance at which siRNA fluorescence is at 50%
of maximum is determined and averaged for animals within each cohort.
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Figure 7.14. Immunofluorescence images of tumor penetration by TPN. Mice bearing s.c. OVCAR-8
tumor xenografts were treated with TPN/siP32 to suppress intratumoral p32 expression prior to
administration of TPN carrying a fluorescently-labeled siRNA. TPN/siGFP pre-treatments were used as
negative controls. Tumor sections were stained with anti-CD31 antibody to delineate blood vessels
(pseudocolored red) and visualize co-localization with fluorescent siRNA payloads (pseudoclored green).
Scale bar, 200um.
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Figure 7.15. Quantification of tumor penetration distance. Immunofluorescence images of tumor
cross-sections were analyzed using the algorithm outlined previously. The distance at which 50% of
VivoTag-750 siRNA fluorescence remained was calculated for each image, and averaged for animals
within the cohort. For each animal, 4-7 randomly selected images were analyzed. Data represent averages
+ s.d. (n = 5 animals per cohort). *p<0.05, unpaired Student's I-test.
Table 7.1. Parameters used for stochastic modeling of TPN penetration
Size of tumor (OV4, mm 3)
Plasma volume in -20 g mouse
Diffusivity of TPN (Rh = 100nm)
Vascular permeability
Capillary radius
Diameter of TPN (nm, in H20)
Slice of tumor section
Volume of tumor section (mm 3)
Average weight of tumor (mg)
Number of TPNs in tumor slice
TPN/p32 apparent affinity
LyP-1/p32 apparent affinity
Total # p32 per cell
% Knockdown of p32 in vivo
% Knockdown of p32 in vitro
On rate (Koff / Kd, M 1s 1)
Off rate (s-1)
Percent of injected dose per gram
Total dose (nmols)
48
2 ml
2.97 x 10~9 cm2/s
1.8 x 108 CM/s
8 pm
100
10 um
1.32E-01
27
2.02E+09
282 nM
4.17 uM
70,000
91.5
65
47.93
1.35E-05
4.51
1
26-120 Measured
Assumed
Jain, 2001
Jain, 1994&1995
Wittrup 2011
Measured
Known
Calculated
24-30 Measured
Calculated
214-321 Measured
2.7-5.64 Measured
Estimated
Measured
60-70 Measured
Calculated
Measured
4.35-4.66 Measured
Known
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7.2.4 Utilization of p32 suppression for tumor imaging
Improvements in the tumor microdistribution of theranostic nanoparticles have been
shown to provide better tumor imaging contrast and significantly enhance therapeutic efficacy in
a variety of cancer types and mouse models [115-116, 315-316]. Therefore, we wondered
whether the high glycolytic phenotype after transient p32 suppression by RNAi can be utilized
for molecular imaging. Specifically, we postulated that cancer cells whose p32 expression is
suppressed have enhanced uptake of glucose and its analog, 2-deoxyglucose (2-DG), the basis
for functional imaging techniques such as positron-emission tomography (PET). To quantify
glucose uptake in cells, we measured the cellular uptake of a fluorescent glucose analog using
flow cytometry. In all three cancer cell lines treated with TPNs carrying p32-specific siRNA, we
observed a consistent increase in the uptake of 2-[N-(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-
2-deoxyglucose (2-NBDG) (Figure 7.16). To visualize glucose utilization in vivo, we probed the
uptake of a near-infrared fluorescent 2-deoxyglucose reporter molecule (IRDye 800CW 2-DG)
in mice bearing s.c. OVCAR-8 human ovarian carcinoma xenografts, 48 h after treatments with
either TPN/p32-specific siRNA or a scrambled control siRNA (Figure 7.17). Whole-animal
optical imaging showed a significant increase in tumor uptake of 2-DG probe in siP32-treated
mice (Figure 7.17). After the probe was cleared from circulation, ex-vivo analysis of explanted
tumors showed over 100% improvement in probe fluorescence after p32 suppression relative to
tumors that received a control siRNA (Figure 7.18).
While we observed an increase in the uptake of fluorescent 2-DG conjugates in siP32-
treated tumors, this may not accurately represent true hypermetabolic activity [317]. Recent
studies have suggested that the bulkiness of the fluorescent dye (700-1000 Da) compared to
glucose (180 Da) could significantly alter the pharmacodynamics of the probe and promote its
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non-specific retention in the tumor interstitial space, which could ultimately contribute to the
enhanced tumor accumulation [318]. Indeed, immunofluorescence analysis of tumor sections
revealed that the near-infrared probe was localized to both vascular structures (CD3 1+) as well
as within the tumor interstitium, phenomena that can be associated with enhanced permeability
and retention (EPR) in addition to tumor cell glucose uptake (Figure 7.19).
In light of these findings, we performed 18F-FDG-PET imaging with computational
tomography (PET/CT) to measure tumor metabolic changes after p32 suppression in vivo. Mice
bearing bilateral s.c. OVCAR-8 tumors were pre-injected with two doses of TPN/siP32 on two
consecutive days (1 mg siRNA/kg/injection) and were subjected to PET/CT imaging 48 h after
the second TPN injection. Tumors treated with p32-siRNA showed over 50% enhancement in
uptake of 18F-FDG compared to controls that received GFP-siRNA, as quantified by the total
fraction of injected dose that is present in the tumor (Figure 7.20). Furthermore, we observed
substantial '8F-FDG uptake in the periphery of TPN/siGFP-treated xenografted tumors, owing to
the presence of avascular, necrotic tumor areas. In contrast, TPN/siP32-treated tumors exhibited
FDG delivery to both the periphery as well as areas near the tumor core (Figure 7.20; Figure
7.21), likely owing to a more uniform distribution of glycolytically-active tumor cells within the
tumor parenchyma resulted from p32 suppression by RNAi. We did not observe a similar
enhancement in 18F-FDG uptake in mice bearing OVCAR-4 ovarian tumor xenografts (Figure
7.21), consistent with in vitro observations that p32 suppression in OVCAR-4 cells did not
significantly shift their metabolism towards glycolysis (Figure 7.8). These observations in
aggregate indicate that suppression of p32 in tumors could enhance the uptake of glucose and its
analog, 2-deoxyglucose, thereby providing better contrast for tumor imaging by 1 F-FDG-PET.
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Figure 7.16. Uptake of fluorescent glucose analog in human cancer cell lines after p32 suppression.
In OVCAR-4, OVCAR-8, and HeLa cells pre-treated with either TPN/siGFP or TPN/siP32, cellular
uptake of 2-[N-(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-2-deoxyglucose (2-NBDG) was examined 24 h
later. Data represents averages ± s.d. (n = 3 independent measurements). *p<0.05; ***p<0.001, unpaired
Student's t-test.
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Figure 7.17. Tumor uptake of fluorescent 2-deoxyglucose in vivo. Mice bearing s.c. OVCAR-8
human ovarian carcinoma xenografts were administered with TPN/siP32 two days prior to injection of
a near-infrared fluorescent glucose analog. Bio-distribution and tumor uptake of 2-DG was determined
via non-invasive whole animal imaging 24 h later.
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Figure 7.18. Quantification of 2-DG fluorescence in tumor explants. Top, data represents averages
± s.d. (n = 3 animals per group). *p<0.05 unpaired student's t-test.Bottom, representative fluorescent
images of whole-tumor explants.
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Figure 7.19. Immunofluorescence imaging of tumor sections.Tumors cross-sections were stained with
anti-p32 (green). NIR 2-DG probe was pseudocolored red. Cell nuclei were counterstained with DAPI
(blue). Scale bar, 50 pm.
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Figure 7.20. 18F-FDG-PET/CT imaging of OVCAR-8 tumor xenografts. Tumor-bearing mice
underwent FDG-PET and tumors were delineated by the dotted line and arrows. Quantification of 18F-
FDG uptake as the amount of injected dose localized to the tumor tissue (%ID/g tissue) are shown on the
right. Data represent mean + s.d. (n = 4 tumors).
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Figure 7.21. '8F-FDG-PET/CT imaging of OVCAR-4 tumor xenografts.Quantification of FDG tumor
uptake is shown on the right.
7.3 Conclusions
In this work, we have demonstrated that spatial- and temporal-control of receptor
expression in the tumor parenchyma can affect the intratumoral microdistribution and
penetration of receptor-targeted nanoparticles. Experimental studies using p32-targeted tumor-
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penetrating nanocomplexes show that the binding site barrier for tumor penetration can be
overcome through knockdown of p32. Specifically, down-regulation of p32 within the tumor
reduces the heterogeneity of successive TPN uptake and improves siRNA delivery to deeper
regions of the tumor parenchyma, potentially in avascular or hypoxic areas that are previously
inaccessible to nanotherapeutics. Finally, the utility of this strategy in improving nanoparticle
delivery is explored in tumor imaging by 18 F-FDG-PET/CT.
The TPN system described in this work is highly modular; other tumor-homing domains
identified from high-throughput screens and siRNA cargoes directed against their receptors can
be independently varied with ease. Efforts utilizing stochastic models for nanoparticle
extravasation are underway to generate a framework and guidelines for overcoming the binding
barrier and improving tumor penetration. By adapting the system to other tumor types and
disease processes, this strategy can serve as a powerful and generalizable tool for overcoming the
binding barriers of tumor transport, enhancing the delivery of theranostic agents to tumors, and
facilitating the development of better diagnostic and therapeutic regimens.
7.4 Materials and Methods
Tumor penetrating nanocomplex (TPN) preparation. TPNs were prepared as described previously
[213]. The sequences of siRNAs (5'-3') are as follows: siGFP (GGCUACGUCCAGGAGCGCA), siP32
#1 (CCCAAUUUCGUGGUUGAAGUUAUAA), siP32#2 (GAAGGCCCUUGUGUUGGAC), siP32#3
(CAGACAGAUGCUGAAAGCC).
Real-time quantitative Reverse-Transcription PCR. Total RNA was extracted using the RNeasy kit
according to manufacturer's instructions (Qiagen). 1 pig of total RNA was used to synthesize cDNA by
using random hexamer primer cocktails and reverse transcriptase (Invitrogen). Quantitative PCR reactions
were performed using SYBR green PCR Master Mix (Applied Biosystems). The primers used are as
follows: GAPDH (forward: 5'-CCTGTTCGACAGTCAGCCG-3'; reverse: 5'-
CGACCAAATCCGTTGACTCC-3') and P32 (forward: 5'-AAAGTTGCCGGGGAAAAA-3'; reverse:
5'-TCCTCCTCACCATCAAATGTT-3'). Triplicate reactions for the gene of interest and the endogenous
control, (GAPDH) were performed separately on the same cDNA samples. The mean cycle threshold (Ct)
was used for the AAC analysis method (ABI User Bulletin #2).
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Flow Cytometry. Fluorescence-activated cell sorting (FACS) analysis of cell-surface p32 was performed
on live cells. Approximately 5 x 105 cells were stained with a polyclonal anti-full-length/NH2-terminal
p32 or rabbit IgG isotype control (1 pg per 1 x 106 cells) and Alexa-647 goat anti-rabbit secondary
antibody, each for 40 min on ice, analyzed by gating for propidium iodide-negative (live) cells. Uptake of
2-NBDG was measured according to manufacturer's instructions (Invitrogen).
Measurements of glucose consumption and lactate production. HeLa, OVCAR-4, and OVCAR-8
cells were seeded in 6-well plates at a density of 0.1x10 6 cells per well. Two days after plating, cells were
treated with TPN according to established protocols. The media from each well was collected at indicated
time points and frozen at -80 'C. The concentrations of glucose and lactate were determined using
glucose and lactate assay kits (BioVision). To determine glucose consumption rates, the concentration at
each time point was normalized to that at time zero. For each experimental condition, media from at least
4 independent experiments was measured and averaged.
Systemic administration of TPNs into mice. Female nude NCR mice (Charles River Laboratories) were
obtained at 4-6 weeks of age. All animal experiments were approved by the MIT Committee on Animal
Care under approved protocols. For in vivo delivery of siRNA, TPNs were prepared as described
previously [213] with siRNAs targeting either P32 or GFP in 5% glucose and injected intravenously into
mice bearing bilateral s.c. OVCAR-8 ovarian carcinoma xenografts. For tumor uptake, TPNs carrying
near-infrared fluorophore labeled siRNA (1.5 nmols) was prepared in 5% glucose and injected via the tail
vein. The mice were imaged using the IVIS 200 imaging system (Caliper Life Sciences). Tumor explants
were examined at 84 jim resolution using the Odyssey imager using an excitation wavelength of 785 nm.
Deoxyglucose imaging in mice. A deoxyglucose probe labeled with a near-infrared fluorophore (IRDye
800CW 2-DG, LI-COR) was injected into tumor bearing mice via the tail vein at a dose of 10 nmols of
probe per injection. One day after probe administration, mice were imaged using the IVIS system (Caliper
Life Sciences) with a 745-nm excitation and 820nm emission filter. Total fluorescence normalized by
tumor area was measured using LivingImage (Caliper Life Sciences) for each tumor.
18 F-FDG MicroPET/CT Imaging. Mice were imaged using '8F-FDG-PET on an Inveon small animal
PET/CT scanner (Siemens). PET/CT data was acquired using standard protocol as described elsewhere.
After imaging, animals were euthanized and tumors were excised to determine the total injected dose per
gram of tissue (%IDGT) within the tumor.
Immunostaining and co-localization analysis. Tumors were fixed in 4% paraformaldehyde at 4'C
overnight and snap frozen in liquid Nitrogen. Rat anti-mouse CD31 (1:50, BD PharMingen) and/or a
polyclonal anti-full length p32 antibody were used for immunofluorescence staining. Sections were
washed and detected with AlexaFluor-488 goat anti-rat or anti-rabbit IgG (1:1000; Invitrogen). The slides
were counterstained with DAPI and mounted on glass slides for microscopic analysis. For co-localization
analysis of CD31 and p32, the number of non-zero pixels in the p32 channel that co-localized with non-
zero pixels in the CD31 channel was normalized by total p32 intensity for each image. The analysis was
repeated for a total of 4-6 images for each condition.
Measurement of tumor penetration on immunofluorescence sections. A method similar to the one
described to measure antibody penetration was adapted [314] to quantify tumor penetration of TPN.
Statistical analysis. Statistical analyses were performed using built-in statistical functions in GraphPad
Prism (GraphPad Software).Averaged fluorescence intensities from immunofluorescence staining, results
from glucose/lactate assays, qPCR, and intratumoral fluorescence intensities were analyzed using
Student's t-test.
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8 Delivery of siRNA to primary ovarian cancer cell samples
8.0 Abstract
p32 (gCIqR/p33/HABP1), is a mitochondrial protein aberrantly expressed on the surface
of ovarian cancer cell lines and the cognate receptor for targeted, tumor-penetrating
nanocomplexes (TPN). Analysis of primary ovarian cancer cell samples freshly isolated from
patients with advanced stage ovarian cancer revealed that p32 is also expressed on the surface in
a subset of primary cancer cells. In vitro, TPN-mediated delivery of siRNA directed against ID4,
an ovarian cancer-specific oncogene amplified in over 32% of high-grade serous ovarian
carcinomas, resulted in significant suppression of ID4 expression in primary ovarian cancer cells.
Additionally, p32 was found to be highly overexpressed in 49% of specimens in a tissue
microarray of late-stage epithelial ovarian carcinomas. Taken together, these data suggest that
p32 is a generalizable target for TPN targeting and RNAi therapy in patients with ovarian cancer.
8.1 Introduction
Ovarian cancer is one of the leading causes of cancer deaths in women, with over 15,000
deaths from over 21,000 cases in the U.S. in 2011 [8]. This high mortality rate is due to a lack of
tools to detect early-stage disease with high sensitivity, as well as a paucity of effective drugs to
control disease progression and metastasis. Despite recent progress in the understanding of the
biology underlying ovarian cancer, our chemotherapeutic arsenal has remained practically
unchanged. Platinum- and taxane-based drugs such as cisplatin and paclitaxel still remain as the
standard of care for patients with advanced HGSOC in conjunction with cytoreductive surgery.
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These genotoxic agents act via exploiting non-specific features that distinguish quiescent cells
from rapidly proliferating cells; they do not target genomic vulnerabilities or genes that drive
ovarian carcinogenesis. Consequently, standard chemotherapy is associated with significant
dose-limiting toxicities due to side effects in organs such as the gastrointestinal tract, skin, bone
marrow, and the central and peripheral nervous system. Furthermore, despite high initial
response rates, over 70% of patients with advanced disease (Stage III or IV) re-present with
progressively chemoresistant cancers, owing to the accumulation of numerous genetic mutations
and activation of redundant survival pathways [18]. Therefore, there is a desperate need to
develop more effective, less toxic, and "personalized" therapeutic strategies for ovarian cancer.
Recent progress in sequencing has provided unprecedented insight into the genetic basis
of cancer initiation and progression by enumerating all genomic alterations in numerous cancer
types including glioblastomas (GBM) and ovarian carcinomas [29, 34]. Efforts led by The
Cancer Genome Atlas (TCGA) have identified 1825 genes located in over 63 regions of the
genome that are targeted by recurrent amplification events and 55 regions that harbored recurrent
focal deletions [29]. In parallel, genome-wide loss-of-function screens based on RNA
interference have led to the identification of genes whose perturbations have direct consequences
on cancer cell survival [48]. Together, the systematic integration of structural and functional
genomics has enabled the distillation of genes that are not only mutated in cancer, but also
represent putative cancer drivers. Nevertheless, a significant fraction of these genes represent
"undruggable" targets that are not amenable to targeting by existing small molecule- or antibody-
based therapies [1]. Furthermore, the number of genes nominated by these integrated efforts is
too large for in vivo validation, as existing approaches based on genetically engineered mouse
models or shRNAs are limited to analyzing only a small number of candidates.
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In Chapters 3 through 6, we developed a solution to overcome this bottleneck of in vivo
target validation which utilizes tumor-penetrating nanocomplexes (TPN), consisted of tandem
tumor-penetrating and membrane-translocating peptides that chaperone siRNA payloads deep
into the tumor parenchyma [213]. p3 2 (p33/HABP1/gClqR) is a mitochondrial protein that is
overexpressed and aberrantly localized to the surface of tumor cells [233, 304]. In Chapter 4, we
showed that delivery of siRNA against ID4, a novel ovarian-specific oncogene amplified in 32%
of HGSOCs, suppressed the growth of ovarian tumor xenografts in mice [213]. In Chapters 5 &
7, we showed that the modularity of the TPN system enabled the tumor-specific delivery of
siRNA against other genes for pre-clinical therapeutic or diagnostic intervention in animals.
While the TPN system holds promise in discovering genes that contribute to cancer
progression and are amenable to RNAi inhibition in mouse models; clinical translation of this
approach to patients requires further evaluation of efficacy and safety in primary human tumor
specimens. In this work, we probe the utility of TPN-mediated delivery of siRNA therapeutics in
human patient tumors. First, we evaluated primary ovarian cancer cells for p32-expression. In
two human patient cell samples that selectively took up TPN in a p32-specific manner, delivery
of siRNA targeting the ovarian oncogene ID4 resulted in significant suppression of gene
expression in vitro. Finally, the generalizability of TPN targeting in human patient tumors was
evaluated via examining p32 expression in ovarian tissue microarrays (TMA).
8.2 Results
To investigate whether primary human patient ovarian cancer cells are amenable to TPN
targeting and siRNA delivery, we began by examining the cell surface expression of p32, the
cognate receptor for LyP- 1 targeted TPN. Fresh primary tumor cells were obtained from
malignant ascites fluids of patients with advanced ovarian carcinoma, purified, and subsequently
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expanded as orthotopic xenografts in nude mice. The resulting primary ovarian cancer cell
strains are further isolated from mouse cells and non-parenchymal cell types in vitro. Of the four
(4) primary patient cell strains (DF09, DF14, DF37, DF59) examined by flow cytometry, three
showed high surface expression of p32 at levels that are comparable to an established human
ovarian cancer cell line, OVCAR-8 (Figure 8.1). To confirm that p32 expression mediates TPN
uptake, primary cell samples were incubated with TPN bearing varying amounts of LyP- 1 on the
surface. In two of the p32-expressing samples (DF09 and DF14), uptake was saturated at
increasing valence of LyP-1, consistent with the hypothesis that cellular binding of TPN is
receptor-specific as all available p32 are engaged in LyP-1 binding (Figure 8.2).
To directly probe the interaction between p32 and TPN, we repeated the uptake assay in
the presence of a p32-blocking antibody. A dose-dependent inhibition of TPN uptake was
observed in samples incubated with the p32 antibody, whereas an isotype-matched control had
no effect (Figure 8.3). Collectively, the data suggests that a subset of human patient ovarian
tumor cells express p32 on the surface and can be targeted by TPN for therapeutic intervention.
We previously established that inhibitor of DNA binding 4 (ID4), a novel oncogene
amplified in 32% of high-grade serous ovarian carcinomas, is a potential therapeutic target. In
mouse models of ovarian carcinoma, TPN mediated suppression of ID4 resulted significant
inhibition or elimination of the tumor burden [213]. Here, we expanded our evaluation of
primary human patient tumors by examining their ID4 status by immunoblotting. Of the 20
different ovarian tumor cell strains analyzed, seven (7) overexpressed ID4, four of which at
levels comparable to an established ovarian cancer cell line (Figure 8.4). The DF14 cell strain
was chosen for further analysis because it overexpressed ID4 and can be targeted by TPN.
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To ascertain whether ID4 can be depleted in primary patient cancer cells for therapeutic
purposes, we investigated the effects of TPN-mediated delivery of ID4-specific siRNA in DF14
cells. Cells treated with TPN carrying siRNAs against ID4 showed significantly decreased ID4
levels on immunoblotting; the amount of ID4 depletion by TPN is dependent on the dose of
siRNA, is similar to that achieved by a commercial lipid reagent, and is similar to RNAi-
mediated suppression in an established ovarian cancer cell line (Figure 8.5). Furthermore, TPN
delivery of siID4 is specific to the LyP- 1 domain, as untargeted control nanocomplex (UCN)
bearing a scrambled domain was unable to achieve gene silencing (Figure 8.5).
Thus far, the utility of p32 overexpression in mediating tumor-specific delivery of siRNA
therapeutics has been examined in established human cancer cell lines, orthotopic xenografts,
and primary cell samples from patients. However, translational application of TPN requires
further substantiation in larger-sized cohorts. Previous studies showed high p32 expression was
observed in tissues from breast, endometrioid, melanoma, and colorectal tumors [217]. However,
the expression of p32 in ovarian tumors has not been extensively examined. To facilitate this, we
employed a tissue microarray (TMA) consisted of formalin-fixed, paraffin-embedded samples
derived from biopsies from patients with primary high-grade, late-stage serous ovarian
carcinomas and/or associated lymph node metastases. Since p32 is a mitochondrial protein that is
also aberrantly expressed on the surface of tumor cells, standard immunohistochemical staining
could fail to distinguish surface-localized p32 from mitochondrial p32. Therefore, we first
quantitatively correlated total p32 levels from immunoblotting with surface p32 measured by
flow cytometry in cell lines from ovarian cancer and melanoma. We observed a highly linear
correlation between surface and total p32 levels; this is consistent with previous investigations
showing that ~2% of total p32 was present on the cell surface of Vero cells [319] (Figure 8.6).
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Results from p32 immunohistochemical staining of TMA showed that of 131 primary
high-grade ovarian epithelial carcinomas, less than 4% (5/131) was p32-negative (score 0), 47%
(62/131) of which showed low expression (score 1+), and 49% (64/131) was p32-positive (score
2+ and 3+) (Figure 8.7). The degree of p32 staining did not correlate with clinical-pathological
outcomes such as overall survival or progression-free survival (data not shown). However, we
observed a statistically significant cross-correlation with ID4 staining intensity in the
dichotomized analysis (P = 0.0363, Fisher's exact test) (Figure 8.8; Table 8.1).
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Figure 8.1. Expression of p32 on the surface of primary human patient ovarian cancer cell samples
as determined by flow cytometry. The amount of p32 on the surface of four (4) primary cell strains(DF09, DF14, DF37, and DF59) was determined using a rabbit polyclonal antibody directed against the
p32 peptide. Cells stained with an isotype-matched control are shown in grey.
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Figure 8.2. Uptake of TPN bearing different LyP-1 ligands on the surface by primary ovarian
cancer cell samples. The cellular uptake of TPN bearing varying valence of the LyP- 1 targeting peptide
was determined by flow cytometry in four primary ovarian cancer cell samples as well as an established
human ovarian cancer cell line (OVCAR-8). The siRNA payloads are labeled with an near-infrared
fluorophore to enable monitoring of TPN uptake by flow cytometry. An exponential binding curve was
fitted and overlaid. Each data point represents average ± s.d. from 6 independent experiments.
BDF09
-'
1.0-
z 0.5-
.ni
Ihr
anti-p32
LL
C
C
La.
C
(I
20
I..
~1
DF14
r
i
1. T
0.5-
an-p32
Figure 8.3. Effects of p32-antibody on TPN uptake. (A) Uptake of TPN carrying a near-infrared
fluorophore-labeled siRNA by DF09 primary ovarian cancer cell samples measured by flow cytometry,
in the presence of increasing concentrations of a p32-specific blocking antibody (anti-p32) or isotype-
matched control (IgG). Error bars represent averages ± s.d. (B) Uptake of TPN in DF14 primary ovarian
cancer cell samples.
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Figure 8.4. ID4 is expressed in a subset of primary human ovarian cancer cell samples. Freshly
isolated patient primary ovarian cancer cells (denoted by DF##) were harvested and immunoblotted for
ID4 expression. Lysates from immortalized ovarian surface epithelial cells (IOSE80) was used as a
negative control. An established human ovarian cancer cell line (IGROV 1) was used as a positive control.
A longer exposure of the immunoblot was shown for better visualization of ID4 expression.
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Figure 8.5. Suppression of ID4 by TPN-mediated siRNA delivery in primary patient-derived
ovarian cancer cell samples and an established human ovarian cancer cell line. (A) Immunoblotting
of ID4 from DF14 primary ovarian cancer cells that were treated on two consecutive days with TPN
carrying 1D4-specific siRNA (100pmol or 200pmol per treatment). Cells were harvested 48 h after the
second transfection and lysed for immunoblotting. Control cells received either media (Mock) or
untargeted control nanocomplex (UCN) carrying ID4-specific siRNA. Lipofectamine/siID4 was used as a
positive control. A-tubulin was used as the loading control. (B) Immunoblotting of OVCAR-4 human
ovarian cancer cell line subjected to similar TPN treatments as DF14.
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Figure 8.6. Correlation between total and surface p32 levels in cancer cell lines. Top,
Immunoblotting of total p32 in lysates from four established human cancer cell lines from ovarian cancer
(OVCAR-8, OVCAR-4, CaOV-3) and melanoma (MDA-MB-435). a-Tubulin was used as a loading
control. Bottom, Correlation between surface p32 levels relative to an isotype-matched control as
determined by flow cytometry with total p32 levels measured by immunoblotting. A linear correlation
(R2=0.97) was overlaid.
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Figure 8.7. p32 expression in tissue microarrays analysis of ovarian cancer. In a TMA of 131 high-
grade serous ovarian carcinomas, 49% of samples was p32-positive (Score 2+ and 3+), 47% of samples
showed moderate p32 expression (Score 1+), while 4% was p32-negative (Score 0). Top, Representative
micrographs of tissues with p32 immunohistochemical staining are shown. Bottom left, Distribution of
p32 scores. Bottom right, An enlarged image for better visualization of p32 localization.
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Figure 8.8. Distribution of ID4 immunostaining intensities. The TMA used for p32 scoring was
also stained with 1D4-antibody and staining intensities were quantified and graded using a similar
scale. The intensities of ID4 and p32 for each tumor section was correlated and analyzed.
Table 8.1. Correlation between p32 and ID4 intensity in a tissue microarray of high-grade
ovarian carcinoma.
p32 Intensity
Low High Total
Low 40 26 66
High 27 38 65
A Total 64 67 131
8.3 Discussion
The primary aim of this study is to evaluate the clinical translational potential of the TPN
platform for delivering siRNA therapeutics. To date, evaluations on the efficacy of TPN-
mediated RNAi inhibition of gene expression are performed in either established human cancer
cell lines or orthotopic xenograft mouse models. While these systems represent important models
in which efficacy and safety studies must be carried out, they also suffer from several drawbacks
that distinguish them from true models of cancer initiation and progression in patients. For
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example, artifacts can be introduced during the process of adherence to tissue-culture plastic, as
changes in the microenvironment may favor the activation of certain survival pathways. As a
result, the phenotype of serially-passaged, adherent cancer cell lines may be drastically different
from uncultured, primary patient-derived cell samples. Furthermore, xenograft mouse models
have found to be poor at predicting cancer drug response, owing to their inability to recapitulate
certain aspects of tumor progression, including the roles of mesenchymal cells, effects of the
immune system, and contributions from tumor vasculature [320-322]. Therefore, the
comprehensive evaluation of TPN in human patient tumor samples that are free of
contaminations from tissue-culture is critical for eventual clinical translation.
Of the four primary patient ovarian cancer cell samples examined, three showed elevated
p32 expression and are amenable to TPN targeting. In one particular cell sample (DF14), p32-
specific TPN delivery and suppression of ID4, an ovarian-specific oncogene, was achieved.
Follow-up studies are underway to evaluate the phenotypic consequences of 1D4-depletion by
siRNA in vitro and in xenografts in vivo. Results from these experiments could highlight a
pathway towards clinical translation and efficacy studies in patients.
The expression of p32 was examined in a large cohort of high-grade ovarian tumor
samples in a tissue microarray. Over half of the samples showed high p32 expression (Score 2+
and 3+), consistent with previous findings that suggest p32 is a general surface marker in a
variety of tumor subtypes. Previous evidence also suggests that there is a correlation between
aberrant p32 localization with mitochondrial dysfunction and maintenance of OXPHOS in
established cancer cell lines. However, the exact functional role of p32 in ovarian cancer is still
being investigated. While preliminary studies did not point to a statistical link between p32
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overexpression and the clinical outcome of patients with HGSOC, a comprehensive examination
of p32 as a potential biomarker for other cancers utilizing expanded TMAs is warranted.
In summary, TPN can target a subset of primary ovarian cancer cells freshly isolated
from the ascites fluid of patients with advanced ovarian cancer. These cell samples also
overexpress ID4, a novel ovarian oncogene recurrently amplified in high-grade serous ovarian
carcinomas. Examination of tumor tissue microarrays revealed that a large fraction of high-grade
ovarian tumors express p32. TPN-mediated delivery of ID4-specific siRNA could represent a
potential therapeutic strategy for clinical implementation.
8.4 Materials and Methods
Primary cells. Primary ovarian cancer cells were obtained from patients with advanced ovarian cancer at
the Dana-Farber Cancer Institute under protocols approved by the Dana-Farber/Harvard Cancer Center
Institutional Review Board (DFHCC IRB) as previously described[235]. Briefly, the ascites fluid from
patients was obtained, processed, and tumor cells were isolated and enriched for their epithelial nature via
EpCAM and HE4 immunostaining.
Tumor penetrating nanocomplex (TPN) preparation. TPNs were prepared as described previously
[213]. TPN/siRNA treatments were performed on two consecutive days in either DF 14 or OVCAR-4
cells, and lysates were harvested 48 h later.
Tissue Microarrays. A microarray of ovarian tumors was constructed from tumor biopsy samples from
patients with late-stage (Stage III or IV) high-grade serous ovarian adenocarcinomas who underwent
cytoreductive surgery at the Dana Farber (n = 131). A quadruplicate set of biopsy cores of 0.8 mm in
diameter was obtained from each patient.
Immunohistochemistry.Formalin-fixed, paraffin-embedded ovarian tumor sections were de-waxed,
rehydrated, and incubated in hydrogen peroxide solution to block endogenous peroxidase. Antigen
retrieval was performed in a pressure cooker in citrate buffer (pH 6.0). Histological staining with a rabbit
polyclonal p32 antibody was carried out at 4 "C overnight (antibody dilution 1 pig/mL). A HRP-
conjugated goat anti-rabbit antibody was applied for I h at room temperature, followed by DAB for 5 min
for visualization.
Statistical analysis. Statistical analyses were performed using built-in statistical functions in GraphPad
Prism (GraphPad Software) and appropriate statistical tests.
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9 Discussion and future directions
9.1 In vivo tumor cell targeting with 'Click' nanoparticles
In Chapter 2, we demonstrated that "click" chemistry can be applied to target
nanomaterials to tumors in vivo. Leveraging peptide discoveries from phage display, we showed
that attachment of the cyclic tumor homing and tissue-penetrating peptide, LyP- 1, to iron-oxide
nanoparticles was able to direct their binding to p32-expressing tumor cells in cell culture and in
tumor xenografts. Importantly, nanoparticles bearing the same valence of a control peptide with
the same net charge and cyclic structure as LyP-1 (LyP-1CTL) did not bind p32. While the work
focused on iron oxide nanoparticles, the attachment chemistry is bio-orthogonal and
generalizable to virtually any peptide or nanomaterial scaffold. Therefore, expansion of "click"
attachment to other systems for in vivo tumor targeting is a critical next step. Specifically, other
cyclic tumor homing peptides such as RGD4C and iRGD can be attached to the end of azido-
bearing 5kDa PEG polymers to enhance the circulation of nanomaterials including
semiconductor quantum dots, gold colloids, polymeric nanoparticles, and peptides.
Despite their moderate circulation half-lives, the macroscopic intra-tumoral accumulation
of LyP- 1 click nanoparticles and PEG-azido-nanoparticles was similar, suggesting that tumor
accumulation was on par with passive delivery and was not enhanced with LyP- 1 targeting. This
is consistent with other reports of long-circulating nanoparticles that passively accumulate in
tumors via their hyper-porous vasculature over time via the enhanced permeability and retention
(EPR) effect [204]. Because the receptor for LyP- 1 is likely located in epithelial tumor cells and
mycloid cells, it is not surprising that receptor binding would have difficulty amplifying the rate
of tumor extravasation for targeted nanoparticles beyond what's achievable by EPR.
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Histological examination revealed that untargeted nanomaterials remain closely localized
to the immediate periphery of blood vessels, consistent with high co-localization with CD31
staining of tumors. By contrast, LyP- 1 nanoparticles penetrated the interstitium and were taken
up by p32-expressing tumor epithelial cells in the parenchyma. These results are in accordance
with existing literature suggesting that targeting ligands alter the micro-distribution of
nanoparticles, but do not increase macroscopic tumor accumulation [323]. Thus, there may also
be unique transportation pathways within tumors that are exploited by this ligand after
extravasation which are not available to untargeted materials. A future area of investigation is to
characterize the intra-tumoral transportation pathways by which LyP- 1-targeted nanomaterials
undertake to access the parenchyma. Also, the unique localization of LyP-1 nanoparticles in
avascular regions deep in the tumor parenchyma may be of interest for directing therapeutics into
hypoxic regions of tumors, where most conventional therapies do not reach.
At 24 h following incubation, particles remain within punctuate compartments outside the
nuclei, which are likely to be endosomal compartments. These nanoparticles likely cannot
actively escape from endosomes as they lack devices to trigger lysis of the endosomal structures.
An important step forward would be to engineer multi-functional Click nanoparticles that
encompass diverse functionalities such as tumor-targeting, endosomal-escape, and release of
therapeutic cargo on demand.
9.2 Tumor-penetrating nanomaterials for siRNA delivery
In Chapter 3, we described the development of a novel siRNA delivery technology
leveraging newly discovered pathways of active tumor penetration through 'stimulated
penetration and retention'. The delivery system consists of a multifunctional tandem peptide
structure that contains a tumor-penetrating motif (LyP- 1), a siRNA binding motif, and a cell-
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penetration motif for transporting siRNA out of the endosomes and into the cytosol of tumor
cells that aberrantly express the mitochondrial protein p32 on the surface. We found that a subset
of tandem peptides bearing cell-penetration motifs such as Transportan (TP) delivered siRNA
payloads into tumor cells in a p32 receptor-specific manner. Furthermore, systemically
administered TP-LyP- 1 nanocomplexes carrying fluorescently-labeled siRNA preferentially
accumulated in tumor xenografts established from cell lines that overexpress p32.
To date, no delivery technologies exist that enables tissue-penetrating delivery of siRNA
after either i.v. or i.p. administration. Current peptide- or viral- based approaches are either
passively targeted, actively target intravascular receptors on endothelial cells in a non-tissue
penetrating manner, or is limited to one particular cell type in non-cancer settings [151, 324]. As
a result, these approaches have met with limited success in delivering siRNA to solid tumors.
Our system offers the distinct advantage of being able to target siRNA to tumors via either i.p. or
i.v. delivery. An immediate follow-up study is needed to elucidate the mechanism of action by
which large nanoparticles with diameters of up to 100 nm can extravasate into systemic
circulation subsequent to intraperitoneal administration. A thorough understanding of the in vivo
pharmacokinetics and transportation pathways would allow us to formulate more sophisticated
nanocarriers for systemic delivery of therapeutic and diagnostic agents.
Looking forward, this versatility could enable the adaptation for targeting other organ
systems beyond the ovaries. We believe that i.v. administration is an exciting application of this
work and the technology could find utility for patients with lung cancer since the pulmonary
vessels are the first vasculature bbed nanoparticles would encounter. Currently, efforts are
underway to test the efficacy of TPN delivery in genetically engineered mouse models of non-
small cell lung cancer (NSCLC) as well as pancreatic ductal carcinomas (PDAC), both of which
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are highly lethal diseases where numerous conventional chemotherapeutics failed to induce
complete remission in a majority of patients.
Furthermore, this approach is synthetically modular, allowing incorporation of arbitrary
tumor-penetrating domains leveraging stimulated penetration pathways. In the future, efforts to
extend this delivery system to other homing ligands should greatly enhance its therapeutic
impact. We have already begun evaluating tandem peptides bearing iRGD, another tumor-
penetrating motif identified recently [117-119]. Preliminary data suggests that TP-iRGD tandem
peptides carrying fluorescent siRNA payloads rapidly penetrated the parenchyma of OVCAR-8
tumor xenografts and distributed to tumor cells that express neuropilin- 1 (NRP- 1), a pattern
similar to that of iRGD-targeted phage and nanoparticles. In the future, the functional delivery of
siRNA cargo by TP-iRGD to suppress gene expression in vivo will be investigated.
In addition to the utility of the technology, what is conceptually novel about our approach
is the finding that tandem peptide construction and complexation can fundamentally alter the
function of one peptide domain while retaining properties of the second. The transportan (TP)
domain, normally a ubiquitous cell penetrating ligand, is restricted to act upon cells that are
entered through a specific receptor. Its cell penetrating property is thwarted whereas its ability to
traverse endosomal membranes is retained. In addition, we employ its cationic charge to serve an
additional siRNA complexation function. In contrast, the tumor-penetrating peptide LyP-1
retains its properties and they are enhanced by multivalency through complexation with siRNA.
In an orthotopic mouse model of disseminated ovarian cancer, a significant dose of
nanocomplexes was able to reach the parenchymal epithelial ovarian tumor cells to silence the
expression of a luciferase reporter. Looking forward, more potent carriers could be designed to
reduce the amount of siRNA and/or peptide carrier required to suppress gene expression. Since
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the tumor-penetrating domain (LyP-1) alone has an effect on cell viability at high doses (100
pM), a reduction in the dosage of siRNA and carrier without sacrificing either the potency of
RNAi or specificity of p32-targeting would also decrease associated non-specific toxicities and
off-target effects. This could be achieved by engineering more stable, long-circulating
nanocomplexes that readily accumulate in tumors over time.
9.3 An integrated platform for credentialing cancer targets
Large-scale efforts to comprehensively characterize cancer genomes, such as The Cancer
Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC), have begun
to uncover a list of loci that exhibit cancer specific copy number variations such as
amplifications and deletions. Results from characterizations of glioblastomas and ovarian
cancers show that most amplified regions encompass hundreds of genes. Looking forward, as
data from other cancers become available, it will become increasingly difficult to dissect the
functional roles of these genetic lesions, and identify from structural genomics data which genes
are relevant cancer drivers that directly contribute to carcinogenesis.
The work presented in Chapters 4 & 5 provides a much-needed and moderate-throughput
approach to distill emerging cancer genome datasets down to viable therapeutic targets, by
functionally validating cancer drivers in vitro and in vivo. Leveraging tumor-penetrating
nanocomplexes (TPN) that enable tumor-targeted delivery of siRNA payloads into the tissue
parenchyma, this integrated platform has the capacity to interrogate the functional consequences
of suppressing any gene-of-interest in vivo through RNAi. Rapid integration between genomics
efforts, loss-of-function approaches, and effective delivery technologies can validate therapeutic
targets in as few as eight (8) weeks.
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To fully investigate the efficacy of p32-mediated, ID4-dependent cancer cell killing,
more comprehensive characterizations are needed. For example, the TPN technology could be
validated in cell lines that either do not express p32 on the surface, do not harbor 6p22
amplifications or CYCLOPS genes, or whose survival do not depend on ID4-mediated signaling.
Moreover, as the in vivo tumor response to RNAi therapy is likely dynamic and heterogeneous,
detailed assessment of single-cell response to ID4 suppression in the context of whole tumors via
immunohistochemistry will be necessary to optimize drug penetration and dosing.
Here, the in vivo validation studies were performed in orthotopic ovarian cancer
xenografts in immunodeficient mice. We chose the orthotopic xenograft model to demonstrate its
clinical utility because it offers three distinct advantages: (1) OVCAR-8 and A2780 cells harbor
defined genetic abnormalities such as amplification of ID4 and loss of copy number of PSMC2,
(2) they express p32 on the cell surface which can be harnessed for nanocomplex targeting, (3)
tumors can be established within several weeks, allowing rapid in vivo evaluation of potential
therapies. While xenograft models provide a facile and robust tool for rapidly validating the role
of cancer-associated genes, these animal models often do not fully recapitulate the pathogenesis
and molecular characteristics of disease. For example, certain xenograft tumor models fail to
reproduce interstitial fluid pressures measured in patients and do not accurately predict the
chemotherapeutic response for certain drugs [94, 320]. Moreover, variations in the host can
influence tumor neo-angiogenesis and the development of tumor stromal microenvironment.
Therefore, as we gain further insight into the molecular events that occur during ovarian cancer
pathogenesis, an important future step is to perform in vivo validation experiments in more
accurate in vitro and in vivo models. These include cell culture models using fallopian tube-
derived secretory epithelial cells (FTSEC) that are most likely the cells-of-origin for ovarian
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cancer; genetically-engineered mouse models (GEMMs) of ovarian cancer and metastases that
recapitulate genetic lesions such as loss of p53 and BRCA1/BRCA2 mutations; and in primary
xenografts of human patient-derived ovarian cancer cells. Results from these studies will be
important in evaluating the therapeutic efficacy of suppressing candidate cancer genes and
paving the way for future clinical studies.
The cognate receptor (p32) for TPN is overexpressed in a large number and type of
tumors, including specific localized expression in avascular regions of tumor hypoxia. Moreover,
the ability of peptides bearing cryptic CendR domains to penetrate into the tissue parenchyma
and deliver any associated cargo should also be generalizable across tumor types. We are
currently applying the TPN technology to deliver nucleic acid therapeutics in GEMMs of non-
small cell lung cancer (NSCLC) as well as pancreatic ductal adenocarcinoma (PDAC). The
ability to suppress candidate oncogenes or restore tumor suppressor genes by TPN-mediated
delivery will be transformative in cancer therapeutic development.
Cancer cells evolve under incredible selection pressures and accumulate a significant
number of genetic alterations (mutations, amplifications, and deletions) over the course of tumor
development. Therefore, siRNA therapeutics against a single gene or pathway is unlikely to be
curative as redundant pro-survival and/or anti-apoptotic pathways emerge. Indeed, in preclinical
therapeutic trials conducted, a proportion of mice undergoing TPN/siJD4 treatments had tumors
that were resistant to ID4 suppression or relapsed after the cessation of RNAi. Therefore, an
important future area of investigation is to identify and overcome mechanisms by which ovarian
cancer cells undertake to become resistant to RNAi therapy. A key advantage of our approach is
the ability to quickly "mix-and-match" siRNAs targeting other genes without the need to re-
synthesize or re-purify the delivery vehicle. Much like the recent successes seen with receptor
225
tyrosine kinase inhibitors for lung cancer and melanoma, this type of molecular approach can
potentially revolutionize ovarian cancer therapy and improve patient outcomes.
In Chapter 4, we have identified ID4 as a putative ovarian cancer-specific oncogene. ID4
belongs to a family of ID proteins, many of which (such as ID 1) have been implicated in cancer
growth and metastasis through regulating cell cycle checkpoints such as CDKNA. While the
precise threshold of lethality was not determined for ID4 knockdown in this work, it is an
important area of future investigation. In other cancer models, the dose-response to Myc
inhibition has been investigated. However, in most other studies on tumor regression, it is
unclear what the exact "threshold" for lethality is for an individual oncogene, such as ID4. This
is an ongoing, fertile field of research in cancer biology and oncogene addiction. In the future,
more definitive studies are needed to uncover the mechanisms through which ID4 act to
transform cells and identify its downstream target genes.
9.4 Characterization of receptor-specific cell-penetrating peptides for
siRNA delivery
In Chapter 6, we performed a quantitative and systematic characterization of the
mechanism by which tumor-penetrating nanocomplexes (TPN) deliver siRNA in a cell type-
specific manner. The winning combination of TP-LyP- 1 tandem peptide and siRNA resulted in
potent cellular uptake that is highly receptor-specific, efficient endosomal escape, and significant
gene silencing. Combined with least square regression analysis, we were able to identify peptide
charge and the valence of the targeting ligand as two converging key structural parameters that
favor cell-selective siRNA delivery.
While these properties are identified within the context of the TPN system, the strategy of
combining experimental investigations with computational analysis could be generalized to other
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delivery systems, where multi-step processes are involved for an exogenous cargo to ultimately
exert its effect. An exciting area for future investigation is the delivery of miRNA therapeutics,
where factors such as cellular uptake, escape from endolysosomal entrapment, and binding to
cognate mRNA sequences could all affect the overall potency of the miRNA. As efforts to
develop miRNA carriers accelerate, a systematic approach could help identify key carrier
properties that enable efficient cellular delivery.
One important area for future follow-up is the experimental validation of computational
modeling results. To fully exploit the power of computational analysis, future tandem peptide
carriers could be rationally designed to exhibit physiochemical characteristics that are predicted
to enhance nanocomplex fitness. Individual amino acid substitutions to the TP-LyP- 1 backbone
should be examined to identify new peptides that can potently transduce siRNA payloads into
cancer cells. Examination of other existing cell-penetrating domains that fit the design criteria
should also be performed to expand the repertoire of TPN.
Here, several assumptions were made in the modeling framework. Due to the sequential
nature of the steps involved in siRNA transduction and activation of RNAi, each step during the
entire process was assumed to be independent from adjacent ones. As a result, the relative
contribution of each step towards the overall RNAi efficiency was modeled using least square
regression. Indeed, preliminary examination of the various functional properties revealed little
inter-dependence (data not shown). A potential area for future investigation is the utilization of
more sophisticated computational models that do not assume linearity, such as artificial neural
networks, to reveal non-linear interactions between TPN functional properties.
In this work, the nanocomplexes are stabilized via hydrophobic interactions between N-
terminal myristic acid domains. The myristic acid motif was selected based on existing evidence
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that suggests the importance of fatty acids and lipids in imparting a stable structure to the self-
assembled polyplexes. Future investigations should explore peptides conjugated with other fatty
acid moieties, such as palmitoyl- and stearoyl-groups, to enhance the hydrophobic interactions
within the nanocomplex and protection of the nucleic acid cargo. Furthermore, since
nanocomplexes are generally cationic, electrostatic stabilization with anionic backbones such as
hyaluronic acid could further promote stability. Current efforts are underway to characterize a
combinational library of hydrophobic materials based on a biodegradable anionic hyaluronic acid
backbone. Combinatorial mixtures of hyaluronic conjugates, tandem peptides, and siRNA will be
generated into nanocomplexes at defined molar ratios. The effect of formulation on particle
stability, siRNA release, endosomal escape, and receptor targeting will be examined to identify
optimal formulations for therapeutic studies.
9.5 Improving the microdistribution of tumor-targeted theranostics
Nanotechnology is an emerging field that has tremendous potential in developing novel
diagnostics and therapeutics for cancer. The unique size (tens to hundreds of nanometers) of
nanoparticles enables them to not only operate at the length scale of biological machinery, but
also attain remarkable biological and material properties that distinguish them from macroscopic
counterparts. Through "top-down" engineering approaches, nanoparticles have been constructed
out of materials with unique electromagnetic properties for imaging and remote actuation, and
loaded with therapeutics such as small molecule drugs and nucleic acids [162, 325]. Already,
several nanotechnology-based formulations have been approved for clinical use, including
ultrasensitive iron-oxide contrast agents for MRI imaging and liposomal carriers that deliver
chemotherapy preferentially to tumors while minimizing systemic toxicity. Recently,
nanoparticles that target receptors overexpressed in tumors but not in normal tissues have gained
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considerable interest. However, targeted therapeutics such as nanoparticles and antibodies suffer
from poor tissue penetration owing to the presence of a binding site barrier. As a result, they
accumulate mostly in tumor vessels and tumor cells in close proximity to vasculature, limiting
the amount of therapeutics that ultimately reach cells located deep in the tumor parenchyma.
To overcome this transport barrier, much effort has been devoted to engineering
monoclonal antibodies with precisely-tuned receptor affinities, allowing them to dissociate from
the receptors after binding to improve intratumoral distribution. It has been established that
antibodies with high receptor affinities typically exhibit a more heterogeneous pattern of tumor
distribution owing to enhanced diffusion prior to antigen-mediated internalization. Taking a
separate but complementary approach, the work presented in Chapter 7 demonstrates a proof-of-
concept methodology to systematically reduce receptor expression prior to administration of
targeted ligands, thereby allowing the ligand to diffuse farther into the tumor tissue before being
bound to its cognate receptor. As the mathematical modeling work showed, the balance of
receptor turnover rate and efficiency of receptor knockdown is critical in influencing the ultimate
intratumoral localization of therapeutics. Therefore, an important area for future investigation is
to fully explore the effects of modulating p32 expression in combination with tuning the receptor
affinity of TPN on tumor distribution. Characterizations of the kinetics of p32 receptor turnover
and the amount of p32 receptors that is available for binding in various tumor subtypes will
improve the current model for more accurate predictions.
FDG-PET imaging is the gold standard for assessing the metabolic status of
glycolytically active tumors, including ovarian cancer. Clinically, the incorporation of
anatomical imaging such as PET/CT has significantly improved the diagnostic accuracy for
primary and metastatic ovarian cancer, with 87-100% sensitivity and 74-100% specificity.
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However, FDG-PET detection of borderline tumors and non-glycolytically active early-stage
adenocarcinomas (< 1cm in diameter) are poor. Moreover, non-specific accumulation of FDG in
metabolically active tissues, including the bowel, activated inflammatory cells, and normal
ovarian tissue could make differentiation of neoplasms from surrounding tissues difficult.
In this work, tumor cells treated with p32-specific siRNA showed an upregulation in
glycolysis, increased glucose consumption, and increased lactate production. This phenotype was
exploited for tumor imaging by FDG-PET. By transiently elevating glycolysis in cancer cells via
RNAi, this technology has the potential to detect tumors that may be previously "PET-silent".
The tumor-targeting aspect of this work may have the potential of reducing background tissue
uptake, as tumor cells that overexpress p32 on the surface can preferentially take up TPN.
Therefore, it may be possible to utilize p32-knockdown as a general means to amplify the tumor
metabolic characteristics detected on PET scans. This may be important in clinical applications
such as detecting small lymph node metastases and tumor recurrence.
Recently it has been proposed that fluorescent glucose analogs such as the near-infrared
probes used in this work may not accurately depict the metabolic state of a cell [318]. Indeed,
histological examination of tumor cross-sections containing the probe showed both intracellular
as well as interstitial accumulation, inconsistent with the hypothesis that only glycolytically-
active tumor cells can take up the injected probe. Therefore, future investigations should utilize
glucose probes that are small in molecular weight (such as 2-NBDG), and studies should be
performed to confirm that uptake is indeed due to glucose uptake via specific transporters such
as GLUT-1, using either knock-out systems or competitive inhibitors of glucose transport.
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9.6 TPN Delivery to human patient ovarian cancer cell samples
In Chapter 8, we showed that a subset of freshly isolated, primary ovarian cancer cells
from patients with advanced, late-stage epithelial ovarian cancer can be targeted by TPN. A
subset of human patient ovarian cell samples examined overexpressed p32 on the cell surface.
DF14, a particular p32-expressing primary cell strain, also took up LyP-1-directed, siRNA-
carrying TPN. Separately, a significant subset of primary ovarian cells also overexpressed ID4,
an ovarian-specific oncogene that interrupts normal differentiation and proliferation pathways of
the ovary and fallopian tube. Together, TPN delivery of ID4-specific siRNA to DF14 primary
cells potently suppressed ID4 expression in a receptor- and siRNA sequence-dependent manner.
Given the findings suggesting the dual-presence of ID4-overexpression and p32-surface
expression in a subset of advanced-stage, patient-derived, uncultured ovarian cancer cells, the
TPN delivery technology could serve as a powerful therapeutic strategy in this subset of
refractory advanced cancers that are resistant to conventional chemotherapy. One immediate and
critical follow-up experiment is to investigate the effects of TPN-mediated RNAi inhibition of
ID4 on cellular survival and proliferation. Successful siRNA-inhibition of growth of primary
cancer cells would represent a major step in shifting the ovarian cancer treatment paradigm
towards personalized, nucleic acid-based therapies.
To further evaluate and substantiate the therapeutic value of ID4-inhibition in ovarian
cancer patients, pre-clinical studies using mice bearing tumor xenografts derived from these
primary cancer cells is of the utmost importance. To best mimic ovarian disease and the host
response, immunocompetent mouse models should be considered. Following establishment of
orthotopic human patient ovarian cancer xenografts, the effect of TPN delivery of ID4-specific
siRNA should be investigated in a longitudinal therapeutic trial.
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Combination therapies with other small molecule-, antibody-, or nucleic acid-based
therapeutics are also worth exploring to maximize the synergistic effects on tumor killing. It has
been recently established that depletion of ErbB3 in these primary cells interrupts a NRG1/ErbB-
3 autocrine loop that is critical in maintaining cell viability [235]. Therefore, suppression of
ErbB3-signalling by RNAi should also be examined. While the existing TPN system failed to
significantly suppress ErbB3 expression via delivering a single siRNA sequence (data not
shown), additional optimizations of siRNA potency should be performed.
Immunoblotting and flow cytometry analyses suggested that p32 is overexpressed in
tumors and is also aberrantly localized to the cell surface. While the p32 protein lacks a
canonical hydrophobic transmembrane-spanning region or a consensus site for GPI anchoring, it
is thought that p32 localizes to the membrane through interacting with other membrane-anchored
proteins. Indeed, this pattern of expression has been previously noted in other cell types,
including Raji human lymphoma cells, neutrophils, and inflammatory cell populations [202, 326-
330]. Here, we detected a linear correlation between total and cell-surface p32 in established
human cancer cell lines, consistent with the observation that a fraction (-2-5%) of total p32 is
"shuttled" to the cell surface. A future area of investigation is to further elucidate the domains
within p32 that is responsible for LyP-1 peptide binding. As p32 expression has been found to
fluctuate due to increased cell stress, approaches to upregulate p32 expression for enhanced
tumor targeting should also be explored. Identification of p32's binding partners that anchors the
protein to the plasma membrane will be crucial in enabling more detailed molecular studies.
Finally, examination of large cohorts of high-grade serous ovarian carcinomas through
tissue microarrays (TMA) revealed that p32 overexpression occurs frequently in patients with
advanced-stage ovarian cancer. It is still unclear whether the expression of this marker is an
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indication of malignancy or predictor of clinical outcome, as p32 alone is insufficient to stratify
this set of patients. Nevertheless, the high prevalence of p32 expression implies that a large
fraction of patients could benefit from p32-targeted TPN/siRNA therapy. Examination of p32
status in expanded tissue arrays from patients with other types of cancers is a critical next step to
evaluate its potential as a biomarker.
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11 Appendix
Experimental contributions for each chapter:
Chapter 2: A versatile surface chemistry - In vivo tumor cell targeting with 'Click'
nanoparticles. Yin Ren and Geoff von Maltzahn contributed equally. Yin Ren synthesized and
characterized nanoparticles. Geoff von Maltzahn designed the concept and conducted in vivo
experiments.
Chapter 3: Development of targeted tumor-penetrating nanomaterials for siRNA delivery. Yin
Ren designed and characterized tandem peptides, performed in vitro gene knockdown and in vivo
tumor homing and penetration experiments.
Chapter 4: Targeted tumor-penetrating siRNA nanocomplexes for credentialing cancer targets.
Yin Ren and Hiu Wing (Tony) Cheung contributed equally. Tony Cheung conducted the
genomic analyses, shRNA screen, ID4 transformation and mechanism experiments. Yin Ren
performed in vitro validation with TPN and in vivo animal therapeutic trials.
Chapter 5: Partial Genomic Loss Reveals Specific Cancer Vulnerabilities. Deepak Nijhawan and
Travis Zack contributed equally. Yin Ren performed TPN therapeutic experiments.
Chapter 6: Characterization of receptor-specific cell-penetrating peptides for siRNA delivery.
Yin Ren conducted structural and functional chacracterizations of TPN. Sabine Hauert
performed least square regression modeling. Yin Ren and Sabine Hauert analyzed the
computational results.
Chapter 7: Receptor down-regulation improves the microdistribution of tumor-targeted
theranostics. Yin Ren performed in vitro and in vivo p32 knockdown experiments. Sabine Hauert
performed stochastic modeling experiments. John Rhoden assisted with image quantification.
Chapter 8: Delivery ofsiRNA to primary ovarian cancer cell samples. Joyce Liu and Karen
Yuan established primary human cell strains. Yin Ren performed p32 expression analysis and
TPN transfections in primary cells. Ronny Drapkin and Alison Karst performed IHC staining of
p32 in ovarian cancer TMAs.
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